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CHAPtER 1
gEnEral introduction and outlinE
radiothErapy in hEad and nEck cancEr
Head and neck squamous cell carcinoma (HNSCC) includes cancer of the oral cavity, 
pharynx and larynx as main tumor sites, and is the sixth most common cancer with 
500.000 new diagnoses per year worldwide [1]. Treatment with either surgery or radio-
therapy can be successful in curing early-stage disease. However, a majority of HNSCC 
patients presents with locoregionally advanced disease for which cure rates remain 
relatively poor [2]. Outcome for these patients with advanced-stage disease have been 
improved by altering the fractionation schedule of radiotherapy (i.e. accelerated 
fractionation or hyperfractionation) and by combining radiotherapy with chemo-
therapy [3-7]. Still, the overall increase in survival is modest and chemoradiotherapy 
is associated with increased and sometimes excessive toxicity, especially in patients 
with coexisting medical conditions and decreased performance status [2]. Hence, to 
further improve outcome in HNSCC patients it will be essential to develop new 
therapeutic strategies to enhance radiotherapy efficacy while limiting toxicity. 
Recent research findings have resulted in a better understanding of the biologic 
features of HNSCC, which has led to the development of new therapeutic agents 
targeting molecules important for tumor growth and cell survival. As these new agents 
target ‘cancer-specific’ molecules they are more likely to be less toxic and more dis-
criminative compared to classic chemotherapy. Especially agents that target molecules 
involved in the three major radioresistance mechanisms (i.e. intrinsic radiosensitivity, 
accelerated proliferation and hypoxia) offer the promise to increase the efficacy of 
radiotherapy and consequently improve patient outcome in the future [8].
radiorEsistancE MEchanisMs
Intrinsic radiosensitivity
The average intrinsic radiosensitivity of HNSCC tumors is moderate to high compared 
to other tumor types [9,10], but varies widely between patients [9]. This indicates that 
at least a part of the HNSCC patients could significantly benefit from a treatment 
that increases the intrinsic radiosensitivity of the tumor. The intrinsic radiosensitivity 
of a tumor cell depends mainly on the ability to repair DNA damage induced by ionizing 
radiation. Hence, therapeutic agents that interfere in the repair of radiation-induced 
DNA damage may be able to enhance the intrinsic radiosensitivity of a tumor and 
consequently improve outcome after radiotherapy. 
Ionizing radiation can induce several types of DNA damage, of which DNA double 
strand breaks (DSBs) are the critical lesions that can cause cell death if unrepaired 
[11]. DNA DSBs can be repaired via two main pathways: non-homologous end joining 
(NHEJ) and homologous recombination (HR). NHEJ is responsible for the repair of 
most DNA DSBs as it is active in all phases of the cell cycle, while HR occurs only 
during the S- and G2-phase of the cell cycle [12]. 
An early step in the response to a DSB is the phosphorylation of histone H2AX, 
which is mainly carried out by the kinase ataxia telangiectasia mutated (ATM). For-
mation of phosphorylated H2AX (γH2AX) is required to retain proteins that mediate 
further signaling and repair, like p53-binding protein 1 (53BP1) [12]. Many of the 
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proteins involved in the repair of DSBs form foci at the site of DNA damage, including 
γH2AX [13,14], 53BP1 [15,16] and Rad51 [14,15]; a focus is a microscopically detectable 
structure containing thousands of copies of a protein. These foci are a reliable way to 
determine the number of DSBs, and the fraction of γH2AX remaining 24h after 
irradiation has been shown to correlate with radiosensitivity [17]. Hence, effects of 
therapeutic agents on intrinsic radiosensitivity of tumors can be investigated by 
determining the number of DNA repair foci at different time points after irradiation 
(Figure 1A). Moreover, effects on a specific pathway can be detected by analyzing 
proteins specific for one of the main DSB repair pathways, e.g. effects on HR can be 
investigated by analyzing Rad51, a central protein of HR.
Tumor cell proliferation
Radiotherapy is generally given as a fractionated treatment since applying the total 
dose in multiple fractions has multiple advantages over a single dose. These include the 
reoxygenation of hypoxic areas (described below), and the reduction of normal tissue 
toxicity as normal cells have the opportunity to repair DNA damage and to repopulate 
during treatment. However, also surviving tumor cells can proliferate during these 
intervals and thereby repopulate the tumor. Tumor cell proliferation accelerates 
during treatment [18] and tumor cell repopulation is, therefore, an important cause 
of treatment failure in radiotherapy [19]. To limit this accelerated repopulation overall 
treatment time can be reduced by delivering multiple fractions per day (accelerated 
fractionation, e.g. in HNSCC [6,7]) or by increasing the dose per fraction and accord-
ingly decreasing the number of fractions (hypofractionation, e.g. in lung cancer [20]). 
Although these modified fractionation schedules have improved outcome, tumor cure 
is still not realized in all patients. Additional therapy that specifically inhibits tumor 
cell proliferation might further enhance radiotherapy efficacy. 
Tumor cell proliferation can be assessed by administration of exogenous markers, 
like bromodeoxyuridine (BrdUrd). This thymidine analogue is rapidly incorporated 
in the DNA of S-phase cells and can be detected immunohistochemically using specific 
anti-BrdUrd antibodies (Figure 1B) [21]. In addition, endogenous markers like Ki67 and 
proliferating cell nuclear antigen (PCNA) can be used to measure proliferation [22].
Hypoxia
Hypoxia is the result of an imbalance between oxygen delivery and oxygen consump-
tion, and hypoxic areas are a common feature in solid tumors, including HNSCC [23]. 
Often hypoxia occurs due to insufficient vascularization, whereby cells further away 
from a functional blood vessel will become deprived of oxygen as a result of limited 
diffusion [24]. Next to this chronic, diffusion limited hypoxia, intermittent blood flow 
due to abnormalities in the tumor vasculature causes acute, or perfusion limited, 
hypoxia followed by reoxygenation [25]. 
Hypoxia influences radiosensitivity directly as oxygen is required to fixate 
radiation-induced DNA damage [23]. Additionally, hypoxia causes radioresistance 
indirectly by changes in the cellular genome, transcriptome and proteome. Hypoxia 
induces genomic instability, possibly by affecting DNA repair pathways [26], and can 
select for cells with increased ability to withstand apoptotic stimuli or with increased 
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proliferation potential, both of which are associated with radioresistance [23]. Hypoxia 
signaling is mainly orchestrated via activation of hypoxia-inducible factor 1 (HIF-1), 
which is a heterodimeric transcriptional factor that induces the transcription of 
numerous genes. These hypoxia-inducible genes regulate a wide variety of cellular 
processes, including cell proliferation, angiogenesis, glucose metabolism, apoptosis, 
and metastasis formation [25]. In addition, radiotherapy itself also influences the 
oxygenation of tumors. Irradiation reduces the hypoxic fraction of tumors making 
them less hypoxic at the time of the next fraction [27]. This reoxygenation will have 
a direct beneficial effect on the amount of DNA damage induced by radiotherapy. In 
contrast, HIF-1 signaling is still induced by the formation of free radicals and disag-
gregation of stress granules [28]. Hence, HIF signaling can still promote cell survival in 
reoxygenated cells and thereby counterbalance the cytotoxic effect of radiotherapy.
Different methods are available to assess the level of hypoxia in tumors varying 
from physically measuring the amount of oxygen using polarographic needle elec-
trodes to immunohistochemically staining exogenous and endogenous markers of 
hypoxia [29]. Clinically relevant exogenous markers are the 2-nitroimidazoles pimo-
nidazole and EF-5, which are reduced at pO2 levels below 10 mmHg in viable hypoxic 
cells [30]. This reduction forms irreversible bonds between the 2-nitroimidazoles and 
thiol-containing proteins. As these 2-nitroimidazole-protein adducts are immunogenic, 
they can be immunohistochemically detected by specific antibodies (Figure 1B) [31]. 
Endogenous hypoxia-related markers are proteins that are upregulated by hypoxia 
and include HIF-1, carbonic anhydrase IX (CAIX), glucose transporter-1 (GLUT-1) and 
vascular endothelial growth factor (VEGF) [29]. In contrast to pimonidazole and EF-5, 
the association between endogenous markers and the actual oxygen status of the 
tissue is less clear. 
Using these methods, multiple clinical studies have shown that tumor hypoxia is 
correlated with a worse outcome after radiotherapy. This adverse prognostic impact 
of tumor hypoxia has been observed in various solid tumor types, including HNSCC, 
cervical cancer and soft tissue sarcomas [32]. In HNSCC hypoxia is not only predictive 
for overall survival, but also for local control [33-35]. This proofs that radioresistance 
induced by hypoxia is a major factor for local failure in these patients. Because of 
this negative effect of hypoxia on radiosensitivity, several approaches have been 
used to target hypoxia, including methods to increase tumor oxygen supply and the 
application of hypoxic cell cytotoxins [24,36,37]. Additionally, therapies targeting 
specific proteins involved in the response to hypoxia, including HIF-1α and its down-
stream effectors like CAIX and GLUT-1, are now under development [38]. Hence, 
therapeutic strategies that increase the oxygenation of a tumor or inhibit hypoxia-
induced pathways have the potential to increase radiosensitivity of a tumor. 
growth factor rEcEptor signaling  
and radiorEsistancE
Research into the molecular basis of radioresistance has revealed that cell signaling 
pathways induced by normal growth factor receptor activation are abnormally acti-
vated in several cancers. Many of these pathways induce cell survival mechanisms 
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figure 2: Main downstream signaling pathways of EGFR. Activation of EGFR by its ligands or by 
irradiation results in homodimerization of two EGFR or a heterodimerization with another member of 
the ErbB receptor family. this is followed by autophosphorylation of the intracellular tyrosine kinase 
domain and activation of downstream signaling molecules. Different signaling pathways can be acti-
vated that regulate cell proliferation, differentiation, apoptosis, cell cycle progression, DNA repair 
and angiogenesis. AKt: protein kinase B, ERK: extracellular signal-regulated kinase, JAK: Janus 
Kinase, Pi3-K: phosphatidylinositol 3-kinase, PKC: protein kinase C, PLCγ: phospholipase C-γ, RAS: 
rat sarcoma oncogene, StAt: signal transducer and activator of transcription.
figure 1: immunohistochemical visualization of DNA repair, proliferation and hypoxia in HNSCC 
xenograft tumors. a) 53BP1 foci in a control tumor and a tumor harvested 24 hours after radiotherapy 
(10 Gy). 53BP1: red, nuclei: blue b) Proliferation and hypoxia visualized by BrdUrd and pimonidazole 
staining, respectively. Hypoxia (pimonidazole): green, proliferation (BrdUrd): red, vessels: blue.
a b
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that also lead to radioresistance. Although different growth factor receptors are over-
expressed in HNSCC, like Human Epidermal Growth Factor Receptor 2 (HER2), Human 
Epidermal Growth Factor Receptor 3 (HER3), Insulin-like Growth Factor type I Receptor 
(IGF-IR), and the Interleukin 6 (IL-6) receptor, the most commonly overexpressed growth 
factor receptor in HNSCC is the Epidermal Growth Factor Receptor (EGFR) [39-41]. 
EGFR is a transmembrane receptor with an intracellular tyrosine kinase domain. 
Ligand binding to the extracellular domain of the receptor leads to homo- or heterodi-
merization with other receptors and induces autophosphorylation of the tyrosine 
kinase domain, which activates downstream signaling pathways [42]. These signaling 
pathways include the RAS/RAF/ERK, PI3-K/AKT, STAT, and PKC pathways, which regu-
late cell proliferation, differentiation, apoptosis, cell cycle progression, DNA repair and 
angiogenesis (Figure 2) [8,43,44]. More importantly, ionizing radiation also activates 
EGFR and its downstream signaling pathways. As a consequence, radiotherapy given 
to tumor cells (over)expressing EGFR will result in activation of cell survival and 
proliferation mechanisms, hence, in radioresistance [8,43,44]. Accordingly, patients 
with EGFR-overexpressing HNSCC have a worse prognosis after radiotherapy [45]. 
Given this important role for EGFR in HNSCC, strategies to block EGFR signaling 
using monoclonal antibodies or tyrosine kinase inhibitors have been developed. 
Multiple in vitro and in vivo preclinical studies have shown that EGFR inhibition 
enhances radiosensitivity by affecting all three radiation resistance mechanisms; 
intrinsic radiosensitivity, tumor cell proliferation and hypoxia [43]. 
EGFR-signaling and radioresistance mechanisms
Inhibition of EGFR has been show to inhibit repair of radiation-induced DNA damage 
by affecting both NHEJ as well as HR [46-49]. EGFR influences repair of DNA DSBs via 
both the RAS/RAF/ERK and the PI3-K/AKT pathway [8,42,47,50,51]. Moreover, next to 
these cytoplasmic pathways, EGFR affects DNA repair directly by translocation to the 
nucleus. In the nucleus EGFR stimulates NHEJ via interaction with DNA-PKcs, a key 
protein in the NHEJ pathway [52,53]. Cetuximab (C225), a chimeric monoclonal anti-
body against the extracellular part of EGFR, inhibits DNA repair by blocking the kinase 
activity or nuclear translocation of EGFR and this results in decreased survival after 
radiation [47,52,53].
Also, the antiproliferative effects of EGFR inhibitors have been shown in pre-
clinical experiments. These effects are predominantly regulated via inhibition of the 
RAS/RAF/ERK pathway [8,54]. Moreover, EGFR inhibitor cetuximab significantly reduced 
tumor repopulation during fractionated radiotherapy in a xenografted human HNSCC 
model [55]. Also, findings from two clinical studies suggest that activation of EGFR is 
important in repopulation of the tumor as a schedule of accelerated radiotherapy only 
improved locoregional control in tumors with high EGFR expression and not in tumors 
with low expression [56,57]. 
EGFR-signaling has also been shown to affect hypoxia-activated pathways. HIF-1α 
expression requires PI3-K activity and ERK is needed for hypoxia-induced HIF-1 trans-
activation activity [58]. In addition, activation of EGFR upregulates VEGF expression 
and, accordingly, inhibition of EGFR reduces VEGF and angiogenesis in multiple tumor 
types [59-61]. More importantly, this anti-angiogenic effect of EGFR inhibitors induces 
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vascular normalization and increases tumor blood flow, leading to decreased hypoxia 
in tumor xenografts [62,63]. EGFR inhibition also improves reoxygenation of HNSCC 
xenografts during fractionated radiotherapy, which contributes to improved local con-
trol after combined treatment [55]. Hence, EGFR inhibition increases radiosensitivity 
via reduction of the hypoxic fraction of tumors and by reducing hypoxia-induced 
signaling. 
EGFR inhibition and radiotherapy in HNSCC
EGFR inhibition also increases the effect of radiotherapy in the clinic; a phase III study 
by Bonner et al. [64] has shown that addition of cetuximab improves the clinical out-
come after radiotherapy in HNSCC patients. However, despite this success, a large 
proportion of patients does not benefit from the addition of EGFR inhibition, while this 
combination generally does induce increased toxicity [65]. In addition, the expres-
sion level of EGFR assessed by immunohistochemistry does not correlate with clinical 
response [66]. Therefore, further research is warranted to identify the critical biological 
characteristics that can predict outcome after combined EGFR inhibition and radio-
therapy. Hereby, it will be essential to use multiple HNSCC tumor models representing 
the variation in tumor phenotypes seen in the clinic, both in terms of biological 
characteristics and in the response to EGFR inhibition and radiotherapy. The knowledge 
obtained can be used to improve patient selection and to more efficiently employ 
EGFR inhibitors for treatment of HNSCC patients. 
Besides improving the potential of combined treatment of EGFR inhibition with 
radiotherapy, it will be essential to develop new therapeutic strategies that target 
other molecules of the EGFR signaling network involved in resistance to radiotherapy 
and cetuximab. Potential candidates are kinases downstream of EGFR and other growth 
factor receptors. There is extensive crosstalk between different growth factor receptors, 
such as EGFR and MET, and they activate similar downstream pathways [67]. Due to 
this redundancy in signaling networks, cells overexpressing multiple growth factor 
receptors can sustain survival signaling when only one of the receptors is blocked. 
This bypass resistance mechanism is supported by the observation that cells with 
acquired resistance to EGFR inhibition overexpress other growth factor receptors [68]. 
Moreover, combining EGFR inhibition with a HER3- or MET-inhibitor overcomes 
resistance to EGFR inhibition [69,70]. Therefore, the common downstream pathway 
that is responsible for cell survival after radiotherapy will be a more attractive target 
to overcome treatment resistance than targeting one specific growth factor receptor. 
However, the redundancy in kinase pathways mediating cell survival after radiotherapy 
will likely be an issue in treatments targeting one particular pathway. Alternatively, 
kinases that are activated by hypoxia might be attractive targets. Hypoxia induces 
pathways that overlap with pathways downstream of growth factor receptors [25,58]; 
hence, hypoxia can induce cell survival pathways independent of receptor signaling 
and can thereby bypass inhibitors of growth factor receptors, including EGFR.
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conclusion
Agents that target growth factor receptor signaling have the potential to improve out-
come after radiotherapy in HNSCC patients. The combination of EGFR inhibition and 
radiotherapy is a successful example of this approach. However, (acquired) resistance 
decreases the impact of this combination. Therefore, to further improve outcome of 
HNSCC patients, it will be essential to determine predictive biological characteristics for 
treatment with EGFR inhibition and radiotherapy. Moreover, it will be critical to develop 
new therapeutic strategies that counteract the mechanisms that cause resistance to 
EGFR inhibition. Kinases of downstream pathways critical for cell survival after radio-
therapy offer interesting targets to increase radiosensitivity in HNSCC even more. 
This research has to be performed in in vitro and in vivo preclinical models that represent 
the variation observed in patients to reliably predict the effect of a new treatment in 
the clinic. 
outlinE of thE thEsis
In this thesis various aspects of enhancing radiosensitivity by inhibition of growth 
factor receptor signaling in preclinical models are investigated. 
In part I of this thesis, chapters 2 and 3, the correlation between in vitro (cell culture) 
and in vivo (xenograft) models and the correlation between xenografts and the primary 
patient tumor they are derived from are examined. In chapter 2, the question whether 
xenograft models are useful preclinical models to predict outcome of a new treatment 
in the clinic is addressed. For this, a panel of HNSCC clinical biopsies and the derived 
xenografted tumors is characterized to determine whether the xenografts show a 
similar biological expression pattern as the primary tumor. In chapter 3, the correla-
tion between the in vitro and in vivo expression of proteins of the EGFR-signaling 
network in 6 HNSCC cell lines is studied. Using this approach hypoxia-induced 
proteins can be found, which are interesting targets to overcome hypoxia-induced 
radioresistance. 
In part II of this thesis, chapters 4 and 5, the effects of EGFR inhibition via cetuximab 
on the three major radiation resistance mechanisms are investigated in multiple 
HNSCC xenograft models and correlated with response to EGFR inhibition and radio-
therapy. In chapter 4, the response to cetuximab and/or radiotherapy is determined 
in 4 HNSCC xenograft models with differing EGFR expression levels, which represent 
the variation observed in the clinic. The response to treatment is correlated to effects 
on hypoxia and proliferation in these models and also the expression levels of proteins 
known to be involved in resistance to EGFR inhibition are determined. The effect of 
cetuximab on repair of radiation-induced DNA damage is investigated in a sensitive 
and a resistant HNSCC xenograft model in chapter 5.
In part III of this thesis, chapters 6 and 7, the aim is to investigate whether inhibitors 
of kinases can enhance radiosensitivity in HNSCC. In chapter 6, a panel of HNSCC 
cell lines is used to determine which kinases are correlated with radiosensitivity. 
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Moreover, inhibitors against these kinases are tested for their ability to increase radio-
sensitivity in a selection of these HNSCC cell lines. The potential of dasatinib, an 
inhibitor of the Src kinase family, to enhance the effect of radiotherapy in vivo and 
the effect of dasatinib on hypoxia, proliferation and DNA repair is investigated in 
chapter 7.
Chapter 8 provides a general discussion including directions for future research and 
treatment of HNSCC patients. This thesis concludes with a summary of the findings 
presented in this thesis in chapter 9. 
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abstract
background: Hypoxia, metabolism and growth factor signaling are important prog-
nostic features in most solid tumors. The aim of this study was to determine whether 
head and neck squamous cell carcinoma (HNSCC) xenografts show similar biological 
and molecular characteristics as the primary tumor they originate from.
Methods: Eighteen HNSCC primary tumor-xenograft pairs were immunofluorescently 
stained for pimonidazole (hypoxia), carbonic anhydrase IX (CAIX), glucose transporter-1 
(GLUT-1), monocarboxylate transporter-1 (MCT-1), monocarboxylate transporter-4 
(MCT-4), Epidermal Growth Factor Receptor (EGFR), and phosphorylated protein 
kinase B (pAKT). 
results: Although no correlation was found for the amount of hypoxia, significant 
correlations between primary tumors and xenografts were observed for the percentage 
of cells positive for expression of CAIX, GLUT-1 and MCT-1, and the hypoxia-related 
expression pattern of MCT-4. For EGFR and MCT-4, the intensity of expression was 
correlated. No correlation was observed for pAKT.
conclusions: Xenografts did not always resemble the primary tumor they originate 
from, but the xenografts did represent the variability in expression levels and patterns 
observed in the primary tumors. 
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introduction
Primary tumor xenografts, established by implanting patient tumor material into 
immunocompromised mice, are important preclinical models in cancer research. 
Xenografts derived from different tumor sites have been shown to resemble the 
original tumor both histologically and molecularly, and are therefore believed to be 
useful models to determine treatment response to newly developed therapies and 
find predictive biomarkers [1-5]. Nonetheless, it is often questioned to what extent 
these models represent the clinical reality and variability, as many new therapies 
that have been proven to be successful in pre-clinical models fail in clinical trials [6]. 
This discrepancy can be caused by a different tumor microenvironment in primary 
tumors compared to xenografts. Although the tumor cells of the xenograft are derived 
from the human patient, the stromal cells and vessels are from the host and may behave 
different from their human counterpart. Moreover, xenografts are often implanted 
subcutaneously, which does not resemble the original tumor site in the patient. 
However, orthotopic models have several practical disadvantages that complicate 
their application in cancer research [7]. Therefore, it is important to assess whether 
tumor behavior in relation to processes important for prognosis in the clinic, like 
hypoxia, metabolism and growth factor signaling, in subcutaneously grown xenografts 
resembles tumor behavior in the primary tumors from which they originate.
Hypoxia is a widespread phenomenon present in many human solid tumors and is 
associated with a poor prognosis and therapy resistance [8-13]. Tumor cell metabolism 
and hypoxia are closely related. The nutrient requirement of tumor cells is high, 
because ATP is often generated via the relatively inefficient glycolytic pathway [14]. 
A high rate of glycolysis is generally observed due to two reasons. First, the phe-
nomenon that tumor cells use glycolysis as their energy source even under normoxic 
circumstances, because of genetic changes (Warburg effect) [15]. Second, the switch 
to glycolysis under hypoxic conditions is a physiological response as oxidative phos-
phorylation depends on the presence of oxygen [16]. 
The variation between tumors in their response to hypoxic conditions can be 
characterized by measuring the expression of metabolic and hypoxia-related markers. 
Several exogenous and endogenous markers are available to visualize hypoxia [17]. 
EF5 and Pimonidazole are exogenous hypoxic markers that are approved for clinical 
studies [10,18]. Endogenous hypoxia-related markers include: carbonic anhydrase IX 
(CAIX), a membranous enzyme upregulated under hypoxic circumstances and involved 
in pH regulation [19]; GLUT-1 (glucose transporter-1), a transporter responsible for 
glucose import [20]; and MCT-1 (monocarboxylate transporter-1) and MCT-4 (mono-
carboxylate transporter-4), which have important roles in lactate transport and 
accordingly are glycolysis-related markers [21,22]. All these hypoxia-related markers 
are involved in metabolic processes and are also linked to resistance to radiotherapy 
and, therefore, have important prognostic and predictive value [23]. In addition to 
the level of expression of these markers, the pattern of expression in relation to 
hypoxia is also an important biological characteristic. 
Besides these hypoxia-related and metabolic-related markers, also the expression 
and activation of growth factor receptors and their downstream pathways, including 
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Epidermal Growth Factor Receptor (EGFR) and the phosphatidylinositol-3-kinase (PI3-K)/
protein kinase B (AKT) pathway, have demonstrated clinical relevance in head and neck 
carcinomas. Expression of EGFR and phosphorylated AKT (pAKT) has important prognos-
tic value and influences response to radiotherapy in head and neck carcinomas [24-26]. 
To be useful as preclinical models, xenograft lines need to have similar characteristics 
as their human counterpart with respect to the parameters investigated. Therefore, 
we characterized a panel of head and neck squamous cell carcinoma (HNSCC) clinical 
biopsies and the derived xenografted tumors to determine whether the xenografts 
show a similar biological expression pattern as the primary tumor. We investigated 
both the extent of expression of important molecular markers involved in hypoxia, 
metabolism and growth factor signaling, as well as their expression pattern in relation 
to hypoxia. 
MatErial and MEthods
Primary and xenograft tumor samples
Biopsy material from 18 patients with squamous cell carcinomas from a range of 
head and neck subsites was collected. Patients received pimonidazole ((1-[(2-hydroxy-
3-piperidinyl)propyl]-2-nitroimidazole hydrochloride, Hypoxyprobe-1; Natural Phar-
macia International, Belmont, MA) intravenously (500 mg/m2) 2 hours before biopsy 
taking to label hypoxic cells. For immunohistochemical staining, a biopsy was snap 
frozen in liquid nitrogen and stored in liquid nitrogen until further processing. The 
Institutional Review Board of the Radboud University Medical Centre Nijmegen 
approved the study and all patients gave written informed consent.
A second biopsy was put in L15 culture medium (Life Technology, Breda, The 
Netherlands) with penicillin and gentamycin, and transported to the animal labora-
tory where 1 mm3 pieces of viable tumor were transplanted subcutaneous in the 
flanks of five nude mice (Balb/c nu/nu mouse). For passaging, one of the tumors was 
excised and cut into 1 mm3 tumor pieces. The tumor pieces were then subcutaneously 
implanted into a new series of nude mice. In this study, one xenograft tumor per 
primary tumor was harvested for analysis. The passage number of the analyzed xen-
ograft tumor depended on the passage reached in the laboratory. For analysis of the 
tumor, animals were injected intraperitoneally with 0.5 ml of saline containing 2 mg 
pimonidazole one hour before tumor excision (tumor diameter >4 mm). After excision, 
tumors were immediately frozen in liquid nitrogen. Animals were kept in a specific 
pathogen-free unit in accordance with institutional guidelines. All experiments were 
approved by the Animal Experiments Committee of the Radboud University Nijmegen 
Medical Centre.   
Histochemical and immunofluorescent staining
From both primary tumors and xenograft tissue samples, frozen sections of 5 μm 
were cut and mounted on poly-L-lysine coated slides and stored at -80 °C. Sections 
from the primary tumor material used for staining were chosen randomly and sections 
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from the xenografts were cut from the central part of the tumor to represent the whole 
tumor. For morphological evaluation of the tissue, a hematoxylin-eosin staining was 
performed. For immunofluorescent staining, sections were fixed in acetone of 4 °C 
for 10 min and rehydrated in phosphate buffered saline (PBS). Sections were stained 
for CAIX, GLUT-1, MCT-1, MCT-4 or EGFR in combination with pimonidazole (hypoxia) 
and vessels. For pAKT, consecutive sections were either stained with pAKT and vessels 
or with pimonidazole and vessels. Antibodies against MCT-1, MCT-4, EGFR and 
pAKT(S473) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) 
and the antibody against GLUT-1 was purchased from Thermo Scientific (Kalamazoo, 
MI, USA). The antibody against CAIX was a gift from E. Oosterwijk (Dept. of Urology, 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands) and the 
antibody against pimonidazole was a gift from J.A. Raleigh (Dept. of Radiation 
Oncology, University of North Carolina, Chapel Hill, NC, USA). Vessels were stained 
with PAL-E (Euro Diagnostica BV, Arnhem, The Netherlands) in primary tumors and 
with 9F1 (rat monoclonal antibody against mouse endothelium, Dept of Pathology, 
Radboud University Nijmegen Medical Centre) in xenograft material. 
CAIX, GLUT-1, MCT-1, MCT-4 and EGFR were detected by incubation with an 
appropriate Cy3-conjugated secondary antibody (Jackson Immuno Research Laborato-
ries Inc., West Grove, PA, USA), pAKT and pimonidazole by incubation with Alexa488-
conjugated donkey anti-rabbit IgG (Molecular Probes, Leiden, The Netherlands), and 
vessels by incubation with an appropriate Alexa647-conjugated secondary antibody 
(Molecular Probes). All stained sections were mounted in Fluorostab (ICN Pharmaceu-
ticals, Inc, Zoetermeer, The Netherlands).
Complete tumor sections were scanned on a digital image processing system 
consisting of a 12-bit charge-couple device camera (Micromax, Roper Scientific Inc., 
Trenton, NJ, USA) on a fluorescence microscope (Axioskop, Zeiss Göttingen, Germany) 
and a computer-controlled motorized stepping stage, using IPLab software (Scanalytics 
Inc., Fairfax, VA, USA). Each section was sequentially scanned multiple times for the 
individual markers with appropriate filters at 100x magnification yielding separate 
images of each of the markers stained in the section. One pseudo-colored composite 
image was reconstructed from the individual microscope images to visualize colocali-
zation of markers as described before [27]. 
Scoring
Molecular markers were semiquantitatively scored for the percentage of cells positive 
for the marker on a scale from 0 to 3 (0 = no expression; 1 = low expression; 2 = moderate 
expression; and 3 = high expression). The scale was adapted to the range of expression 
observed for that particular marker in such a way that a score of 3 represented the 
maximum percentage of positive cells observed in all tumor samples and a score of 
1 the lowest percentage of positive cells observed in all tumor samples. For example, 
EGFR was scored 3 when 70-100% of cells were positive, while CAIX was scored 3 
when 25-100% of cells were positive. This range of expression differed sometimes 
between primary tumors and xenograft tissue and this resulted in a different scaling 
for primary tumors and xenografts for that marker. MCT-4 and EGFR showed a wide 
variation in staining intensity between tumors and these markers were also scored for 
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intensity on a scale from 0 to 3 (0 = no staining; 1 = weakly positive; 2 = moderately 
positive; and 3 = strongly positive staining). 
The expression pattern of a marker in relation to hypoxia was scored as a 
“hypoxic” or “non-hypoxic” pattern. The pattern was hypoxic when the marker was 
predominantly expressed in pimonidazole-positive cells or when the expression was 
on the border of pimonidazole-positive and pimonidazole–negative areas. The pattern 
was non-hypoxic when the marker was expressed both in pimonidazole-positive and 
pimonidazole-negative cells or when the marker was predominantly expressed in 
pimonidazole-negative cells. No pattern was scored when the marker was not expressed 
or when no pimonidazole-positive areas were present in the tumor section.
All sections were scored by two independent investigators (HS and SR) and dis-
crepancies were solved by simultaneous viewing.
Statistics
Statistical analyses were performed using Prism 4.0c (GraphPad Software, Inc., LA 
Jolla, CA, USA). The Spearman correlation coefficient test was applied to determine the 
correlation between the score of the primary tumors and the score of the xenograft 
tumors for all parameters. To compare the expression patterns in relation to hypoxia, 
contingency tables were used and tested with the Fisher’s exact test. Any p-values of 
<0.05 were considered statistically significant. 
rEsults
Eighteen primary tumor-xenograft pairs, of which the tumor and patient character-
istics are shown in Table 1, were included in this study. All xenografted tumors 
exhibited the histological characteristics of a squamous cell carcinoma and keratin 
pearls were seen in most tumors. 
Hypoxia and expression of molecular markers in primary tumors vs xenografts
To determine whether xenografted tumors are biologically similar to the primary 
tumors, hypoxia and representative markers involved in hypoxia response, metabolism 
and growth factor signaling were semiquantitatively scored for the percentage of 
expressing tumor cells (Table 2). CAIX, GLUT-1, MCT-1 and MCT-4 showed a mem-
branous staining pattern, while pAKT showed cytoplasmic staining. Pimonidazole, 
the exogenous marker for hypoxia, also showed cytoplasmic staining. EGFR was pre-
dominantly present in the membranes of tumor cells, but also nuclear expression 
was observed. Images of immunofluorescent stainings of CAIX, GLUT-1, MCT-1 and 
EGFR in representative primary tumor-xenograft tumor pairs are shown in Figure 1.
Overall, xenografts were collected at a size (diameter >4 mm) at which hypoxic 
areas were expected. Indeed, all xenografted tumors had a relative high hypoxic frac-
tion compared to primary tumors, which sometimes did not show any hypoxia at all. 
This resulted in a poor, non-significant, correlation for the hypoxic fraction between 
primary and xenograft tumors. 
Significant and strong correlations between the percentage of expressing tumor 
cells in primary tumors and xenograft tumors were observed for CAIX (r=0.69, p=0.02), 
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table 1: Patient/tumor characteristics
characteristic no. of patients
tumor site
Larynx 3
Hypopharynx 9
oropharynx 4
oral cavity 2
t classification
t1 1
t2 3
t3 9
t4 5
N classification
N0 3
N+ 15
Histopathological grade
Moderately differentiated 8
Poorly differentiated 9
unknown 1
table 2: Quantity of markers: expression in primary tumors and corresponding xenografts 
Marker spearman correlation  
coefficient
p-value agreement low/high expression  
vs total number (%)*
Pimonidazole 0.15 NS 10/17 (59)
CAix 0.69 0.002 16/18 (89)
GLUt-1 0.58 0.01 17/18 (94)
MCt-1 0.66 0.003 15/18 (83)
MCt-4 0.06 NS 15/17 (88)
EGFR 0.22 NS 13/16 (81)
pAKt 0.24 NS   6/13 (46)
* total number of pairs differs between markers, because of missing scores due to staining errors or  
unavailable patient material.
CAix: carbonic anhydrase ix, GLUt-1: glucose transporter-1, MCt-1: monocarboxylate transporter-1,  
MCt-4: monocarboxylate transporter-4, EGFR: Epidermal Growth Factor Receptor,  
pAKt: phosphorylated protein kinase B
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figure 1: immunofluorescent staining of CAix, GLUt-1, MCt-1 and EGFR in combination with hypoxia 
in primary tumors and associated xenograft tumors. Fluorescent microscopic images of patient-
xenograft tumor pairs stained for CAix, GLUt-1, MCt-1, or EGFR in combination with pimonidazole 
(hypoxia) and vessels. CAix and GLUt-1 were predominantly expressed in hypoxic tumor areas and 
MCt-1 and EGFR predominantly in oxic tumor regions. CAix, GLUt-1, MCt-1, and EGFR: red, pimoni-
dazole: green, vessels: blue. Magnification: 100x.
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GLUT-1 (rs=0.58, p=0.01) and MCT-1 (rs=0.66, p=0.003) (Table 2). When the tumors were 
divided into high (score 2 or 3) and low (score 0 or 1) expressing tumors, at least 83% of 
the xenograft tumors scored the same level as the primary tumor for these 3 markers. 
Also, MCT-4 showed a high agreement of 88% when tumors were divided into high 
and low, but overall for MCT-4 no correlation was found with respect to expression 
levels between primary tumors and xenografts. This is because of the fact that almost 
all tumors, both primary tumors and xenografts, showed a relatively high percentage 
of cells positive for MCT-4 (score 2-3). However, the highest expressing primary 
tumors (score 3) did not always give rise to the highest expressing xenograft tumors 
and, therefore, no overall correlation was found. In contrast to the percentage of 
positive cells, clear differences were observed in the intensity of MCT-4 staining and 
a trend was observed for a correlation between the intensity score of the primary 
tumor and the xenograft (rs=0.45, p=0.07).
This high percentage of agreement, albeit with a weak and non-significant cor-
relation, was also observed for EGFR expression (Table 2, Figure 1). Like MCT-4, EGFR 
is also highly expressed in almost all primary and xenografted tumors. This marker 
also showed a wide range in intensity and scoring of the intensity resulted in a highly 
significant and strong correlation between primary tumors and xenografts (rs=0.60, 
p=0.01). Interestingly, in two primary tumors only nuclear and no membranous EGFR 
was observed, whereas this nuclear expression was not observed in any of the xeno-
graft tumors.
For pAKT expression, a poor correlation and a low percentage of agreement 
were observed (Table 2). This was generally due to a higher expression of pAKT in the 
xenografts relative to a low expression in the primary tumors.
Hypoxia-related expression patterns in primary tumors versus xenografts 
Additionally, the pattern of expression of the endogenous markers in relation to 
hypoxia was scored as an important biological characteristic of these tumors (Table 
3). Only the pattern of MCT-4 expression correlated significantly between primary 
tumors and xenografts (Table 4). For CAIX, MCT-1 and GLUT-1 at least 60% of the 
expression pattern observed in the xenograft was comparable to the pattern in the 
original primary tumor (Table 4). Expression of CAIX, GLUT-1 and MCT-4 was observed 
in hypoxic areas of the tumor. However, especially GLUT-1 and MCT-4 expression was 
also noted in both oxic and hypoxic areas. This non-hypoxia related expression pattern 
was more often observed in the primary tumors than in the xenografted tumors 
(GLUT-1: 63 vs 44%, MCT-4: 62% vs 54%, CAIX: 27% vs 0%) (Table 3). Figure 2 shows 
representative images of a hypoxia-related and a more diffuse, non-hypoxia related, 
staining pattern for MCT-4 in primary tumor-xenograft pairs. Overall, the different 
expression patterns were observed both in primary tumors and in xenografts, except 
for CAIX, which showed only the hypoxia-related expression pattern in xenografts. 
In contrast, MCT-1 was either predominantly expressed in oxic areas or in both 
oxic and hypoxic areas. Again, both patterns were seen in primary tumors and xeno-
graft material and the more diffuse, non-hypoxia related, expression pattern was more 
often observed in primary tumors than in xenografts (Table 3).  
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table 3: Hypoxia-induced expression of markers: distribution of expression patterns related to 
hypoxia in primary tumors and xenografts 
Marker primary tumor xenograft
hypoxic pattern 
(% of tumors)
non-hypoxic pattern  
(% of tumors)
hypoxic pattern 
(% of tumors)
non-hypoxic pattern  
(% of tumors)
CAix 73 27 100 0
GLUt-1 37 63 56 44
MCt-1* 47 53 60 40
MCt-4 38 62 46 54
EGFR* 67 33 58 42
pAKt 89 11 33 67
* Hypoxic pattern represents expression predominantly in oxic areas and non-hypoxic pattern represents 
expression in both oxic and hypoxic areas. 
CAix: carbonic anhydrase ix, GLUt-1: glucose transporter-1, MCt-1: monocarboxylate transporter-1,  
MCt-4: monocarboxylate transporter-4, EGFR: Epidermal Growth Factor Receptor,  
pAKt: phosphorylated protein kinase B
table 4: Hypoxia-induced expression of markers: expression patterns related to hypoxia in primary
tumors vs xenografts
Marker agreement hypoxic/non-hypoxic pattern  
vs total number (%)*
p-value
CAix 8/11 (73) NA
GLUt-1  11/16 (69) NS
MCt-1** 9/15 (60) NS
MCt-4  12/13 (92) 0.005
EGFR** 7/12 (58) NS
pAKt 3/9 (33) NS
* total number of pairs differs between markers, because the pattern could not be scored when the  
marker was not expressed or when no pimonidazole-positive areas were present in the tumor section.
** Hypoxic pattern represents expression predominantly in oxic areas and non-hypoxic pattern  
represents expression in both oxic and hypoxic areas. 
CAix: carbonic anhydrase ix, GLUt-1: glucose transporter-1, MCt-1: monocarboxylate transporter-1,  
MCt-4: monocarboxylate transporter-4, EGFR: Epidermal Growth Factor Receptor,  
pAKt: phosphorylated protein kinase B
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figure 2: Hypoxia-related and 
diffuse expression pattern of 
MCt-4 in primary tumors and 
associated xenograft tumors. 
Fluorescent microscopic 
images of patient-xenograft 
tumor pairs with either MCt-4 
predominantly expressed in 
hypoxic tumor areas (hypoxic 
pattern) or MCt-4 diffusely 
expressed in both oxic and 
hypoxic tumor areas (diffuse 
pattern). MCt-4: red, pimo-
nidazole: green, vessels: blue. 
Magnification: 100x.
figure 3: Expression of pAKt 
in relation to hypoxia in pri-
mary tumors and associated 
xenograft tumors. Fluores-
cent microscopic images of 
consecutive tumor sections 
stained for pAKt (red) and 
vessels (blue) or pimonida-
zole (green) and vessels 
(blue). pAKt is predominantly 
expressed in hypoxic regions 
in primary tumor, while in 
the associated xenograft 
tumor pAKt expression is 
more widespread and also 
present in oxic regions. 
Magnification: 100x.
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EGFR and downstream signaling kinases, including pAKT, have also been described 
to be affected by hypoxia. Indeed, pAKT expression was predominantly observed in 
hypoxic areas in most primary tumors (8/9, 89%) (Table 3). This hypoxic pattern was 
less pronounced in xenografted tumors as most of these showed pAKT expression 
both in oxic and hypoxic areas (6/9, 67%) (Table 3). An example of the hypoxia-related 
expression pattern of pAKT in a primary tumor compared to the more diffuse expres-
sion pattern in the corresponding xenograft is shown in Figure 3. Consequently, this 
resulted in a relatively low percentage of agreement between the expression pattern 
in the xenografts and the primary tumors (Table 4). On the other hand, the expression 
of EGFR was predominantly observed in oxic areas or as a diffuse expression through-
out the whole tumor both in xenografts and primary tumors (Table 3). However, mis-
match between primary tumors and xenografts was often observed and no correlation 
was present (Table 4). 
discussion
It has been known for a long time that hypoxia is involved in therapy resistance in 
solid tumors and, thus, several approaches have been applied to modify hypoxia 
including methods to increase tumor oxygen supply or to target hypoxic cells with 
hypoxic cytotoxins [10,28,29]. More recently, a better understanding of the biological 
features of solid tumors has led to the development of new therapeutic agents targeting 
specific molecules involved in processes important for tumor growth and cell survival. 
These molecules include proteins involved in the response to hypoxia, metabolism 
and growth factor signaling [18,30,31]. However, hypoxia targeting has been applied 
with varying success and also targeted therapies often fail in the clinic because of 
intrinsic and/or acquired resistance. Failure in the clinic could partially be caused by 
poor patient selection for such therapies. Therefore, it is of great importance to perform 
preclinical research with relevant models, which can increase the knowledge necessary 
for optimizing patient selection for novel targeted therapies.  
In this study, we characterized a panel of HNSCC patient-xenograft tumors to deter-
mine whether the xenografted tumors show similar biological expression patterns in 
relation to hypoxia as the primary tumor and also whether the variability in expres-
sion levels and patterns observed in the clinic is represented in the xenograft models. 
This is essential for these xenografts to be useful as preclinical models. Our panel 
consisted of primary tumors from different tumor sites and with differing T-stage, 
N-stage and histopathological grade and, thus, represented the variation in phenotypes 
encountered in the clinic. Previous studies have shown that successful engraftment 
of a tumor is associated with poor prognostic clinical parameters [2,32]. This could 
indicate that xenograft tumors only represent patients with a poor prognosis. However, 
our panel also includes tumors with good prognostic features and this implies that 
also tumors from patients with good clinical parameters form xenograft tumors.  
We did not observe a correlation between the amount of hypoxia in the primary and the 
xenografted tumor. All xenografts were grown to a size whereby large hypoxic areas 
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were present, while primary tumors sometimes showed no hypoxia at all. Nonetheless, 
we did observe a significant and strong correlation for the percentage of cells express-
ing CAIX, GLUT-1, or MCT-1. These results suggest that the biological adaptation of 
the tumor cells to hypoxia was maintained during xenotransplantation, independent 
of the amount of initial hypoxia (i.e. in the primary tumor). However, one should 
keep in mind that the overall expression of these hypoxia-related markers was higher 
in xenografted tumors than in primary tumors because of a higher hypoxic fraction. 
Adam et al. [33] have also shown that experimental mouse tumors from different 
tumor types are markedly more hypoxic than patient tumors of the same histology. 
The use of xenograft models could thus result in an overestimation of the possible 
effect of agents that target hypoxia or proteins involved in the response to hypoxia 
compared to the effect that can be achieved in clinical studies. 
As expected, the hypoxia-inducible facor-1-alpha (HIF-1α) related proteins CAIX, MCT-4 
and GLUT-1 were observed in hypoxic areas of the tumor. However, also a more diffuse 
pattern with expression in oxic areas was observed indicating another activating 
factor. Besides hypoxia, also other factors, including pH and growth factor signaling 
can have a great influence on the expression of these “hypoxia”-induced proteins 
[30,34]. The expression pattern seems to be an important prognostic feature of the 
tumor. Primary tumors with perinecrotic expression of HIF-1α have a worse prognosis 
compared to tumors with a diffuse expression pattern [35,36]. Recent data from our 
own lab indicate that the pattern more than the extent of expression of CAIX predicts 
prognosis in HNSCC patients [37]. MCT-1 showed an opposite expression pattern in 
well-oxygenated (pimonidazole negative) regions as well as a more diffuse expression 
pattern, which is partly in agreement with the observations made by Sonveaux et al. 
[22] in lung carcinomas. Although the expression pattern of the xenografted tumor did 
not always match the pattern of the primary tumor, the different expression patterns 
were observed both in primary tumors and in xenografted tumors. 
These results indicate that xenograft models can represent the phenotypes in 
the patient, but that models have to be chosen on the basis of both the amount and 
the pattern of expression of the relevant marker.  
Similar relations between primary tumor and xenograft were seen for proteins 
involved in growth factor receptor expression and downstream signaling, like EGFR 
and pAKT. For these markers, often mismatches were observed in both the amount 
and expression pattern between primary tumor and xenograft. However, the intensity 
of EGFR expression did show a significant correlation between primary tumor and 
xenograft. Tumors can have increased copy numbers of the EGFR gene and this cor-
relates with a higher protein expression [38,39]. Although we only evaluated protein 
expression in this study, intensity of the staining could resemble the variation in 
copy number and can therefore explain the agreement between the intensity score 
in the primary tumor and the xenograft. However, microenvironmental factors 
inducing translation and thus expression can differ between xenograft and primary 
tumor and this could be the cause of the lack of correlation for the percentage of 
cells expressing EGFR. Remarkably, nuclear EGFR expression was only observed in 
35HyPoxiA, MEtABoLiSM AND SiGNALiNG iN PAtiENt-xENoGRAFt PAiRS
primary tumors and not in xenografted tumors. The presence of EGFR in the nucleus is 
associated with both poor survival and resistance to a variety of treatments, including 
radiotherapy and EGFR inhibition [40]. Further research will be necessary to determine 
why nuclear EGFR was not observed in xenografts, while it was present in the primary 
tumors they are derived from. 
Activation of AKT by hypoxia has been observed in vitro and in vivo [41], and especially 
in the primary tumors pAKT expression was observed in hypoxic areas. In xenografted 
tumors, pAKT expression was present in hypoxic areas as well as in oxic regions. AKT 
can be activated by a wide variety of stimuli, including growth factor signaling, and 
is involved in various pathways involved in cell survival [42]. These factors can be 
differentially regulated in xenografted tumors and be responsible for the activation 
of AKT in oxic regions of these tumors. 
In conclusion, we observed good correlations between the expression levels and also 
the hypoxia-related expression pattern of some molecular markers in HNSCC primary 
tumor-xenograft pairs. However, this was not true for all markers and often mismatch 
was observed between the xenograft tumor and the primary tumor they originated 
from. Nevertheless, the variability in expression levels and patterns observed in the 
primary tumors were represented in the xenograft tumors. Both the level of expres-
sion and the hypoxia-related expression pattern are important indicators of tumor 
biology and will, therefore, be critical for the response of a tumor to a new therapy. 
Hence, our data demonstrate the significance to choose a representative panel of xeno-
graft models to match the variation observed in patients. This enhances the reliability 
of preclinical research to predict the effect of a new treatment in the clinic. Thus 
although xenografts not always resemble the primary tumor exactly, when used 
critically they are valuable tools to investigate the effects of new anti-cancer treat-
ments.
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abstract 
background: Only a minority of cancer patients benefits from the combination of EGFR 
inhibition and radiotherapy in head and neck squamous cell carcinoma (HNSCC). 
A potential resistance mechanism is activation of EGFR and/or downstream pathways 
by stimuli in the microenvironment. The aim of this study was to find molecular 
targets induced by the microenvironment by determining the in vitro and in vivo 
expression of proteins of the EGFR-signaling network in 6 HNSCC lines. As hypoxia is 
an important microenvironmental parameter associated with poor outcome in solid 
tumors after radiotherapy, we investigated the relationship with hypoxia in vitro and 
in vivo.  
Methods: Six human HNSCC cell lines were both cultured as cell lines (in vitro) and 
grown as xenograft tumors (in vivo). Expression levels were determined via western 
blot analysis and localization of markers was assessed via immunofluorescent staining. 
To determine the effect of hypoxia and pAKT inhibition on cell survival, cells were 
incubated at 0.5% O2 and treated with MK-2206. 
results: We observed strong in vitro -in vivo correlations for EGFR, pEGFR and HER2 
(rs=0.77, p=0.10, rs=0.89, p=0.03), and rs=0.93, p=0.02, respectively), but not for pAKT, 
pERK1/2 or pSTAT3 (all rs<0.55 and p>0.30). In vivo, pAKT expression was present in 
hypoxic cells and pAKT and hypoxia were significantly correlated (rs=0.51, p=0.04). 
We confirmed in vitro that hypoxia induces activation of AKT. Further, pAKT inhibi-
tion via MK-2206 caused a significant decrease in survival in hypoxic cells (p<0.01), 
but not in normoxic cells. 
conclusions: These data suggest that (p)EGFR and HER2 expression is mostly deter-
mined by intrinsic features of the tumor cell, while the activation of downstream 
kinases is highly influenced by the tumor microenvironment. We show that hypoxia 
induces activation of AKT both in vitro and in vivo, and that hypoxic cells can be specifi-
cally targeted by pAKT inhibition. Targeting pAKT is thus a potential way to overcome 
therapy resistance induced by hypoxia and improve patient outcome. 
42 CHAPtER 3
introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
with 500.000 new diagnoses per year worldwide [1]. Recent research findings have 
resulted in a better understanding of the biologic features of HNSCC tumors, which 
has led to the development of new therapeutic agents targeting specific molecules 
important for tumor growth and cell survival. One of these new successful targeting 
agents is cetuximab, a monoclonal antibody against the Epidermal Growth Factor 
Receptor (EGFR), which improves survival in HNSCC patients treated with radiotherapy 
[2]. However, despite this success, a significant proportion of patients does not benefit 
from the addition of anti-EGFR treatment. In addition, most clinical trials find no cor-
relation between EGFR expression assessed by immunohistochemistry and response 
to treatment with EGFR inhibitors [3]. 
To improve patient outcome with these new intensified treatments, a large amount 
of research has been focused on identifying resistance mechanisms using different in 
vitro models [4-7]. However, it is uncertain to what extent these in vitro results can be 
translated towards the in vivo situation. A potential reason for the absence of a correla-
tion between EGFR expression and response to EGFR inhibition is the EGFR-independent 
activation of signaling pathways, including the phosphatidylinositol-3-kinase (PI3-K)/
protein kinase B (AKT) pathway, by other stimuli in the microenvironment [8]. The 
tumor microenvironment is complex and includes fluctuating oxygen and nutrient 
gradients, which are not present in standard 2D cell culture assays, but which can have 
a great impact on tumor behavior and treatment response. Hypoxia is an important 
microenvironmental parameter known to induce the transcription and activation of 
a wide variety of proteins and is an inherent negative factor for treatment outcome 
in solid tumors, including treatment outcome after radiotherapy [9-11]. Hence, it is 
of great importance to discover molecular targets that could be used to specifically 
kill hypoxic cells and consequently improve patient outcome. 
Therefore, the aim of this study was to find molecular targets in the EGFR-
pathway, which are induced by the microenvironment and thus not detected in 
standard in vitro assays. For this, we determined the in vitro and in vivo expression of 
proteins involved in the EGFR-signaling network in HNSCC lines both cultured as cell 
lines and grown as xenograft tumors. We investigated the tyrosine kinase receptors 
EGFR and human epidermal growth factor receptor 2 (HER2), and the activated form 
of kinases of the main signaling pathways downstream of EGFR: protein kinase B 
(AKT), extracellular signal-regulated kinase 1/2 (ERK1/2), and signal transducer and 
activator of transcription 3 (STAT3) [12]. Using this method, we were able to determine 
that pAKT, pERK1/2 and pSTAT3 were differentially expressed between cells in culture 
and in tumors, as an indication that these proteins were likely to be influenced by the 
tumor microenvironment. More importantly, we observed that AKT is activated by 
hypoxia both in vivo and in vitro and that the hypoxic cells are more sensitive to AKT 
inhibition. These data implicate that pAKT inhibition could be a promising way to 
specifically target hypoxic tumors in the clinic and improve outcome after a variety 
of treatments, including radiotherapy and EGFR inhibition.
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MatErial and MEthods
Cell lines
Six human head and neck squamous cell carcinoma cell lines (UT-SCC lines) were 
both cultured in vitro and grown as xenografts in nude mice. The characteristics of 
the cell lines are shown in Table 1. Cells were cultured in T75 culture flasks, under 
humidified conditions (37 ºC, 5% CO2), and passaged weekly or twice weekly in DMEM 
containing 2 mM L-glutamine, 1% nonessential amino acids, 20 mM Hepes, 10 units/
ml penicillin, 10 units/ml streptomycin, and 10% fetal bovine serum.
Hypoxic incubation and MK-2206 treatment 
To determine expression levels after hypoxia and/or AKT inhibition, UT-SCC5 and 
UT-SCC15 cells were treated overnight (16h) with 0 or 2 μM MK-2206 (Selleckchem, 
Houston, TX, USA) under standard normoxic conditions and thereafter incubated 
under normoxic conditions or under hypoxic conditions (0.5% O2, H35 hypoxystation, 
Don Whitley Scientific Ltd., West Yorkshire, UK) for 1h. 
To assess cell survival after hypoxia and/or AKT inhibition, UT-SCC5 and UT-SCC15 
cells were seeded in 96-well plates. After the cells were allowed to attach overnight 
under standard normoxic conditions, 0 or 2 μM MK-2206 was added and cells were 
incubated under normoxic conditions or under hypoxic conditions (0.5% O2) for 72h. 
Cell survival was determined 72h after normoxic or hypoxic incubation using a Cell-
Counting Kit-8 assay (CCK8, Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands).
Xenograft tumors
Animal experiments were performed using 6-8 week-old BALB/c nu/nu mice. Of all six 
carcinoma cell lines, 5x106 cells were injected subcutaneously into the flank. Tumor 
size was measured by the same technician twice a week. Tumors with a diameter of 
4 mm or larger were harvested or passaged. For passaging, the tumor was excised and 
cut into 1 mm3 tumor pieces. The tumor pieces were then subcutaneously implanted 
into the flank. In this study first, second, and third passage tumors were analyzed. 
One hour before tumor excision, animals were injected intraperitonally with 0.5 ml 
of saline containing 2 mg pimonidazole hydrochloride (1-[(2-hydroxy-3-piperidinyl) 
propyl]-2-nitroimidazole hydrochloride, Natural Pharmaceuticals International Inc., 
Research Triangle Park, NC, USA) to label hypoxic cells. After excision, tumors were 
immediately frozen in liquid nitrogen. The number of harvested tumors ranged from 
2 to 4 per cell line with a total of 19. 
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines. All experiments were approved by the Animal Experiments Committee of 
the Radboud University Nijmegen Medical Centre.   
Western blot analysis
To determine protein expression in vitro and in vivo, cultured cells or tumor sections 
were lysed, cell debris was removed by centrifugation and protein was quantitated 
using a standard Bradford absorbance assay. Proteins (25 μg per lane) were separated 
by SDS-PAGE and blotted onto PVDF membrane. Membranes were incubated with the 
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appropriate primary antibodies followed by incubation with HRP-conjugated anti-
bodies. Finally, proteins were detected with an ECL chemiluminescence system. Anti-
bodies against the following antigens were used: EGFR, pEGFR (Y1173), HER2, AKT, 
STAT3, and HRP-conjugated goat-anti-rabbit IgG, goat-anti-mouse IgG and donkey-anti-
goat IgG were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 
pHER2(Y1221/1222), pAKT(S473), pERK1/2(T202/Y204), ERK1/2, and pSTAT3(Y705) were 
purchased from Cell Signaling Technology (Beverly, MA, USA) and α-tubulin was 
obtained from Calbiochem (San Diego, CA, USA).
To obtain a quantitative measure for total protein expression, the integrated 
optical density (IOD) of the chemiluminescent signal was measured using ImageJ 
software (NIH, Bethesda, MD, USA). IOD values of all proteins were normalized to 
those of α-tubulin. 
Immunohistochemical staining, image acquisition and analysis of tumor sections
To determine localization of protein expression in vivo, frozen tumor sections (5 μm) 
were thawed, fixed in acetone (4 ºC) and rehydrated in PBS. Two consecutive tumor 
sections from each tumor were stained for pAKT or pimonidazole in combination with 
EGFR and vessels. EGFR and pAKT were stained with the same antibodies used for 
western blot analysis. The antibody against pimonidazole was a gift from J.A. Raleigh 
(University of North Carolina) and 9F1 supernatant, a rat monoclonal antibody against 
mouse endothelium, was a gift from the Department of Pathology, Radboud University 
Nijmegen Medical Centre. EGFR was detected by incubation with Cy3-conjugated 
donkey-anti-goat IgG (Jackson Immuno Research Laboratories Inc., West Grove, PA, 
USA), pAKT and pimonidazole by incubation with Alexa488-conjugated donkey-anti-
rabbit IgG (Molecular Probes, Leiden, The Netherlands), and 9F1 by incubation with 
Alexa647-conjugated chicken-anti-rat IgG (Molecular Probes). Stained sections were 
mounted in Fluorostab (ICN Pharmaceuticals, Inc, Zoetermeer, The Netherlands).
Stained tumor sections were scanned on a digital image processing system 
consisting of a 12-bit charge-couple device camera (Micromax, Roper Scientific Inc., 
Trenton, NJ, USA) on a fluorescence microscope (Axioskop, Zeiss Göttingen, Germany) 
table 1: Characteristics of Ut-SCC cell lines
cell line tnM* primary tumor location type of lesion grade
Ut-SCC5 t1N1M 0 tongue Primary 2
Ut-SCC8 t 2N0M0 Supraglottic larynx Primary 1
Ut-SCC15 t1N0M0 tongue Recurrence 1
Ut-SCC29 t2N0M0 Glottic larynx Primary 1
Ut-SCC38 t2N0M0 Glottic larynx Primary 2
Ut-SCC45 t3N1M0 Floor of mouth Primary 3
*tNM status of primary tumors according to the international Union against Cancer (1997).
Note: Grade: 1, well differentiated; 2, moderately differentiated; 3, poorly differentiated.
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and a computer-controlled motorized stepping stage, using IPLab software. Each sec-
tion was sequentially scanned three times at 100x magnification, yielding an image 
of hypoxia (pimonidazole) or pAKT-expression, an image of EGFR-expression and an 
image of the vasculature structures (9F1). One pseudo-colored composite image was 
reconstructed from the individual microscope images. Using this composite image, 
total tumor area was delineated and non-tumor tissue, necrotic area and staining 
artifacts were excluded from the analysis. Thereafter, thresholds for the fluorescence 
signals were interactively set at intensities where the steepest gradient occurred 
between background and foreground intensity levels, and grey value images were 
converted to binary images. Using ImageJ software (NIH, Bethesda, MD, USA), the 
fraction positive for pAKT or hypoxia was calculated by dividing the tumor area 
positive for the respective marker by the total tumor area. The overlap fraction of 
EGFR and pAKT was calculated by dividing the tumor area positive for both markers 
by the tumor area positive for EGFR. 
Statistics
Statistical analyses were performed using Prism 4.0c (GraphPad Software, Inc., LA 
Jolla, CA, USA). Correlations between parameters were assessed using the Spearman 
correlation test. The significance of differences in cell survival between different 
treatments was assessed using a Kruskal-Wallis test in combination with a Dunn’s 
multiple comparison test. P-values < 0.05 were considered to be significant. 
rEsults
Expression of activated kinases, but not of tyrosine kinase receptors, induced by tumor 
microenvironment 
Using western blot analyses, expression levels of various proteins involved in the 
EGFR-signaling network were assessed in 6 different HNSCC cell lines both grown in 
culture (in vitro) and grown as xenograft tumors (in vivo). As example, western blots for 
(p)EGFR and (p)AKT are shown in Figure 1.
The tyrosine kinase receptors EGFR and HER2 showed a wide variation of expres-
sion levels in both cells and tumors. Overexpression of these membrane receptors 
seems to be an intrinsic feature of the cell lines as for both EGFR and HER2 a strong 
correlation was found between in vitro and in vivo expression levels (rs=0.77, p=0.10 
and rs=0.93, p=0.02, respectively) (Figure 2A). Although there was only a trend towards 
a correlation between in vitro and in vivo EGFR expression (p=0.10), the correlation for 
the activated form pEGFR was significant (rs=0.89, p=0.03). This was not the case for 
pHER2 (rs=0.26, p=0.66), which showed different levels of expression in the tumors, 
but was invariably low in vitro. 
In contrast to the tyrosine kinase receptors, no in vitro-in vivo correlation was 
observed for the activated kinases pAKT, pERK1/2 or pSTAT3 (all rs<0.55 and p>0.30) 
(Figure 2B). The lack of correlation was predominantly due to the fact that there was 
a wide range of expression levels in vitro while in vivo the kinases were activated at 
relatively high levels in all tumor lines (Figure 1 and 2B). These results suggest that 
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stimuli in the tumor microenvironment activate the different cell signaling pathways 
and consequently lead to relatively high in vivo levels of pAKT, pERK1/2 and pSTAT3. 
pAKT expression present in hypoxic cells in vivo
A variety of stimuli within the tumor microenvironment can activate kinases like 
AKT, ERK1/2 and STAT3, including hypoxia. Therefore, EGFR, pAKT, and hypoxia were 
immunohistochemically stained in tumor sections to visualize their spatial relation-
ship and to find a possible explanation for the absence of a correlation between the 
in vitro and in vivo expression of pAKT. 
We observed that EGFR expression was predominantly present in tissue sur-
rounding blood vessels, whereas pAKT was mostly expressed further away from the 
vessels in hypoxic areas indicated by pimonidazole staining in the consecutive tumor 
section. Using quantitative image analysis, we observed that in average only 7.7% 
(range: 1.0-33.6%) of cells expressing EGFR also expressed pAKT. Thus, although cells 
were present that expressed both EGFR and pAKT, the overall overlap was relatively 
low. Moreover, we found that the fraction of the tumor positive for pimonidazole 
(hypoxic fraction) was significantly correlated with the fraction positive for pAKT 
(rs=0.51, p=0.04) (Figure 4). These results suggest that pAKT is activated by hypoxia in 
an EGFR-independent way in these tumors. 
a
b
figure 1: in vitro and in vivo expression of EGFR, pEGFR, pAKt and AKt in 6 HNSCC lines. Cell lines 
were both cultured as cell lines (in vitro) and grown as xenograft tumors (in vivo) and expression 
levels were determined with western blot. Expression of α-tubulin was used as loading control. a) in 
vitro expression of EGFR, pEGFR, pAKt and AKt. b) in vivo expression of EGFR, pEGFR, pAKt and 
AKt. Number of harvested tumors ranged from 2 to 4 per cell line.
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a b
figure 2: Correlation between in vitro and in vivo 
expression of EGFR/HER2 and pAKt/pStAt3/
pERK1/2 in 6 HNSCC lines. 
a) Correlation between in vitro and in vivo 
expression of EGFR and HER2.
b) Correlation between in vitro and in vivo 
expression of pAKt, pERK1/2 and pStAt3.
Expression was assessed by western blot analy-
sis and depicted in relative units. the integrated 
optical density (ioD) was measured and all 
values were normalized to those of α-tubulin by 
dividing the ioD value for that specific marker by 
the ioD value of α-tubulin. in vitro expression of 
Ut-SCC5 was set as standard. Error bars repre-
sent standard error of the mean and all axes are 
in log scale. Correlations between in vitro and 
in vivo expression were assessed using the 
Spearman correlation test.
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figure 3: Expression of EGFR, pAKt and hypoxia in vivo. Expression of EGFR and pAKt in relation to 
hypoxia was analyzed by immunohistochemical analysis in Ut-SCC xenograft tumors of 4 different 
lines. Left column: EGFR (red), pAKt (green), vessels (blue). Right column: EGFR (red), hypoxia 
(green), vessels (blue). Non-specific staining present in necrotic regions. Scale bars represent 500 
µm. Magnification: 100x.
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figure 4: Correlation between pAKt and hypoxia in vivo. Correlation between the pAKt and hypoxic 
fraction in tumors of 6 HNSCC lines was assessed with the Spearman correlation test. Symbols 
represent individual tumors of the different Ut-SCC lines. 
figure 5: Effect of hypoxia and MK-2206 on pAKt levels and cell survival in vitro. a) Expression of 
(p)AKt after treatment with MK-2206 under normoxic and hypoxic (1h, 0.5% o2) conditions in Ut-SCC5 
and Ut-SCC15. b) Cell survival after treatment with MK-2206 under normoxic and hypoxic (72h, 0.5% 
o2) conditions in Ut-SCC5 and Ut-SCC15. **: p<0.01 compared to control.
a
b
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pAKT is induced by hypoxia in vitro, and is important for cell survival under hypoxia 
To confirm that hypoxia itself is an activating factor for AKT in vivo, cells of two HNSCC 
lines were cultured under hypoxic conditions (0.5% O2). One hour after hypoxia, pAKT 
was indeed increased in both cell lines (Figure 5A). As pAKT plays an important role 
in cell survival, these results suggest that hypoxic cells could be specifically targeted 
by pAKT inhibition. To test the hypothesis that hypoxic cells are more sensitive to 
pAKT inhibition, both normoxic and hypoxic (0.5% O2) cells were treated with the 
specific pAKT inhibitor MK-2206 and cell survival was assessed. MK-2206 treatment 
decreased pAKT expression efficiently under normoxic and hypoxic conditions (Figure 
5A). In both HNSCC cell lines hypoxia itself did not cause a decrease in cell survival 
(Figure 5B). Under normoxic conditions, MK-2206 had a small, but non-significant, 
effect on cell survival. However, when hypoxic cells were treated with MK-2206 this 
resulted in a significant decrease in cell survival (p<0.01). These results indicate that 
activation of AKT by hypoxia is important for cell survival under hypoxic conditions 
and can be specifically targeted by MK-2206. 
discussion
In recent years, a variety of newly developed targeted anti-cancer therapies have 
successfully been combined with classic therapies, including the combination of EGFR 
inhibition and radiotherapy in HNSCC [2]. However, these new intensified combina-
tions also induce increased toxicity and (acquired) resistance [3,13]. The a priori selec-
tion of patients that will respond is thus paramount, and research has focused on the 
identification of resistance mechanisms using different in vitro models. However, the 
complex tumor microenvironment can also be a source of therapy resistance. Hypoxia 
can have a great impact on the behavior of a tumor cell and also on the response to 
treatment [14]. Therefore, it is important to determine which proteins are influenced 
by hypoxia, because these proteins could be potential targets to reduce therapy 
resistance to a variety of treatments, including radiotherapy and EGFR inhibition. 
In the current study, we found that the expression of EGFR and HER2 in vitro was 
correlated with the in vivo expression, which indicates that the expression of these 
tyrosine kinase receptors is largely an intrinsic feature of a tumor cell. The in vitro 
expression of activated EGFR (pEGFR) was also highly correlated with the in vivo 
expression, while the levels of pHER2 in vivo were clearly higher and varied more in 
the xenografts than in vitro. These observations suggest that activation of EGFR is 
possibly more genetically determined, e.g. by mutations present in the different 
tumor lines, while the activation of HER2 is more determined by factors in the tumor 
microenvironment that are not present in standard 2D cell culture. Also, in head and 
neck cancer patients a strong correlation between EGFR and pEGFR levels has been 
observed [15]. This correlation supports our observation that the extent of activated 
EGFR is predominantly influenced by EGFR overexpression and not by other stimuli 
in the microenvironment. 
In contrast to the tyrosine kinase receptors, no in vitro-in vivo correlation was 
observed for the activated kinases pAKT, pERK1/2 or pSTAT3, indicating that the 
expression of these activated kinases is influenced by factors in the tumor micro-
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environment. Here, we show that hypoxia is an activating stimulus for AKT in vivo. 
This hypoxia-induced increase in pAKT cannot be explained by hypoxia-induced acti-
vation of EGFR as is observed in different in vitro models [16,17]. EGFR expression was 
namely predominantly present in oxygenated areas and there was a relatively low 
overlap between EGFR and pAKT expression in vivo. Besides these observations in our 
preclinical models, mismatch in EGFR-pAKT expression and the presence of pAKT in 
hypoxic regions is also observed in HNSCC patient samples [8]. EGFR-independent 
upregulation of pAKT by hypoxia has also been observed in lung cancer cells, whereby 
activation of AKT was induced via the IGF1R/PI3K/AKT pathway [18]. Also oxidative 
stress, which can occur during reoxygenation, has been shown to activate AKT in 
HNSCC cells [19]. Hypoxia-induced, EGFR-independent, activation of AKT could thus be 
an important resistance mechanism in HNSCC patients treated with EGFR inhibition 
and radiotherapy. Although EGFR is the most commonly overexpressed tyrosine kinase 
receptor in head and neck cancer, also other receptors are overexpressed like HER2, 
HER3, and IL-6 receptor [20,21], which could possibly play a role in hypoxia-induced 
activation of AKT. However, we focused on our major finding that activation of AKT is 
a characteristic of hypoxic cells in HNSCC and therefore a potential target to specifically 
kill hypoxic cells. Extensive crosstalk between different growth factor receptors, such 
as EGFR and MET, has been reported [22]. These growth factor receptors activate 
similar pathways, which means that cells that overexpress multiple growth factor 
receptors can sustain survival signaling even if one of the receptors is blocked [23]. 
This is exemplified by the study of Erjala et al., which also used a panel of UT-SCC cell 
lines, that showed that EGFR or pEGFR levels were not correlated, but pHER2 and 
HER3 levels were correlated with sensitivity to EGFR inhibition [4]. Also downstream 
signaling molecules like pAKT en pERK1/2 were not correlated with sensitivity for 
EGFR inhibition. In our cell lines, we did also not observe that overexpression of pEGFR 
was consistently linked to overexpression of pSTAT3, pAKT or pERK1/2. Therefore, it is 
more important to determine activation of the common downstream pathway, which 
is responsible for cell survival, as this will be a more attractive target to overcome 
treatment resistance than targeting one specific growth factor receptor. In the HNSCC 
tumor lines studied, we indeed show that pAKT inhibition decreases cell survival in 
hypoxic cells, but not in normoxic cells. Hypoxic cells are resistant to a variety of 
treatment regimens, including radiotherapy [9], and as pAKT signaling is an important 
cell survival pathway [24], targeting of pAKT in hypoxic tumors could be a promising 
way to significantly improve patient outcome. Additionally, multiple animal studies 
have shown that MK-2206 also inhibits pAKT in vivo and reduces tumor growth [25-27]. 
Moreover, Knowles et al. showed that MK-2206 not only reduced primary tumor size in 
an orthotopic HNSCC model, but also inhibited HNSCC migration in vitro and reduced 
the number of lymph node metastases in vivo [25]. Although the effect of AKT inhibi-
tion on HNSCC migration could explain the reduced metastases formation in this 
study, it is also known that hypoxia can induce a metastatic phenotype [28]. Killing 
hypoxic cells via pAKT inhibition, as we show in this study, could thus potentially 
reduce not only tumor growth, but also the metastatic potential of the tumor. AKT is 
also a highly druggable target in the clinic since multiple specific AKT inhibitors, 
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including the inhibitor we used in our study, are already tested in phase I/II clinical 
trials and are generally well tolerated [29]. 
Although our data show that the microenvironment can induce the expression 
of activated kinases and that therefore expression levels in tumors do not correspond 
with cells in vitro, they do not explain why we see very little variation in total expression 
between the tumors. A possible reason for this is the technique we used to determine 
expression levels. Western blot analysis determines the total expression in all tumor 
cells together. However, using immunohistochemistry we observed that the level of 
expression of the different proteins varied widely between cells in the tumors under 
the influence of e.g. hypoxia and this spatial information is totally lost by western 
blot analysis. Thus, possibly by determining the expression in all cells together, these 
differences between individual cells level out and result in an ‘average’ level of 
expression, which differs relatively little between tumors as we observed in this study. 
One of the main advantages of immunohistochemistry is the possibility to analyze 
specifically tumor cells. Although we used tumors that had a large fraction of viable 
tumor cells and a very low amount of stromal cells, we cannot exclude the possibility 
that the presence of small amounts of normal cells affected our results. 
conclusion
Our data indicate that the expression of (p)EGFR and HER2 is largely an intrinsic 
feature of a tumor cell, while the in vivo expression of activated kinases of important 
cell signaling pathways can be substantially affected by the tumor microenvironment. 
Moreover, we show that AKT is activated by hypoxia both in vivo and in vitro and that 
hypoxic cells are more sensitive to AKT inhibition. As hypoxic tumors are resistant 
to a variety of treatment regimens, AKT might thus be a promising druggable target 
in hypoxic tumors. Further research is warranted to confirm our hypothesis that 
anti-cancer treatment can be improved by specifically targeting hypoxic cells with 
pAKT inhibition and in which way this finding can be optimally used to improve 
patient outcome in the future. 
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abstract 
background and purpose: EGFR-inhibitor Cetuximab (C225) improves the efficacy of 
radiotherapy in only a subgroup of HNSCC patients. Identification of predictive tumor 
characteristics is essential to improve patient selection. 
Material and Methods: Response to C225 and/or radiotherapy was assessed with tumor 
growth delay assays in 4 HNSCC xenograft models with varying EGFR-expression 
levels. Hypoxia and proliferation was quantified with immunohistochemistry and 
expression of proteins involved in C225-resistance with western blot.
results: EGFR-expression did not predict response to C225 and/or radiotherapy. 
Reduction of hypoxia by C225 was only observed in SCCNij202, which was highly 
sensitive to C225. Proliferation changes correlated with response to C225 and C225 
combined with radiotherapy, as proliferation decreased after C225 treatment in 
C225-sensitive SCCNij202 and after combined treatment in SCCNij185, which showed 
a synergistic effect to combined C225-radiotherapy. Furthermore, C225-resistant 
SCCNij153 tumors expressed high levels of (activated) HER3 and MET. 
conclusions: EGFR-expression is needed for C225-response, but is not sufficient to 
predict response to C225 with or without radiotherapy. However, basal expression of 
additional growth factor receptors and effects on proliferation, but not hypoxia, cor-
related with response to combined C225-radiotherapy treatment and are potential 
clinically relevant predictive biomarkers.
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introduction
Ionizing radiation activates the epidermal growth factor receptor (EGFR) and its 
downstream signaling pathways, including the phospatidylinositol-3-kinase (PI3-K)/
protein kinase B (AKT) pathway [1]. The PI3-K/AKT pathway promotes DNA repair, cell 
growth, and proliferation and is, therefore, associated with major radioresistance 
mechanisms [2]. Accordingly, patients with EGFR-overexpressing head and neck 
squamous cell carcinomas (HNSCC) have a worse prognosis after radiotherapy [3]. 
Given this important role for EGFR in HNSCC, strategies to block EGFR signaling using 
monoclonal antibodies or tyrosine kinase inhibitors have been developed. Cetuximab 
(C225), a chimeric monoclonal antibody against the extracellular part of EGFR, is a 
successful example of these new molecular targeted therapies, since a phase III study of 
Bonner et al. [4] has shown that addition of C225 treatment to radiotherapy improves 
clinical outcome in HNSCC patients. However, despite these successes, a significant 
proportion of patients does not benefit from the addition of this targeted therapy. In 
addition, the expression level of EGFR assessed by immunohistochemistry does not 
correlate with clinical response [5]. To allow a better selection of patients, biological 
tumor characteristics that predict the response to these intensified treatments need 
to be identified [6]. 
In search of these predictive biological tumor characteristics, we treated 4 human 
head and neck xenograft lines (SCCNij) with radiotherapy, C225, and concurrent C225 
and radiotherapy. These 4 tumor models were selected from a panel of primary xeno-
grafts to represent the diversity of EGFR expression patterns observed in the clinic. 
Effects on tumor growth delay were correlated with effects on the important radiation 
resistance mechanisms hypoxia and proliferation. Moreover, the expression levels of 
various proteins of the EGFR-signaling network shown to be involved in resistance to 
EGFR-inhibitors [5] were determined in the different xenograft models.
MatErial and MEthods
Xenograft tumor models and treatment
Tumor models SCCNij202, SCCNij167 and SCCNij153 were derived from human larynx 
carcinomas and SCCNij185 from a human hypopharynx carcinoma. Viable 1 mm3 
tumor pieces were implanted subcutaneously in 6-10 week-old athymic BALB/c nu/nu 
mice and passaged at a diameter of 1 cm. Tumors with a mean diameter of 5-8 mm 
transplanted at the hind leg were used in the experiments. Animals were treated 
with 1 mg i.p. C225 (ErbituxTM, Merck, Darmstadt, Germany), 10 or 20 Gy single dose 
radiotherapy (16 MV photon beam, dose rate 2 Gy/min with 2 cm Perspex build-up 
material), or a combination of C225 and radiotherapy (C225 was given 24h before 
radiotherapy). 
For effects on tumor growth delay, tumor diameters were measured twice a week 
in three perpendicular directions and tumor volumes were determined by the formula: 
V= (a*b*c*π)/6. Endpoint was reached when the tumor volume tripled compared to 
the start volume. Maximal follow up was 120 days. Number of animals per group 
varied from 7 to 14.  
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For effects on proliferation and hypoxia, tumors were harvested 1 or 4 days after 10 
Gy radiotherapy and/or 1, 2 or 5 days after C225. One hour before euthanization, 
animals were injected with 80 mg/kg of the hypoxia marker pimonidazole (Natural 
Pharmaceuticals International Inc., Research Triangle Park, NC, USA) and 15 minutes 
before euthanization with 50 mg/kg of the proliferation marker bromodeoxyuridine 
(BrdUrd) (Sigma, St Louis, MO, USA). Tumors were snap frozen in liquid nitrogen 
immediately after euthanizing the animals. Number of animals per group varied 
from 4 to 6.
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines. All experiments were approved by the Animal Experiments Committee of 
the Radboud University Nijmegen Medical Centre.
Multiplex ligation-dependent probe amplification (MLPA)
To identify EGFR copy number changes and EGFR variant III (EGFRvIII) in the tumor 
models, MLPA analysis was performed as described by Jeuken et al [7]. 
K-RAS mutation analysis
To detect mutations in codon 12 and 13 of K-RAS, mutation analysis was performed 
as described by Knijn et al [8]. 
Immunohistochemical staining, image acquisition and analysis of tumor sections
Frozen tumor sections (5 μm) were stained for BrdUrd, pimonidazole, vessels and all 
nuclei or for EGFR, pimonidazole and vessels. The antibody against pimonidazole 
was a gift from J.A. Raleigh (University of North Carolina). 9F1, a rat monoclonal 
antibody against mouse endothelium, was a gift from the Department of Pathology, 
Radboud University Nijmegen Medical Centre. The antibodies against EGFR and 
BrdUrd were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and 
Genetex (Irvine, CA, USA), respectively. Primary antibodies were detected by appropriate 
Cy3-conjugated (Jackson Immuno Research Laboratories Inc., West Grove, PA, USA) 
Alexa488-conjugated or Alexa647-conjugated (Molecular Probes, Leiden, The Nether-
lands) secondary antibodies. All nuclei were stained with Hoechst 33342 (Sigma). 
Stained tumor sections were scanned with a fluorescence microscope (Axioskop, 
Zeiss, Göttingen, Germany). Each section was sequentially scanned at 100x magnifica-
tion to yield images of the different fluorescent signals. Thresholds for the fluorescence 
signals were interactively set above the background and the grey value images were 
converted to binary images. Using ImageJ software (NIH, Bethesda, MD, USA), the hypoxic 
fraction (HF) was calculated by dividing the tumor area positive for pimonidazole by 
the total tumor area and the BrdUrd labeling index (LI) by dividing the nuclear area 
positive for BrdUrd by the total nuclear area of the tumor. Necrotic areas and staining 
artifacts were excluded from the total (nuclear) tumor area and further analyses. 
Western blot analysis
Tumor sections were lysed in NP-40 lysis buffer and protein was quantitated using a 
standard Bradford absorbance assay. Proteins were separated by SDS-PAGE and blotted 
onto PVDF membranes. Membranes were incubated with the appropriate primary 
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antibodies followed by incubation with HRP-conjugated antibodies. Finally, proteins 
were detected with an ECL chemiluminescence system. Antibodies against the fol-
lowing antigens were used: EGFR, pEGFR(Y1173), HER2, HER3, E-cadherin, vimentin, 
AKT, STAT3 and HRP-conjugated goat-anti-rabbit IgG, goat-anti-mouse IgG and donkey- 
anti-goat IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
pHER2(Y1221/1222), pHER3(Y1289), MET, pMET(Y1234/1235), B-RAF, p-B-RAF(S445), 
pAKT(S473), ERK1/2, pERK1/2(T202/Y204), pSTAT3(Y705) were purchased from Cell 
Signaling Technology (Beverly, MA, USA) and α-tubulin was obtained from Calbiochem 
(San Diego, CA, USA).
Statistics
Changes in HF and BrdUrd LI were tested for significance using the Mann-Whitney 
test. Tumor growth delay data was analyzed using Kaplan-Meier survival curves and 
Cox proportional-hazards regression. To determine synergism between C225 and 
radiotherapy, the relative excess risk due to interaction (RERI) was calculated as 
described by Andersson et al [9] RERI values above 0 indicate biological interaction 
between treatments. Prism 4.0c (GraphPad Software, Inc., LA Jolla, CA, USA) and the 
statistical package R (R version 2.14.1, The R Development Core Team) with library 
“survival” and “eha” were used and p-values <0.05 were considered significant.
rEsults
Differential EGFR expression in 4 HNSCC xenograft models
The 4 human HNSCC xenograft models were selected on the basis of their EGFR 
expression levels to represent the range of phenotypes found in HNSCC patients. 
SCCNij202 showed high levels of EGFR, SCCNij153 and SCCNij185 showed inter-
mediate levels, while EGFR expression was hardly detectable in SCCNij167 (Figure 1). 
These expression levels correspond to the copy number of EGFR as assessed by MLPA-
analysis; SCCNij202 had a gene amplification, SCCNij153 and SCCNij185 a (partial) 
gain, and SCCNij167 a hemizygous loss of the EGFR gene. The mutant form EGFRVIII 
or K-RAS mutations in codon 12 and 13 were not detectable in any of the models. 
Using immunohistochemistry, EGFR expression was predominantly observed at 
the membranes of cells near blood vessels, which were mostly non-hypoxic, based on 
pimonidazole staining (Figure 1B). However, some colocalization of EGFR-expression 
and hypoxia was observed (Figure 1B, yellow). 
Sensitivity for Cetuximab (C225) and radiotherapy correlates partly with EGFR-expression 
Sensitivity for C225 and/or radiotherapy was assessed by growth delay assays, whereby 
the endpoint was a tripling of the tumor volume compared to the start volume (Figure 
2). High EGFR-expressing SCCNij202 tumors were highly sensitive to EGFR inhibition 
by C225 (p<0.001), but were relatively radioresistant as even 20 Gy induced only a 
small, albeit significant delay in tumor growth (p<0.001) (Figure 2A). Combining 
C225 with either 10 Gy or 20 Gy did also result in a large significant growth delay 
(both p<0.001), which was comparable to the effect of C225 alone. Although the 
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figure 1: EGFR expression in 4 HNSCC xenograft models. 
a) Expression of EGFR and pEGFR assessed with western blot analysis in 4 SCCNij lines.  
two tumors per line were analyzed. 
b) Expression of EGFR in relation to hypoxia and vessels assessed with immunohistochemical 
staining in 4 SCCNij lines. EGFR (red), hypoxia (green), vessels (blue). Scale bars represent 200 
µm. Magnification: 200x.
a
b
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combined treatment induced a larger growth delay than radiotherapy alone no syner-
gism was observed, as the effect on growth delay was comparable with the effect of C225 
alone. SCCNij167 did not respond to C225, while radiotherapy induced a significant 
dose-dependent growth delay (p<0.001) (Figure 2B). Again no interaction between 
the treatments was observed. The absence of response to C225 is in accordance with 
the low EGFR-expression and hemizygous loss of the EGFR gene in this latter tumor 
model. 
SSCNij185 (Figure 2D) and SCCNij153 (Figure 2C) tumors, both with intermediate 
EGFR expression, were insensitive to C225 alone, but showed opposing effects to 
concurrent treatment: there was no synergistic effect of C225 with radiotherapy in 
SCCNij153, while a synergistic effect was observed in the SCCNij185 tumors when 
C225 was combined with radiotherapy (p=0.001). To quantify this interaction, we cal-
culated a RERI (relative excess risk due to interaction) of 12.7, confirming a significant 
synergistic effect of C225 and radiotherapy in this tumor model. 
Thus, EGFR-expression is needed for C225-response, but is not sufficient to predict 
response to C225 alone or combined with radiotherapy. EGFR expression was also not 
correlated with radiosensitivity as low EGFR-expressing SCCNij167 tumors showed 
an intermediate radioresponse in the growth delay experiments.
Changes in proliferation, but not hypoxia, correlate with response to C225 and  
C225 combined with radiotherapy
Preclinical studies suggest that EGFR-inhibition enhances radiosensitivity by reduction 
of hypoxia and tumor cell proliferation rate [10]. In our study, significant changes in 
both the hypoxic fraction (HF) and BrdUrd labeling index (LI) after C225 alone were 
only observed in SCCNij202 (Figure 3), which is in accordance with the large effect on 
tumor growth by C225 in this tumor model. Hypoxia was significantly reduced at all 
time points (p<0.04), while proliferation was only reduced at 2 days after C225 treat-
ment (p=0.02) (Figure 3A). Combined C225 and radiotherapy also induced a significant 
reduction in hypoxia at 4 days after treatment (p=0.02), while a trend towards reduc-
tion of proliferation was observed at both time points (p=0.056). In SCCNij185, where 
there was an interaction between C225 and radiotherapy, no effects on hypoxia were 
observed, while proliferation was significantly reduced at 4 days after combined 
treatment (p=0.02) (Figure 3D). At time of radiation, 1 day after C225, proliferation was 
not reduced in SCCNij185 tumors. In contrast, proliferation was significantly increased 
at 1 day after combined treatment in SCCNij153 (p=0.01) (Figure 3C), in which no inter-
action between C225 and radiotherapy was observed. An overview of the effects of the 
different treatments on growth delay and on hypoxia and proliferation is shown in 
Table 1. Overall, changes in proliferation, but not in hypoxia, correlated with response 
to C225 alone and to C225 combined with radiotherapy. The basal level of hypoxia 
correlated with radiosensitivity as radioresistant SCCNij202 tumors had the highest 
HF and radiosensitive SCCNij153 and SCCNij185 had the lowest HF (Figure 3). 
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figure 2: Effects of EGFR-inhibition and/or radiotherapy on tumor growth delay. Kaplan-Meier sur-
vival curves showing the effect of C225 and/or radiotherapy on the tumor growth of 4 SCCNij lines: 
a) SCCNij202, b) SCCNij167, c) SCCNij153, d) SCCNij185. Events were scored when the tumor volume 
tripled compared to the start volume and % tumor response represents the percentage of tumors 
that did not reach the event. tumors were treated with C225 (1 mg i.p.), 10 or 20 Gy radiotherapy, or 
concurrent treatment of C225 and radiotherapy. C225 was given 24h before radiotherapy. Number of 
animals per group varied from 7 to 14.
a
d
c
b
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afigure 3: Effects of EGFR-inhibition and/or radiotherapy on hypoxia and proliferation. Effects of C225 
and/or radiotherapy on the hypoxic fraction (HF) and BrdUrd labeling index (Li) of 4 SCCNij lines: 
a) SCCNij202, b) SCCNij167, c) SCCNij153, d) SCCNij185. tumors were treated with C225 (1 mg i.p.) 
and/or 10 Gy radiotherapy and harvested 1 or 4 days after radiotherapy and/or 1, 2 or 5 days after C225. 
tumors harvested 2 or 5 days after C225 correspond with tumors harvested 1 or 4 days after com-
bined C225-radiotherapy, respectively. Differences between treated tumors and controls were tested 
for significance using Mann-Whitney tests, *: p<0.05, **: p<0.01. Error bars represent SEM. Number 
of animals per group varied from 4 to 6.
c
b
d
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Expression of tyrosine kinase receptors associated with C225-resistance
To further investigate resistance mechanisms, we studied expression of receptor tyros-
ine kinases, kinases downstream of EGFR, and markers for epithelial-mesenchymal 
transition (EMT). Next to EGFR, additional tyrosine kinase receptors were present in 
all tumor lines (Figure 4A), but C225-resistant SCCNij153 tumors had relatively the 
highest levels of the (activated) tyrosine kinase receptors (p)HER3 and (p)MET. Expres-
sion of the activated kinases pAKT, p-B-RAF, pERK1/2 and pSTAT3 was relatively 
abundant in all tumor lines (Figure 4B). Expression of pAKT was lowest and p-B-RAF 
and pSTAT3 expression highest in C225-resistant SCCNij153 tumors. Also in C225- 
sensitive SCCNij202 tumors pSTAT3 expression was relatively high compared to the 
other models. However, differences were small and no correlation was observed with 
response to C225 and/or radiotherapy. EMT characteristics could also not explain dif-
ferences in treatment sensitivity, as expression of vimentin was present in both C225- 
sensitive, radioresistant SCCNij202 as in C225-resistant, radiosensitive SCCNij153 
tumors (Figure 4C). Thus, only overexpression of additional growth factor receptors 
were involved in C225-resistance in the tumor models investigated.
discussion
We investigated the response to EGFR-inhibition and/or radiotherapy in 4 HNSCC 
xenograft models with differing EGFR-expression levels, which represent the varia-
tion observed in the clinic. The tumor models showed a diverse response to C225 
and/or radiotherapy, again representing the clinical situation. High EGFR-expressing 
SCCNij202 tumors were highly sensitive to C225, but radioresistant, whereas SCCNij167 
table 1: overview of treatment response and significant changes in hypoxia and proliferation after 
treatment with C225 and/or radiotherapy
Model response to treatment changes in hypoxia changes in proliferation
SCCNij202 Sensitive to C225
Radioresistant
No synergism C225+Rt
Decrease in hypoxia by C225
No effect of Rt
Decrease in hypoxia by  
C225+Rt
Decrease in proliferation by C225
No effect of Rt
trend towards decreased  
proliferation by C225+Rt
SCCNij167 Resistant to C225
intermediate radioresistant 
No synergism C225+Rt
Decrease in hypoxia by C225
No effect of Rt
No effect of C225+Rt
No effect of C225
No effect of Rt
No effect of C225+Rt
SCCNij153 Resistant to C225
Radiosensitive
No synergism C225+Rt
No effect of C225
No effect of Rt
No effect of C225+Rt
No effect of C225
increase in proliferation by Rt
increase in proliferation by 
C225+Rt
SCCNij185 Resistant to C225
Radiosensitive
Synergism C225+Rt 
No effect of C225
No effect of Rt
No effect of C225+Rt
No effect of C225
No effect of Rt
Decrease in proliferation by 
C225+Rt
Rt: radiotherapy, C225: Cetuximab
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figure 4: Expression of tyrosine kinase receptors, activated kinases and EMt markers. a) Expression 
of tyrosine kinase receptors (p)HER2, (p)HER3 and (p)MEt. b) Expression of kinases (p)AKt, (p-)B-Raf, 
(p)ERK1/2 and (p)StAt3. c) Expression of EMt markers E-cadherin and vimentin. Expression levels 
were determined with western blot analysis in 4 SCCNij lines. two tumors per line were analyzed.
a
b
c
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tumors with low EGFR were C225-resistant, but more sensitive to radiotherapy. The 
low expression level of EGFR in SCCNij167 is associated with a lack of response to C225 
in this model. In contrast EGFR is amplified in SCCNij202, constituting oncogene 
addiction as inhibition of EGFR alone even cured tumors in this model. On the other 
hand, high-EGFR expressing SCCNij153 tumors did not show any growth delay upon 
C225 treatment. This difference in response between high EGFR-expressing tumors 
is also seen in the clinic, where EGFR copy number, but not EGFR expression assessed 
by immunohistochemistry, has been found to be predictive for response to EGFR-
inhibition [5]. Surprisingly, SCCNij185, which has a lower expression of EGFR than 
SCCNij153, shows a synergistic response when C225 is combined with radiotherapy, 
possibly representing the responding patients in the clinic [4]. 
EGFR-expression correlates with poor survival after radiotherapy in head and neck 
cancer patients [3]. We did not find a similar correlation between radiosensitivity and 
EGFR expression, which is probably due to the number of tumor models investigated. 
The observed variation in response was also not due to the presence of EGFRvIII 
or activating K-RAS mutations, which have been implicated in resistance to both EGFR- 
inhibition and radiation [11-13]. Both these genetic changes were not detected in the 
tumor models investigated in this study. Also, in contrast to others, EMT characteristics 
did not correlate with response to EGFR-inhibition [14,15].
The amount of hypoxia in our models was a good predictor for radiosensitivity, which 
has already been found in preclinical and clinical studies [16-21]. However, changes 
in hypoxia did not correlate with response to radiotherapy, C225 or both. Changes in 
proliferation did correlate with response to C225 and to C225 combined with radio-
therapy, as proliferation was decreased after C225 treatment in C225-sensitive SCC-
Nij202 tumors and after combined C225-radiotherapy in SCCNij185 tumors, which 
showed a synergistic effect when C225 was combined with radiotherapy. These results 
implicate that changes in proliferation after EGFR-inhibition and radiotherapy could 
be used to predict response in an early phase of treatment. Imaging proliferation by 
3’-deoxy-3’-18F-fluorothymidine (18F-FLT) has already been shown to detect prolifera-
tion changes after (chemo-)radiotherapy and EGFR-inhibition [22-24] and could be an 
attractive way to asses early treatment response in the clinic. Moreover, the reduction 
of proliferation after combined treatment in SCCNij185 suggests that C225 radio-
sensitizes these tumors by reducing their ability to repopulate after radiotherapy. 
However, we did not use a fractionated irradiation scheme and can, therefore, not 
assess to what extent a decrease in repopulation by C225 contributed to the increase 
in tumor response to radiotherapy observed in this model. Nonetheless, our data are 
in agreement with a study by Krause et al. [10] that showed that decreased repopula-
tion by C225 contributes to improved local control after fractionated radiotherapy in 
a HNSCC xenograft model. 
Interestingly, proliferation significantly increased after combined treatment in 
SCCNij153, where no interaction was observed between these treatments. This is in line 
with data from Gurtner et al [25], who established an increase in pERK1/2 expression, 
a regulator of proliferation, in a C225-resistant xenograft model after combined treat-
ment. This increased tumor cell proliferation rate might constitute a compensatory 
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mechanism triggered by radiotherapy that cannot be blocked by EGFR- inhibition in 
this tumor model. 
Changes in proliferation were thus predictive for response to C225, either alone or 
combined with radiotherapy. However, the described experiments were performed 
with single dose radiotherapy and further research is warranted to determine whether 
proliferation can be used to assess early treatment response in a fractionated setting 
in the clinic.
We also investigated the expression of multiple proteins implicated in resistance to 
C225 and radiotherapy. C225-resistant SCCNij153 had relatively high levels of (p)HER3 
and (p)MET, two receptor tyrosine kinases that have been implicated in C225-resistance 
[26,27]. There is extensive crosstalk between these receptors and they activate down-
stream signaling pathways important for cell survival similar to pathways activated 
by EGFR, including the PI3K-AKT and RAS/RAF pathways [28]. Due to this overlap in 
signaling networks, cells overexpressing multiple growth factor receptors can sustain 
survival signaling when one of the receptors is blocked. This bypass resistance mech-
anism is supported by the observations that combining EGFR-inhibition with a HER3- 
or MET-inhibitor overcomes resistance to EGFR-inhibition [27,29].
Either activation via alternate tyrosine kinase receptors, or constitutive activation 
of downstream signaling pathways could represent another resistance mechanism. 
The expression of pAKT, pERK1/2, p-B-RAF, and pSTAT3 was relatively abundant in all 
tumors without any relation with sensitivity to C225 and/or radiotherapy. Expression 
of pAKT, an important activator of radiation resistance mechanisms [2], was even 
lowest in C225-resistant SCCNij153 tumors and highest in SCCNij185 tumors, which 
showed similar growth delay after radiotherapy. The activation of B-RAF and STAT3, 
both implicated in C225-resistance [30,31], were indeed highest in C225-resistant 
SCCNij153 tumors. However, the differences with the other models were small, and 
activated STAT3, pSTAT3, was also relative high in C225-sensitive SCCNij202 tumors. 
In contrast to other studies [30,32], our data indicate that basal expression levels of 
these kinases were not predictive for response to C225. This difference can be due to 
the use of in vitro models in these studies as data of our own lab shows that in vivo 
expression of these kinases can be substantially affected by the tumor microenviron-
ment and consequently does not necessarily correlate with in vitro expression [33]. 
In conclusion, we studied 4 HNSCC xenograft models that represent the variation in 
biological characteristics and consequently treatment response observed in the 
clinic. EGFR-expression is needed for C225-response, but is not sufficient to predict 
response to C225 with or without radiotherapy. Effects on tumor cell proliferation 
correlated with response to C225, either alone or combined with radiotherapy. 
Importantly, the C225 resistant model had relative high basal expression of HER3 
and MET. Further research is warranted to confirm that overexpression of HER3 and 
MET is involved in resistance to EGFR-inhibition combined with radiotherapy and 
whether early changes in proliferation could be used to assess early treatment 
response. Such knowledge will be instrumental for the optimization and customiza-
tion of targeted therapies in combination with radiotherapy.
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abstract
Epidermal Growth Factor Receptor (EGFR) inhibition using cetuximab improves the 
efficacy of radiotherapy in only a subgroup of head and neck squamous cell carcinoma 
(HNSCC) patients. Therefore, better understanding of tumor characteristics that affect 
treatment is necessary to improve patient selection. Here, we investigated the effect 
of cetuximab on repair of radiation-induced DNA damage in a HNSCC xenograft 
model, which shows a synergistic effect to cetuximab and radiotherapy (SCCNij185), 
and a HNSCC model, which shows no additive effect of cetuximab to radiotherapy 
(SCCNij153).
In both tumor models, clear increases were seen in the number of 53BP1 and 
Rad51 foci after radiation. 53BP1 foci were present at comparable levels in hypoxic 
and normoxic tumor areas, while the number of Rad51 foci was significantly higher in 
normoxic areas compared to hypoxic areas (p<0.05). In both SCCNij185 and SCCNij153 
an increased number of 53BP1 foci was observed in tumors treated with cetuximab 
and radiotherapy compared to radiotherapy alone. In SCCNij185 this increase was 
statistically significant in normoxic tumor areas (p=0.04) and in SCCNij153 in both 
hypoxic and normoxic areas (p=0.007 and p=0.02, respectively). The number of Rad51 
foci was not significantly different when cetuximab was added to radiotherapy 
compared to radiotherapy alone. Levels of pEGFR and pERK1/2 were decreased when 
cetuximab was added to radiotherapy in SCCNij185, but not in SCCNij153. Apoptosis 
was also only increased in SCCNij185 tumors at 4 days after cetuximab-radiotherapy 
treatment (p<0.01). 
In conclusion, cetuximab inhibited DNA repair in both HNSCC models, but this 
effect was not predictive for the radiosensitizing effect of cetuximab in vivo. This lack 
of correlation may be related to differential effects of cetuximab and radiotherapy on 
ERK1/2 signaling and a decreased induction of apoptosis by cetuximab and radio-
therapy in the resistant model.
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introduction
The Epidermal Growth Factor Receptor (EGFR) is often overexpressed in head and 
neck squamous cell carcinomas (HNSCC) and is correlated with a poor prognosis 
after radiotherapy [1]. Accordingly, Bonner et al. [2] have shown that EGFR-inhibition 
by cetuximab, a chimeric monoclonal antibody against the extracellular part of 
EGFR, improves the outcome after radiotherapy in HNSCC patients. However, a large 
proportion of patients does not benefit from the addition of EGFR-inhibition, while 
this combination is associated with high rates of grade ≥ 3 oral mucositis and skin 
dermatitis [3-5]. Hence, there is a great need for the identification of tumor charac-
teristics that could predict response to this combination treatment. Multiple studies 
have already correlated various characteristics to response to EGFR-inhibition. EGFR 
expression assessed by immunohistochemistry does not correlate with clinical response, 
although EGFR copy number does seem to be predictive for response to EGFR-inhibition 
[6]. Also markers of epithelial-mesenchymal transition (EMT) have been implicated in 
resistance to EGFR-inhibition [7,8]. Mutations in the kinase domain of EGFR and K-RAS 
mutations are already used in the clinic to select patients for EGFR-inhibition in lung 
and colorectal cancer, respectively [9-11]. However, both mutations in K-RAS and EGFR 
are rare in HNSCC and consequently are not useful predictive biomarkers for this 
patient category [12,13]. Moreover, most studies address the efficacy of EGFR-inhibition 
itself, while this does not necessarily reflect the efficacy of EGFR-inhibition to radio-
sensitize the tumor and consequently improve outcome after radiotherapy.  
Increasing the knowledge about the exact mechanism by which EGFR-inhibition 
increases radiosensitivity will identify characteristics that could be predictive for 
response to the combination of cetuximab and radiotherapy. One of the proposed 
mechanisms of action is inhibition of repair of radiation-induced DNA damage by 
EGFR-inhibition, resulting in increased cell death [14,15]. It has been shown that 
ionizing radiation activates repair of DNA double strand breaks (DSBs) via EGFR-
mediated activation of both the RAS/RAF/ERK and the PI3-K/AKT pathway [16-20]. 
Moreover, radiation induces the translocation of EGFR to the nucleus, where it inter-
acts with DNA-PKcs and stimulates repair of DNA DSBs [21,22]. DNA repair is inhibited 
when the kinase activity or nuclear translocation of EGFR is blocked by cetuximab 
and this results in decreased survival after radiation [17,21,22]. DNA DSBs can be 
repaired via two main pathways: non-homologous end joining (NHEJ) and homologous 
recombination (HR). NHEJ is responsible for the repair of most DNA DSBs as it is active 
in all phases of the cell cycle, while HR occurs only during the S- and G2-phase of the 
cell cycle [23]. Inhibition of EGFR has been show to inhibit both NHEJ as well as HR 
in vitro [17,24-26]. 
Although there is sufficient evidence that EGFR-inhibition attenuates repair of 
radiation-induced DNA damage, these studies have been performed in in vitro models 
and it still has to be determined whether repair of DNA DSBs is also inhibited by 
EGFR-inhibition in vivo. Important tumor microenvironmental factors like hypoxia 
are not present in standard 2D cell culture assays, but can have a great impact on 
biological processes like DNA repair. Therefore, it is essential to determine how 
microenvironmental features influence the effect of EGFR-inhibition on repair of 
DNA DSBs in vivo. Hypoxia affects DNA damage directly as oxygen is required to fixate 
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radiation-induced DNA damage, but also indirectly by e.g. reducing proliferation and 
inducing changes in gene expression of DNA repair enzymes [27]. Chronic hypoxia 
has been shown to decrease the expression of proteins involved in HR, including 
Rad51, thereby decreasing HR activity in these cells [28,29]. 
We investigated the effect of cetuximab on repair of radiation-induced DNA 
damage in two HNSCC xenograft models, which have been shown to have different 
responses to treatment with radiation and cetuximab in tumor growth delay assays 
[30]. SCCNij185 shows a clear synergism between cetuximab and radiotherapy, while 
SCCNij153 shows no additional effect when cetuximab is added to irradiation. As EGFR-
inhibition has been implicated in regulating NHEJ as well as HR, we quantified the 
number of 53BP1 foci as a measure of overall DNA damage repair (NHEJ and HR) and 
the number of Rad51 foci as a measure of HR activity [23]. Hypoxic and normoxic 
tumor areas were analyzed separately to determine the interaction between DNA 
repair, hypoxia and EGFR-inhibition. 
MatErial and MEthods
Xenograft tumor models and treatment
Tumor model SCCNij153 was derived from a human larynx carcinoma and SCCNij185 
from a human hypopharynx carcinoma. Viable 1 mm3 tumor pieces were implanted 
subcutaneously in 6-10 week-old athymic BALB/c nu/nu mice and passaged at a diameter 
of 1 cm. Tumors with a mean diameter of 5-8 mm transplanted at the hind leg were 
used in the experiments. Animals were treated with 10 Gy single dose radiotherapy 
(320 KV, dose rate 3.8 Gy/min, X-RAD, RPS Services Limited, Surrey, UK), with 1 mg 
i.p. cetuximab (C225, ErbituxTM, Merck, Darmstadt, Germany) or with 10 Gy radio-
therapy 24h after cetuximab. Tumors were harvested 1 and 4 days after radiotherapy, 
or 2 and 5 days after cetuximab (corresponds to 1 and 4 days after radiotherapy in 
combined cetuximab-radiotherapy group). Each treatment group consisted of 5-7 mice. 
One hour before euthanization, animals were injected with 80 mg/kg of the hypoxia 
marker pimonidazole hydrochloride (1-[(2-hydroxy-3-piperidinyl) propyl]-2-nitroimi-
dazole hydrochloride, Natural Pharmaceuticals International Inc., Research Triangle 
Park, NC, USA). Tumors were snap frozen in liquid nitrogen immediately after eutha-
nizing the animals. 
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines. All experiments were approved by the Animal Experiments Committee of 
the Radboud University Nijmegen Medical Centre.
Immunohistochemical staining 
For quantification of DNA repair frozen tumor sections (5 μm) were stained for 53BP1 
or Rad51 combined with pimonidazole, vessels and nuclei. For quantification of 
apoptosis tumor sections were stained for active caspase-3 and vessels. 
The antibody against pimonidazole was a gift from J.A. Raleigh (University of 
North Carolina). Vessels were detected with 9F1, a rat monoclonal antibody against 
mouse endothelium (Department of Pathology, Radboud University Nijmegen Medical 
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Centre). The antibody against 53BP1 was purchased from Thermo Scientific (Waltham, 
MA, USA). The antibody against Rad51 was obtained from both Calbiochem (Darmstadt, 
Germany) and Epitomics (Burlingame, CA, USA) due to a stop in the manufacturing 
of the Rad51 at Calbiochem. Tests with both Rad51 antibodies showed comparable 
staining. SCCNij185 tumors were stained with the Calbiochem antibody and SCCNij153 
tumors with the Epitomics antibody against Rad51. The antibody against activated 
caspase-3 was purchased from R&D systems (Minneapolis, MN, USA).
Primary antibodies were detected by appropriate Cy3-conjugated (Jackson Immuno 
Research Laboratories Inc., West Grove, PA, USA), Alexa488-, Alexa647- or Alexa55-
conjugated (Molecular Probes, Leiden, The Netherlands) secondary antibodies. Nuclei 
were stained with DAPI (Abcam, Cambridge, UK). 
Image acquisition and computerized analysis of DNA repair
Four to eight single fields were randomly chosen and recorded per tumor section 
using a digital image processing system consisting of a 16-bit camera (Coolsnap HQ2, 
Photometrics, Tucson, AZ, USA) on a fluorescence microscope (Axioscope A1 Led, 
Zeiss, Göttingen, Germany) using iVision software (BioVision Technologies, Exton, 
PA, USA). Each single field was recorded multiple times with different filters at 400x 
magnification to obtain images of the different fluorescent signals: 53BP1 or Rad51, 
pimonidazole (hypoxia), and DAPI (nuclei). Single fields were both acquired in normoxic 
and hypoxic tumor areas.
Grey value images from 53BP1, Rad51 and nuclei were converted to binary images 
by setting thresholds for the fluorescence signals at intensities where the steepest 
gradient occurred between background and foreground intensity levels using ImageJ 
software (NIH, Bethesda, MD, USA). Hypoxic tumor areas were delineated using the 
pimonidazole grey value images. The number of 53BP1 or Rad51 foci and the number 
of nuclei were quantified in hypoxic and normoxic regions separately. The number of 
Rad51 or 53BP1 foci per nucleus was calculated by dividing the total number of 53BP1 
or Rad51 foci by the total number of nuclei. At least 550 nuclei per tumor section 
were analyzed. 
Image acquisition and computerized analysis of apoptosis
Complete tumor sections stained for activated caspase-3 and vessels were scanned 
with a fluorescence microscope (Zeiss). Each section was sequentially scanned at 100x 
magnification to yield an image of the fluorescent signal of activated caspase-3. 
Thresholds for the fluorescence signal were interactively set above the background 
and the grey value image was converted to a binary image. The apoptotic fraction 
was calculated by dividing the tumor area positive for activated caspase-3 by the total 
tumor area. Necrotic areas and staining artifacts were excluded from analysis.
Western blot analysis
Tumor sections of 3 tumors per treatment group were lysed in NP-40 lysis buffer and 
protein was quantitated using a standard Bradford absorbance assay. Proteins (40 μg 
per lane) were separated by SDS-PAGE and blotted onto PVDF membrane. Membranes 
were incubated with the appropriate primary antibodies followed by incubation with 
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HRP-conjugated antibodies and proteins were detected with an ECL chemiluminescence 
system. Antibodies against the following antigens were used: EGFR, pEGFR(Y1173), 
AKT, and HRP-conjugated goat-anti-mouse IgG were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). ERK1/2, pERK1/2(T202/Y204), pAKT(S473), and 
HRP-conjugated goat-anti-rabbit IgG were purchased from Cell Signaling Technology 
(Beverly, MA, USA) and α-tubulin was obtained from Calbiochem (San Diego, CA, USA).
Statistics
For statistics, the values of all single fields of one tumor were averaged to obtain one 
value per tumor for the number of Rad51 or 53BP1 foci per nucleus. Differences in 
numbers of Rad51 and 53BP1 foci and apoptotic fraction between treatments and 
between hypoxic and normoxic tumor regions were tested for significance using the 
unpaired t test. Differences in apoptotic fraction between treatments were tested for 
significance using a one-way ANOVA followed by Sidak’s post hoc tests. All tests were 
performed using Prism (GraphPad Software, Inc., LA Jolla, CA, USA) and p-values 
<0.05 were considered significant. 
rEsults
Assessment of DNA repair after radiotherapy 
We have shown before that in a panel of 4 HNSCC xenograft models EGFR expression 
did not predict for response to cetuximab and/or radiotherapy [30]. No K-RAS muta-
tions were detected in the investigated models [30]. To determine whether the effect 
of cetuximab on repair of radiation-induced DNA damage does predict for response, 
two tumor models with differential response to combined cetuximab-radiotherapy 
were selected. Combining cetuximab and radiotherapy has a synergistic effect on tumor 
growth in SCCNij185 tumors, while SCCNij153 tumors showed no additive effect of 
cetuximab [30]. 
Sections of SCCNij185 and SCCNij153 tumors were immunohistochemically 
stained for 53BP1 and Rad51 to determine the effect of combining cetuximab and radio-
therapy on repair of radiation-induced DNA damage. The hypoxic marker pimonidazole 
was also visualized to investigate the effect on DNA repair in hypoxic and normoxic 
tumor areas separately. The number of both 53BP1 and Rad51 foci was clearly increased 
24h after radiotherapy (Figure 1 and Supplemental Figure 1, example of SCCNij185). 
Rad51 foci were predominantly present in normoxic tumor regions, while 53BP1 foci 
were present in both normoxic and hypoxic tumor regions.
Increased number of 53BP1 foci after combined cetuximab and radiotherapy  
in sensitive and resistant HNSCC model 
In both SCCNij185 and SCCNij153 tumors there was a significant increase in the 
number of 53BP1 foci per nucleus after radiotherapy, while cetuximab alone did not 
affect the number of 53BP1 foci per nucleus (Figure 2). There was a further increase in 
both hypoxic and normoxic tumor areas of SCCNij185 tumors treated with cetuximab 
and radiotherapy compared to radiotherapy alone (Figure 2). This increase in 53BP1 foci 
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figure 1: 53BP1 and Rad51 expression in control and 24h after 10 Gy. Expression of 53BP1 and Rad51 
in relation to hypoxia was visualized by immunofluorescence staining in a control tumor and a tumor 
harvested 24h after radiotherapy (10 Gy), both SCCNij185. 53BP1 or Rad51: red, hypoxia: green. 
Scale bars represent 50 µm. Magnification: 400x.
figure 2: 53BP1 foci after cetuximab and/or radiotherapy. Average number of 53BP1 foci per nucleus 
in control tumors and tumors harvested 24h after radiotherapy (10 Gy) and/or cetuximab (C225, 1 mg). 
tumors treated with cetuximab only were harvested 48h after treatment, which corresponds to 24h after 
combined cetuximab-radiotherapy. Differences in the number of foci between groups treated with or 
without cetuximab in hypoxic or normoxic areas were tested for significance using t tests, *: p<0.05, 
**: p<0.01. Error bars represent SEM. Number of animals per group: 5-7. 
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was strongest and statistically significant (p=0.04) in normoxic tumor areas. These data 
indicate increased residual DNA damage, and thus a reduction of DNA repair, due to 
cetuximab treatment. However, cetuximab also increased the number of 53BP1 foci in 
both hypoxic (p=0.007) and normoxic (p=0.02) tumor areas of irradiated SCCNij153 
tumors. This was unexpected as the SCCNij153 tumors are resistant to the radiosensi-
tizing effect of EGFR-inhibition. In both tumor lines no significant differences in 53BP1 
foci were observed between hypoxic and normoxic tumor areas after any treatment.
Also Rad51 foci significantly increased after radiotherapy in both tumor lines, 
but this was most pronounced in normoxic tumor areas (Figure 3). The number of 
Rad51 foci per nucleus after radiotherapy was not affected by addition of cetuximab 
in SCCNij185 tumors. In SCCNij153 tumors a trend for a reduced number of Rad51 foci 
after combined cetuximab-radiotherapy treatment was observed (p=0.07). In both 
tumor models, the number of Rad51 foci was significantly lower in hypoxic areas 
compared to normoxic areas after any treatment (p<0.05).
Decreased pEGFR and pERK1/2 after treatment with cetuximab and radiotherapy  
in sensitive HNSCC model
As the effect of cetuximab on DNA repair does not explain the differential response 
to cetuximab and radiotherapy in our two models, western blot analyses were per-
formed to determine the effects of cetuximab and/or radiotherapy on EGFR signaling 
(Figure 4). Combined cetuximab-radiotherapy decreased total EGFR in both SCCNij185 
and SCCNij153, but had differential effects on pEGFR levels. Radiotherapy increased 
pEGFR levels in SCCNij185 tumors, while this increase was not observed after com-
bined treatment with cetuximab and radiotherapy. In contrast, pEGFR levels increased 
after combined treatment in SCCNij153 tumors indicating that cetuximab was not able 
to inhibit EGFR signaling in this model despite reduced total EGFR. Moreover, pERK1/2 
levels were lower after combined treatment with cetuximab and radiotherapy in 
SCCNij185, while this was not observed for SCCNij153 (when corrected for α-tubulin). 
No differences in pAKT levels were observed between tumors treated with combined 
cetuximab-radiotherapy and tumors treated with radiotherapy alone. 
Increased apoptosis after treatment with cetuximab and radiotherapy  
in sensitive HNSCC model
A possible explanation for the lack of correlation between the effect of cetuximab on 
DNA repair and the response on tumor growth is a differential enhancement of radi-
ation-induced apoptosis by cetuximab. In both tumor models, apoptosis was not 
increased at day 1 after radiotherapy or cetuximab, and also no significant differences 
were observed between cetuximab and combined cetuximab-radiotherapy (Figure 5A). 
However, at day 4 after treatment clear differences were observed. While no significant 
differences between treatment groups were observed in SCCNij153 (ANOVA: p>0.05), 
apoptosis was significantly increased in SCCNij185 tumors treated with cetuximab 
and radiotherapy compared to control tumors (p<0.001) and tumors treated with 
cetuximab only (p<0.01) (Figure 5A and B).
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figure 3: Rad51 foci after cetuximab and/or radiotherapy. Average number of Rad51 foci per nucleus 
in control tumors and tumors harvested 24h after radiotherapy (10 Gy) or cetuximab, (C225, 1 mg) 
and radiotherapy. Error bars represent SEM. Number of animals per group: 5-7. 
figure 4: Effects of cetuximab and/or radiotherapy on EGFR signaling. Expression of (p)EGFR, 
(p)ERK1/2), and (p)AKt in SCCNij185 and SCCNij153 tumors in control tumors and tumors har-
vested 24h after radiotherapy (10 Gy) and/or cetuximab (C225, 1 mg). tumors treated with cetuximab 
only were harvested 48h after treatment, which corresponds to 24h after combined cetuximab-radio-
therapy. α-tubulin was used as loading control. three tumors per treatment group were analyzed and 
tumor lines were blotted on separate membranes.
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figure 5: Apoptosis at different time points after cetuximab and/or radiotherapy. 
a) Apoptotic fraction in control tumors and tumors harvested 1 and 4 days after radiotherapy (10 Gy) 
and/or cetuximab (C225, 1 mg). tumors treated with cetuximab only were harvested 2 and 5 days 
after treatment, which corresponds to 1 and 4 days after combined cetuximab-radiotherapy. Differ-
ences between treatment groups were tested for significance with a one-way ANovA followed by 
Sidak’s post hoc tests, **: p<0.01. Error bars represent SEM. Number of animals per group: 5-7. 
b) Expression of activated caspase-3 in relation to hypoxia was visualized by immunofluorescence 
staining in tumors harvested 4 days after treatment with cetuximab (C225, 1 mg) and radiotherapy 
(10 Gy). Apoptosis: red, hypoxia: green, vessels: blue. Scale bars represent 500 µm. Non-specific 
staining present in necrotic regions. 
Magnification: 100x. 
a
b
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discussion
Combining radiotherapy with EGFR-inhibition using cetuximab in HNSCC is one of 
the most successful combinations of a newly developed targeted therapy with radio-
therapy [2]. However, this new combination is only effective in a subgroup of patients 
and is accompanied with high rates of grade ≥ 3 oral mucositis and skin dermatitis 
[3-5]. Identification of biological characteristics that predict treatment response is 
thus essential to improve patient outcome in the future. In the present study, we 
investigated whether the effect of cetuximab on repair of radiation-induced DNA 
damage was predictive for the radiosensitizing effect of cetuximab in two HNSCC 
xenograft models, which differ in their response to cetuximab combined with radio-
therapy [30].
Although multiple in vitro studies have shown that EGFR-inhibition decreases repair 
of radiation-induced DNA damage [17,19,22,26], this is the first in vivo study to show 
that cetuximab affects DNA repair after radiotherapy. The number of 53BP1 foci, as a 
measure of residual unrepaired DNA damage, was increased in hypoxic and normoxic 
tumor areas in a similar way in both tumor models. This increase reached statistical 
significance in normoxic tumor areas in SCCNij185 and in both hypoxic and normoxic 
areas in SCCNij153. Cetuximab alone did not affect the number of 53BP1 foci, which 
is consistent with the hypothesis that cetuximab affects repair of radiation-induced 
DNA damage. In both models the increase in 53BP1 foci induced by cetuximab was 
smaller in hypoxic tumor regions than in normoxic regions. An explanation for this 
difference in effect of EGFR-inhibition in normoxic and hypoxic areas is differential 
expression of EGFR in hypoxic and normoxic tumor regions. Although several in vitro 
studies have shown upregulation of EGFR by hypoxia [31,32], we observed EGFR 
expression predominantly in cells near blood vessels and thus more in normoxic areas 
than in hypoxic areas in these xenograft models [30]. Hence, decreased expression of 
EGFR in hypoxic cells could explain the lower increase in residual DNA damage induced 
by EGFR-inhibition in hypoxic tumor areas. Another possibility is that the effectiveness 
of cetuximab was less in hypoxic tumor areas due to poorer distribution of cetuximab 
into those areas [33]. 
As oxygen is required for fixation of radiation-induced DNA damage, less DNA 
damage is induced in hypoxic cells and consequently hypoxic cells are more radio-
resistant [27]. Accordingly, reduced γH2AX levels have been observed in hypoxic tumor 
cells compared to normoxic tumor cells [34,35]. However, we did not see a significant 
difference in the number of 53BP1 foci between hypoxic and normoxic tumor areas 
24h after radiotherapy in both tumor models. This lack of difference in the number 
of residual 53BP1 foci between hypoxic and normoxic cells could be due to a reduced 
rate of DNA repair in hypoxic cells. It has been shown that chronic hypoxia decreases 
the expression of DNA repair proteins both involved in NHEJ and HR and that this 
leads to a decrease in repair of radiation-induced DNA damage [29,36,37]. Moreover, 
despite reduced numbers of 53BP1 and γH2AX foci at early time points after radio-
therapy, the number of residual foci at later time points was higher in chronically 
hypoxic cells compared to normoxic cells due to slower repair kinetics [36]. The 
hypoxic cells observed in our xenograft models were mainly chronic hypoxic as the 
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pimonidazole staining was predominantly observed in tumor areas further away from 
the vessels The absence of a difference between the hypoxic and normoxic cells in 
our xenograft tumors can be explained by differences in DNA repair kinetics between 
normoxic and hypoxic tumor cells. Consequently, this results in comparable foci 
levels at 24 hours after radiotherapy despite reduced induction of double strand 
breaks in hypoxic cells. We indeed observed a significant lower number of Rad51 foci, 
representing HR activity, in hypoxic cells compared to normoxic cells in irradiated 
tumors in both tumor models. Another explanation of this decrease of HR activity in 
hypoxic areas is a lower fraction of proliferating cells in hypoxic tumor areas. HR occurs 
during the S- and G2-phase of the cell cycle and as hypoxia inhibits cell proliferation, 
fewer cells under hypoxic conditions will be able to perform HR to repair DNA damage 
and hence, less Rad51 foci will be detected. 
Although clear differences were seen between hypoxic and normoxic areas, no 
significant differences were observed for the number of Rad51 foci between tumors 
treated with cetuximab and radiotherapy compared to radiotherapy alone. There was 
a trend for a reduced number of Rad51 foci per nucleus in SCCNij153 tumors treated 
with cetuximab and radiotherapy indicating a reduction of HR mediated DNA repair. 
These findings are in accordance with in vitro studies that have shown that EGFR-
inhibition reduces HR mediated DNA repair [25,26]. Nonetheless, as there were sig-
nificant increases in the number of 53BP1 foci when cetuximab was added, our data 
suggest that cetuximab mainly affects DNA repair via NHEJ in both of our models.
In both the model showing synergistic effects of cetuximab and radiotherapy 
(SCCNij185) as well as in the model that does not show any additive effect of cetuximab 
to radiotherapy (SCCNij153), we observed an increase in residual DNA damage 24h 
after radiotherapy when cetuximab was added. However, this increased residual DNA 
damage in SCCNij153 tumors did not lead to an increase in growth delay. Differences 
in effects of cetuximab and radiotherapy on EGFR signaling could possibly explain 
the differential response of SCCNij153 and SCCNij185 tumors. While cetuximab was 
able to counteract radiation-induced activation of EGFR in SCCNij185 tumors, pEGFR 
levels were still high in SCCNij153 tumors treated with cetuximab and radiotherapy. 
pERK1/2 levels were also only reduced in SCCNij185 tumors after cetuximab plus 
radiotherapy. ERK1/2 signaling plays an important role in the induction of proliferation 
via growth factor signaling [38]. The decrease in ERK1/2 signaling in SCCNij185 
corresponds to our earlier findings that combined treatment induced a decrease in pro-
liferation in SCCNij185, while an increase in proliferation was observed in SCCNij153 
tumors [30]. 
The ability of cetuximab to induce apoptosis has been linked to its effect on cell 
radiosensitivity and tumor response after radiotherapy [39]. Therefore, we investi-
gated whether the lack of correlation between the effects of cetuximab on repair of 
radiation-induced DNA damage and the effects of cetuximab on tumor growth was due 
to a differential induction of apoptosis. Indeed, we detected an increase in apoptotic 
fraction in SCCNij185 at day 4 after combined cetuximab-radiotherapy treatment, 
while apoptosis was not increased by cetuximab and radiotherapy in in SCCNij153 
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tumors. This observation suggests that SCCNij153 has an increased ability to with-
stand apoptotic stimuli, while cetuximab is more effective in inducing apoptosis due 
to increased DNA damage in SCCNij185 tumors. Although apoptosis was increased 
3-fold in SCCNij185 tumors after combined treatment, the apoptotic fraction was in 
absolute terms still relatively small and it can be questioned whether this difference 
in apoptosis could explain the large difference in response between the two models. 
It is likely that the combined effect of different mechanisms results in the synergistic 
effect of cetuximab and radiotherapy in SCCNij185. We have already shown that also 
proliferation is decreased after combined treatment in SCCNij185 tumors [30], but 
additional mechanisms including differences in induction of antibody-dependent 
cellular cytotoxicity by cetuximab has to be further evaluated in these models. 
In conclusion, the effect of cetuximab on repair of radiation-induced DNA damage is not 
predictive for the radiosensitizing effect of cetuximab in vivo as both the resistant and 
sensitive model showed comparable effects of cetuximab on DNA repair. Differential 
effects of cetuximab and radiotherapy on ERK1/2 signaling and an increased ability 
to withstand apoptotic stimuli in the resistant model may cause this lack of correlation. 
Further research is warranted to determine the exact mechanisms by which cetuximab 
radiosensitizes tumors and thereby identify the critical biological characteristics that 
can predict outcome after combined EGFR-inhibition and radiotherapy treatment.  
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abstract
background: Kinases downstream of growth factor receptors have been implicated 
in radioresistance and are, therefore, attractive targets to improve radiotherapy out-
come in head and neck squamous cell carcinoma (HNSCC) patients. 
Methods: An antibody-based array was used to quantify the expression levels of 
multiple phospho-kinases involved in growth factor signaling in nine untreated or 
irradiated HNSCC lines. Radiosensitivity was assessed with clonogenic cell survival 
assays and correlated with the expression levels of the phospho-kinases. Inhibitors 
of the kinases that were associated with radiosensitivity were tested for their ability 
to increase radiosensitivity in the 3 most radioresistant HNSCC lines.  
results: The basal expression of phosphorylated Yes, Src and STAT5A, and the expres-
sion after radiotherapy of phosphorylated AKT, MSK1/2, Src, Lyn, Fyn, Hck, and STAT6, 
were correlated with radiosensitivity in the panel of HNSCC lines. In combination 
with radiotherapy, inhibitors of AKT, p38 and Src Family Kinases (SFK) were variably 
able to reduce survival, whereas MEK1/2, STAT5 and STAT6 inhibition reduced survival 
in all cell lines. The combined effect of radiotherapy and the kinase inhibitors on cell 
survival was mostly additive, although also supra-additive effects were observed for 
AKT, MEK1/2, p38 and STAT5 inhibition.
conclusions: Kinases of the AKT, MAPK, STAT and SFK pathways correlated with radio-
sensitivity in a panel of HNSCC lines. Particularly inhibitors against MEK1/2, STAT5 
and STAT6 were able to decrease survival in combination with radiotherapy. Hence, 
inhibitors against these kinases have the potential to improve radiotherapy outcome 
in HNSCC patients and further research is warranted to confirm this in vivo.
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introduction
Radiotherapy is an integral part of the treatment of head and neck squamous cell 
carcinoma (HNSCC) and is successful in curing early-stage disease. However, the 
majority of HNSCC patients presents with locoregionally advanced disease for which 
cure rates remain relatively poor [1]. Increasing insight in the biological features of 
HNSCC tumors has resulted in the development of new therapeutic agents that target 
molecules important for survival after radiotherapy, including the Epidermal Growth 
Factor Receptor (EGFR). Combining these new agents with radiotherapy has already 
been successful in the clinic as a phase III study by Bonner et al. [2] has shown that 
cetuximab, a monoclonal antibody against EGFR, improves survival in patients treated 
with radiotherapy. However, despite this effect, a significant proportion of the patients 
is resistant to EGFR inhibition and does not benefit from the addition of cetuximab. 
One of the proposed resistance mechanisms is activation of other growth factor recep-
tors [3-6]. Different growth factor receptors, such as EGFR, other members of the ErbB 
family and MET, activate similar downstream pathways [7]. Due to this redundancy in 
signaling networks, cells overexpressing multiple growth factor receptors can sustain 
survival signaling when one of the receptors is blocked. Therefore, it will be important 
to determine the common downstream pathways that are responsible for cell survival 
after radiotherapy as they will be more attractive targets to overcome radioresistance 
than targeting one specific growth factor receptor. 
Multiple kinase pathways downstream of growth factor receptors have already 
been implicated in radioresistance, including the RAS/RAF/ERK and the PI3-K/AKT 
pathways [8-10]. To identify kinases that can be targeted to increase radiosensitivity 
in HNSCC, it will be important to explore multiple pathways. In this study, we used 
an antibody-based array to quantify the expression levels of multiple phosphorylated 
kinases in a panel of HNSCC lines. The expression levels of these phospho-kinases 
were correlated with radiosensitivity. Inhibitors of the kinases that were associated 
with radiosensitivity were tested for their ability to enhance the radiotherapy effect 
in HNSCC. We identified several kinase inhibitors that have the potential to increase 
radiosensitivity of tumors and thereby improve the outcome of HNSCC patients.
MatErial and MEthods
Cell lines and chemicals
Nine human head and neck squamous cell carcinoma cell lines (UT-SCC lines, generated 
by R.G., University of Turku) were used in this study. The characteristics of the cell 
lines are shown in Table 1. Cell lines were not further authenticated or tested. Cells 
were cultured in T75 culture flasks, under humidified conditions (37 ºC, 5% CO2), and 
passaged weekly or twice weekly in DMEM containing 2 mM L-glutamine, 1% non-
essential amino acids, 20 mM Hepes, 10 units/ml penicillin, 10 units/ml streptomycin, 
and 10% fetal bovine serum. The following kinase inhibitors and concentrations 
were used: Src Family Kinase inhibitor dasatinib (100 nM, LC Laboratories, Woburn, 
MA, USA) [11], AKT inhibitor MK-2206 (2 μM, Selleckchem, Houston, TX, USA) [12], 
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MEK1/2 inhibitor U0126 (10 μM, Merck Millipore, Billerica, MA, USA) [8], p38 inhibitor 
SB203580 (10 μM, Selleckchem) [13], STAT5 inhibitor 573108 (100 μM, Merck Millipore) 
[14], and STAT6 inhibitor leflunomide (100 μM, Sigma, St Louis, MO, USA) [15].
Human phospho-kinase antibody array
To determine levels of phospho-kinases at baseline and after radiotherapy, cells were 
harvested after no treatment or 1h after a single dose of 4 Gy (320 KV, dose rate 3.1 
Gy/min, X-RAD, RPS Services Limited, Surrey, UK). Cells were lysed using lysis buffer 
of the Human phospho-kinase array kit (ARY003, Proteome ProfilerTM, R&D Systems, 
Minneapolis, MN, USA) and protein was quantitated using a standard Bradford 
absorbance assay. The Human phospho-kinase array was performed according the pro-
tocol of the manufacturer. In this array, 46 capture antibodies are spotted in duplicate 
on nitrocellulose membranes. The capture antibodies were directed against the 
following antigens: AKT(S473), AKT(T308), AMPKα1(T174), AMPKα2(T172), Chk-2(T68), 
c-Jun(S63), CREB(S133), eNOS(S1177), ERK1/2(T202/Y204), T185/Y187), FAK(Y397), 
Fgr(Y412), Fyn(Y420), GSK-3α/β(S1/S9), Hck(Y411), HSP27(S78/S82), JNK pan (T183/
Y185, T221/Y223), Lck(Y394), Lyn(Y397), MEK1/2(S218/S222, S222/226), MSK1/2(S376/
S360), p27(T157), p27(T198), p38α(T180/Y182), p53(S15), p53(S46), p53(S392), p70 S6 
kinase (T229), p70 S6 Kinase (T389), p70 S6 kinase (T421/S424), Paxillin(Y118), 
PLCγ-1(Y783), Pyk2(Y402), RSK1/2(S221), RSK1/2/3(S380), Src(Y419), STAT1(Y701), 
STAT2(Y689), STAT3(Y705), STAT4(Y693), STAT5a(Y699), STAT5a/b(Y699), STAT5b(Y699), 
STAT6(Y641), TOR(S2448), Yes(Y426) and β-catenin. In short, cell lysates were incubated 
with the membrane overnight. Thereafter, the membranes were incubated with a 
cocktail of biotinylated detection antibodies and streptavidin-HRP. Finally, proteins 
were detected using an ECL chemiluminescent system. To quantify expression levels, 
the integrated optical density (IOD) of each spot was measured using ImageJ software 
(NIH, Bethesda, MD, USA). IOD values were corrected for background signal and to 
compare different membranes levels were normalized to those of the positive controls 
on each membrane. Both the absolute expression levels after radiotherapy as well as 
the relative levels (expression after radiotherapy/expression in control) after radio-
therapy were quantified.
Radiosensitivity: Clonogenic cell survival assays
Cells were irradiated with graded doses (2, 4, or 8 Gy) at room temperature. After 1.5-3 
weeks, depending on the growth speed of the cell line, cells were stained with 0.5% 
crystal violet and colonies with more than 50 cells were counted. Clonogenic survival 
curves were fitted using the linear quadratic model and the surviving fraction after 
4 Gy (SF4) was calculated using the α and β values obtained from the curve. 
Kinase inhibition: Clonogenic cell survival assays & western blot analyses
For clonogenic cell survival assays, cells were incubated with the kinase inhibitor for 
16h and then irradiated with 4 Gy. Thereafter, cells were treated with the kinase 
inhibitor for 72 h (total 88h of treatment) and subsequently cells were incubated in 
drug free medium. After 1.5-3 weeks, cells were stained with crystal violet and colonies 
were counted. Survival fraction after combined treatment with 4 Gy and the kinase 
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inhibitor was calculated by correcting for plating efficiency of the untreated control 
or by correcting for plating efficiency of cells treated with the inhibitor alone.
For western blot analyses, cells were treated with the inhibitor for 16h followed by 
irradiation with 4 Gy and harvested 4h after radiotherapy or 20h after kinase treatment. 
Cells were lysed in RIPA buffer and protein was quantitated using a standard Bradford 
absorbance assay. Proteins (25 μg per lane) were separated by SDS-PAGE and blotted 
onto PVDF membrane. Membranes were incubated with the appropriate primary anti-
bodies followed by incubation with HRP-conjugated antibodies. Finally, proteins were 
detected using chemiluminescence. Antibodies against the following antigens were 
used: p-p38(T180/Y182), pMEK1/2(S217/221), pMSK1(S376), pSFK(Y416), pSTAT6(Y641), 
pSTAT5(Y694), pAKT(S473), pERK1/2(T202/Y204), and HRP-conjugated goat-anti-rabbit 
IgG were purchased from Cell Signaling Technology (Beverly, MA, USA), HRP-conju-
gated goat-anti-mouse IgG was purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), and α-tubulin was obtained from Calbiochem (San Diego, CA, USA).
Statistics
Correlations between expression levels of phospho-kinases and SF4 values were 
assessed using the Spearman correlation test. To determine additive effects of com-
bined treatment, differences between survival after 4 Gy and 4 Gy + inhibitor were 
tested for significance using the Mann-Whitney test. To determine supra-additive 
effects of combined treatment, differences between survival after 4 Gy and 4 Gy + 
inhibitor corrected for effect of inhibitor alone were tested for significance using the 
Mann-Whitney test. Tests were performed using Prism (GraphPad Software, Inc., LA 
Jolla, CA, USA) or SPSS (SPSS, Chicago, IL, USA). P-values ≤0.05 were considered 
significant. 
rEsults
Expression of phospho-kinases correlated with radiosensitivity in a panel  
of HNSCC cell lines
The radiosensitivity of 9 HNSCC cell lines was assessed with clonogenic survival assays 
after 0, 2, 4 and 8 Gy. Using the linear quadratic model, the surviving fraction after 4 
Gy (SF4) was calculated for each cell line (Table 1). To determine which kinases are 
important for cell survival after radiotherapy in HNSCC, we quantified the expression 
of a panel of phospho-kinases using an antibody-based array in untreated and irradiated 
cells p (Figure 1). The effect of radiotherapy on most phospho-kinases varied widely 
among cell lines, only the expression of p-Chk2 was increased in all cell lines after 
radiotherapy (Figure 1). The expression levels of multiple phospho-kinases were found 
to be significantly correlated with radiosensitivity (Table 2). For some phosphorylated 
kinases the basal expression level was correlated with radiosensitivity (Yes and STAT5A), 
whereas for others the expression level after radiotherapy (AKT, MSK1/2, Lyn, Fyn, 
Hck, STAT6). For phosphorylated Src both the basal expression level as well as the 
expression level after radiotherapy were correlated with radiosensitivity. 
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figure 1: Phospho-kinase array in control and irradiated Ut-SCC24A cells. Example of phospho-
kinase array in untreated Ut-SCC24A cells and 1 h after 4 Gy irradiation. Cell lysates were incubated 
with membranes containing capture antibodies (spotted in duplicate) against 46 kinase phosphorylation 
sites. thereafter, the membranes were incubated with a cocktail of biotinylated detection antibodies 
and streptavidin-HRP. Proteins were detected using chemiluminescence and expression levels were 
quantified by measuring the integrated optical density (ioD) of each spot. 
table 1: Characteristics of Ut-SCC cell lines
cell line tnM* primary tumor location type of lesion grade sf4
Ut-SCC5 t1N1M 0 tongue Primary 2 0.42
Ut-SCC8 t 2N0M0 Supraglottic larynx Primary 1 0.22
Ut-SCC15 t1N0M0 tongue Recurrence 1 0.31
Ut-SCC19A t4N0M0 Glottic larynx Primary 2 0.19
Ut-SCC24A t2N0M0 tongue Primary 2 0.40
Ut-SCC29 t2N0M0 Glottic larynx Primary 1 0.23
Ut-SCC38 t2N0M0 Glottic larynx Primary 2 0.23
Ut-SCC40 t3N0M0 tongue Primary 1 0.33
Ut-SCC45 t3N1M0 Floor of mouth Primary 3 0.28
*tNM status of primary tumors according to the international Union against Cancer (1997).
Note: Grade: 1, well differentiated; 2, moderately differentiated; 3, poorly differentiated.
SF4: surviving fraction after 4 Gy 
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table 2: Phospho-kinases correlated with radiosensitivity in HNSCC
phospho-kinase condition spearman correlation coefficient p-value
Src(y419) Expression in control 
Expression after Rt
0.67
0.75
0.049
0.019
StAt5A(y699) Expression in control 0.70 0.036
yes(y426) Expression in control 0.67 0.050
AKt(S437) Relative expression after Rt 0.67 0.050
MSK1/2(S376/S360) Expression after Rt 0.67 0.050
Lyn(y397) Expression after Rt 0.70 0.036
Fyn(y420) Expression after Rt 0.70 0.036
Hck(y411) Expression after Rt 0.72 0.030
StAt6(y641) Expression after Rt 0.67 0.050
Rt: 4 Gy of radiotherapy
Radiosensitizing effect of kinase inhibitors
The significant correlation between the expression levels of these phosphorylated 
kinases and radiosensitivity indicates that the activity of these kinases might be 
important for cell survival after radiotherapy. Indeed, AKT and Src have been impli-
cated in resistance to radiotherapy in HNSCC before [9,11] and were also found to be 
correlated with radiosensitivity in this study. Hence, these kinases might represent 
new targets to increase radiosensitivity in HNSCC. To test this hypothesis, clonogenic 
survival assays were performed with inhibitors against these various kinases in com-
bination with radiotherapy in 3 UT-SCC lines with the highest SF4 values i.e. the 
most radioresistant tumor cell lines; UT-SCC5, 24A and 40 (Figure 2A-F). MK-2206, 
573108 STAT5 inhibitor, and leflunomide were used to inhibit AKT, STAT5 and STAT6, 
respectively. Dasatinib was used to inhibit the kinases of the Src Family Kinase (SFK), 
which include Src, Yes, Lyn, Fyn and Hck. MSK1/2 can be activated via both the MEK/
ERK pathway as well as the p38 pathway [16]. Therefore, both U0126 and SB203580 
were used to inhibit MEK1/2 and p38, respectively, and thereby inhibit downstream 
MSK1/2. Next to the clonogenic survival assays, western blot analyses were performed 
on cells treated with the inhibitor and/or radiotherapy to determine the effects of 
the inhibitors on the phosphorylated kinases (Figure 3A-F). 
As shown in Figure 2A, AKT inhibition significantly decreased survival after 4 
Gy in UT-SCC24A (p=0.030) and UT-SCC40 (p=0.002). This effect was supra-additive in 
UT-SCC40 (p=0.002). In all three cell lines AKT inhibition with or without radiotherapy 
clearly decreased pAKT levels (Figure 3A). SFK inhibition only decreased survival after 
4 Gy in UT-SCC24A (p=0.002), and this was not a synergistic effect (Figure 2B). Western 
blot analyses also showed only a clear decrease in pSFK levels in UT-SCC24A cells 
(Figure 3B). MEK inhibition significantly decreased survival after 4 Gy in all cell lines 
(p<0.001), which was supra-additive in UT-SCC24A (p=0.004) (Figure 2C). MEK inhibition 
increased pMEK1/2 levels in all cell lines (Figure 3C). In contrast, downstream pERK1/2 
levels were decreased after MEK inhibition, indicating that the kinase activity of MEK1/2 
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figure 2 (page 100): Effects of kinase inhibitors on survival after radiotherapy. Ut-SCC5, 24A and 40 
cell lines were treated with the inhibitor overnight (16h), irradiated with 4 Gy and changed to drug 
free medium 72 h after irradiation. Survival was assessed via colony counting. a) AKt inhibitor: 
MK-2206 (2 µM), b) SFK inhibitor: dasatinib (100 nM), c) MEK1/2 inhibitor: U0126 (10 µM), d) p38 
inhibitor: SB203580 (10 µM), E) StAt5 inhibitor: 573108 (100 µM), f) StAt6 inhibitor: leflunomide (100 µM). 
Survival fraction shown in graph was not corrected for the effect of the inhibitor alone. Differences 
between survival after 4 Gy and 4 Gy + inhibitor (additive effect, first asterisks) or 4 Gy and 4 Gy + 
inhibitor corrected for effect of inhibitor alone (supra-additive effect, second asterisks) were tested 
for significance using Mann-Whitney tests. *: p<0.05, **: p<0.01. Error bars represent SD.
was decreased despite a higher level of phosphorylated MEK1/2. However, this inhibition 
of ERK1/2 did only lead to reduced pMSK1 levels in UT-SCC40 (Figure 3C). Inhibition of 
p38 in combination with radiotherapy also led to a reduction of survival in UT-SCC24A 
(p=0.002), which was a supra-additive effect (p=0.002) (Figure 2D). Similar to what was 
seen using the MEK inhibitor, p38 inhibition did not lead to reduced p-p38 levels; 
rather p-p38 levels were increased in UT-SCC24A that showed a synergistic effect of 
p38 inhibition and radiotherapy (Figure 3D). However, no decrease in downstream 
pMSK1 levels were seen in any of the three cell lines after p38 inhibition indicating 
that the effect of p38 inhibition was not related to effects on MSK1 activity.
As shown in Figure 2E and 2F, both STAT5 and STAT6 inhibition led to a signifi-
cantly decreased survival after 4 Gy in all cell lines (p<0.001 and p<0.05). For STAT6 
inhibition this was only an additive effect, while STAT5 inhibition and 4 Gy had a 
supra-additive effect on cell survival in UT-SCC40. Both pSTAT5 and pSTAT6 levels 
were low and difficult to detect on western blot. Reduction of pSTAT5 was observed 
in UT-SCC40 and of pSTAT6 in UT-SCC5 and UT-SCC40 (Figure 3E,F).  
discussion
In this study, an antibody-based array was used to determine which activated kinases 
involved in growth factor signaling were correlated with radiosensitivity in HNSCC. 
This screen resulted in multiple kinases of different pathways, which could be poten-
tial targets to increase radiosensitivity. Pathways known to be associated with radio-
sensitivity were found, including the RAS/RAF/ERK and the PI3-K/AKT pathways [8-10], 
validating our approach. In addition, kinases not known to be involved in radiosensi-
tivity were identified, including STAT5 and STAT6. Moreover, inhibitors of these kinases 
were able to decrease survival after radiotherapy, particularly inhibitors against MEK1/2, 
STAT5 and STAT6. Hence, these kinases represent potential new targets to improve 
outcome after radiotherapy in HNSCC patients. 
The PI3-K/AKT pathway has been shown to regulate important cell survival mechanisms 
that induce radioresistance, including DNA repair and proliferation [9]. Hence, inhibi-
tion of this pathway has been shown to be a major mechanism for the radiosensitizing 
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figure 3: Western blot analysis of phospho-kinases after treatment with inhibitor and/or radiotherapy. 
Ut-SCC5, 24A and 40 cells were incubated with the inhibitor overnight (16h), irradiated with 4 Gy and 
harvested 4h after radiotherapy treatment or 20h after kinase treatment. a) AKt inhibitor: MK-2206 
(2 µM), b) SFK inhibitor: dasatinib (100 nM), c) MEK1/2 inhibitor: U0126 (10 µM), d) p38 inhibitor: 
SB203580 (10 µM), E) StAt5 inhibitor: 573108 (100 µM), f) StAt6 inhibitor: leflunomide (100 µM). 
α-tubulin was used as loading control.
a
b
c
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effect of EGFR inhibitors [17,18] and this is strengthened by the observation that 
activation of AKT has been implicated in resistance to EGFR inhibition [19]. Here, we 
show that pAKT inhibition via MK-2206 can decrease survival after radiotherapy. This 
effect was supra-additive in one cell line, indicating that pAKT inhibition specifically 
decreased survival after radiotherapy in this cell line. However, pAKT inhibition did 
not decrease survival in all cell lines we tested, despite consistently good inhibition 
of pAKT levels (Figure 3A). Several mechanisms could explain this difference in radio-
sensitizing effect of MK-2206 between cell lines. Firstly, the importance of AKT activity 
for cell survival could differ between cell lines; for example also other kinases were 
highly expressed in resistant line UT-SCC5, and, therefore, inhibition of pAKT would 
not be deleterious for all cell lines. Moreover, numerous feedback systems are present 
between growth factor receptors and their downstream pathways, whereby inhibition 
of one kinase can lead to activation of receptors and consequently activation of other 
downstream pathways [20,21]. These feedback mechanisms can greatly impact the 
sensitivity of cells to kinase inhibitors. In addition, these mechanisms are likely dif-
ferentially active between cell lines as they will be dependent on which receptors 
and kinases are (over)expressed or preferentially activated in a cell.   
Several members of the family of Src kinases were also found to be correlated 
with radiosensitivity. SFKs have been shown to be involved in pathways that control 
cell division and survival [22,23] and Src has been implicated in AKT activation after 
radiotherapy [24]. However, dasatinib was only able to reduce survival after radio-
therapy in UT-SCC24A cells in an additive way. This is in contrast with a recent study 
by Raju et al. [11], which showed that dasatinib enhances radiosensitivity in HNSCC 
cells via inhibition of radiation-induced DNA repair. A possible reason for this dis-
crepancy is that due to differential sensitivity our panel of 3 cell lines was too small 
to detect the radiosensitizing effect of dasatinib. Namely, in the study of Raju et al. 
only 2 out of 6 cancer lines showed radiosensitization by dasatinib [11]. Nonetheless, 
if assumed that the cell lines used by Raju et al. and our panel represents the variation 
in the clinic, these data together suggest that dasatinib can radiosensitize tumors, 
but probably only in a small proportion of HNSCC patients.
 In contrast to dasatinib, inhibition of MEK1/2 did result in decreased survival after 
radiotherapy in all cell lines, with a supra-additive effect in UT-SCC24A. MEK1/2 and 
its downstream kinases ERK1/2 have been implicated in radioresistance in HNSCC 
before, although the effect of pathway inhibition on radiosensitivity is inconsistent 
[8,25]. In this study, MEK1/2 inhibition was used to inhibit downstream phosphoryla-
tion of MSK1/2, which was correlated with radiosensitivity. Though clear inhibition 
of pERK1/2 was detected in all cell lines, pMSK1 was only decreased in UT-SCC40, 
which only showed an additive effect of MEK inhibition. Hence, these data suggest 
that the radiosensitizing effect of MEK inhibition is not regulated via MSK. Specific 
inhibition of MSK will be necessary to further investigate the role of MSK in radio-
resistance in HNSCC. Interestingly, the cell line that showed synergism between MEK 
inhibition and radiotherapy, also showed a synergistic effect of p38 inhibition. Also 
with this inhibitor no decrease of pMSK1 levels was observed. MEK and p38 both 
belong to the family of mitogen-activated protein kinases (MAPKs) [16]. Therefore, 
MEK and p38 may activate another common pathway that is important for survival 
103ENHANCiNG RADioSENSitivity viA KiNASE iNHiBitoRS
after radiotherapy in UT-SCC24A cells, for example both MEK and p38 can activate 
MNK1 and thereby regulate mRNA translation [16].  
Surprisingly, increased pMEK1/2 levels were observed in all cell lines after MEK 
inhibition (Figure 3C), and also p-p38 was increased by p38 inhibition in the cell line 
that showed decreased survival after radiotherapy (UT-SCC24A, Figure 3D). Upregula-
tion of pMEK1/2 after MEK inhibition has also been observed by Turke et al. [21] and 
they attributed it to a negative feedback mechanism that activates an upstream sign-
aling molecule. Indeed, we did observe decreased pERK1/2 levels indicating that MEK 
activity was decreased by the inhibitor despite increased pMEK1/2 levels. Accordingly, 
increased p-p38 levels after p38 inhibition in the sensitive cell line might indicate 
effective inhibition of p38 and its downstream pathways instead of increased activity 
of p38.
Members of the STAT family have been shown to be activated in epithelial tumors, 
including HNSCC, and are known to induce the transcription of genes involved in 
cell survival, proliferation and angiogenesis [26]. Activation of STAT5 has also been 
shown to contribute to tumor growth and resistance to cisplatin and EGFR inhibition 
in HNSCC cell lines [27]. However, it has not been previously described that STAT5 
and STAT6 correlate with radiosensitivity as we find in our study. Another member of 
the STAT family, STAT3, has been shown to be involved in resistance to radiotherapy 
[28]. Hence, our results indicate that also other STAT members play an important role 
in radiosensitivity in HNSCC. This is also indicated by a study of Lesterhuis et al. [29], 
who observed a trend toward a shorter progression-free survival for STAT6 expressing 
tumors in a cohort of HNSCC patients treated with radiotherapy only. More impor-
tantly, inhibition of STAT5 and STAT6 consistently decreased survival after radiation 
in all cell lines. Although these effects on survival were mostly additive, these data 
do suggest that inhibition of STAT5 and STAT6 has the potential to improve outcome 
after radiotherapy in a large proportion of HNSCC patients. However, our results have 
to be interpreted with caution. The effects of the inhibitors on pSTAT5 and pSTAT6 
levels were small, although as we demonstrated for other kinases (MEK, p38), this 
does not necessarily reflect the activity of these kinases. Furthermore, leflunomide is 
not a very specific STAT6 inhibitor and we cannot exclude the possibility that the 
effect of leflunomide on cell survival is independent of STAT6 inhibition. 
Altogether, mostly additive effects of the kinase inhibitors were observed in this 
study indicating that these inhibitors decreased tumor cell survival in general and 
not specifically after radiotherapy. Although a synergistic effect of a kinase inhibitor 
and radiotherapy would be preferred, combination therapies that result in reduced 
survival due to additive effects could still offer the promise of improving patient 
outcome after radiotherapy in the clinic. Especially when these additive effects occur 
in a large proportion of the patients. Recurrences after radiotherapy often occur from 
a few surviving clonogenic cells and this suggests that additional kill of clonogenic 
cells by a kinase inhibitor would contribute to local tumor control [30]. The challenge 
for the future will be to determine which kinase pathway(s) are crucial for tumor cell 
survival in an individual patient and, hence, to determine which kinase inhibitor(s) 
will most likely be effective in that patient. 
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In conclusion, kinases of the PI3-K/AKT, MAPK, STAT and SFK pathways were shown 
to be correlated with radiosensitivity in HNSCC cells. Inhibitors of these kinases were 
able to decrease survival after radiotherapy, in particular MEK1/2, STAT5 and STAT6 
inhibitors. Hence, kinase inhibitors have the potential to increase radiosensitivity of 
tumors and thereby improve the outcome of HNSCC patients after radiotherapy. 
However, as with inhibitors against growth factor receptors, tumor cell lines display 
differential sensitivity. Further research is warranted to increase insight in mechanisms 
involved in resistance to these kinase inhibitors and how they can be counteracted 
to increase the efficacy of these kinase inhibitors. Secondly, kinase inhibition should 
be tailored to the preferential signaling pathway activation of individual tumors. 
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abstract
Src family kinases (SFKs) have been implicated in resistance to both radiation and 
epidermal growth factor receptor (EGFR) inhibition. Therefore, we investigated whether 
inhibition of SFK through dasatinib (DSB) can enhance the effect of radiotherapy in 
two in vivo human head and neck squamous cell carcinoma (HNSCC) models. 
Response to DSB and/or radiotherapy was assessed with tumor growth delay 
assays in two HNSCC xenograft models, SCCNij153 and SCCNij202. Effects on EGFR 
signaling were evaluated with Western blot analysis and effects on DNA repair, hypoxia 
and proliferation were investigated with immunohistochemistry.
DSB and radiotherapy induced a significant growth delay in both HNSCC xenograft 
models, although to a lesser extent in SCCNij202. DSB did not inhibit phosphorylated 
protein kinase B (pAKT) or phosphorylated extracellular signal-regulated kinase 1/2 
(pERK1/2), but did inhibit (phosphorylated) DNA-dependent protein kinase. Moreover, 
DSB reduced repair of radiation-induced DNA double strand breaks as shown by an 
increase of 53BP1 staining 24 hours after radiation. This effect on DNA repair was only 
observed in the cell compartment where pSFK was expressed: for SCCNij153 tumors 
in both normoxic and hypoxic areas, for SCCNij202 tumors only in hypoxic areas. No 
consistent effects of DSB on hypoxia or proliferation were observed. 
In conclusion, DSB enhances the effect of radiotherapy in vivo by inhibition of 
radiation-induced DNA repair and is a promising way to improve outcome in HNSCC 
patients. 
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introduction
Overexpression of the epidermal growth factor receptor (EGFR) is a frequent event in 
head and neck squamous cell carcinoma (HNSCC) and is associated with a worse 
prognosis after radiotherapy [1]. Accordingly, a randomized clinical trial has shown 
that addition of cetuximab, a chimeric monoclonal antibody against the extracellular 
part of EGFR, improves the clinical outcome in HNSCC patients treated with radio-
therapy [2]. However, locoregional control at 3 year was only improved from 34% in 
the group treated with radiotherapy alone to 47% in the group treated with radio-
therapy and cetuximab combined, while most patients experienced additional side 
effects due to the addition of cetuximab [2]. Hence, to further improve outcome in 
these patients it will be essential to develop therapeutic strategies that target other 
molecules of the EGFR signaling network involved in resistance to radiotherapy. 
Src family kinases (SFKs) are non-receptor kinases involved in pathways that 
control cell division, motility, adhesion, angiogenesis and survival [3,4]. It has been 
shown that SFKs interact with growth factor signaling, including signaling through 
EGFR [5-7]. More importantly, activated SFKs are required for the nuclear translocation 
of EGFR induced by cetuximab or radiation [8,9]. Nuclear EGFR increases DNA repair via 
interaction with DNA-dependent protein kinase (DNA-PK) and consequently decreases 
radiosensitivity [10]. Although radiation-induced translocation of EGFR to the nucleus 
can be blocked by cetuximab [11], nuclear EGFR is also a cause of resistance to cetuximab 
[12]. Therefore, inhibition of nuclear EGFR via inhibition of SFKs could enhance radio-
sensitivity by decreasing repair of radiation-induced DNA damage. 
Activity of SFKs can be inhibited by dasatinib (DSB), a small molecule tyrosine kinase 
inhibitor that also inhibits other kinases, including ABL [13]. DSB inhibits the in vitro 
growth of different tumor lines [13], including head and neck cancer lines [14]. 
However, SFK inhibition does not seem to have large effects on tumor growth in vivo 
[15,16] and also the clinical efficacy of DSB as a single agent in HNSCC seems low 
despite effective c-Src inhibition [17]. Nevertheless, the important role of SFKs in 
growth factor signaling and nuclear translocation of EGFR makes DSB an interesting 
candidate for enhancing the efficacy of radiotherapy in HNSCC. A recent study by 
Raju et al. [18] has indeed shown that DSB enhances radiosensitivity in HNSCC cells 
in vitro via inhibition of nuclear EGFR and by decreasing radiation-induced DNA 
repair. However, the tumor microenvironment, which exposes tumor cells to fluctu-
ating oxygen and nutrient gradients, can have a great impact on tumor behavior and 
tumor response. Therefore, it is of great importance to determine the effects of DSB 
and radiotherapy in the context of the tumor microenvironment in in vivo models 
before these results can be translated to the clinic. 
In this study, we investigated the potential of combining DSB with radiotherapy 
in vivo by analyzing effects of DSB and radiotherapy on tumor growth, EGFR signaling 
and DNA repair in two human HNSCC xenograft models. These HNSCC models both 
show high EGFR expression [19], but differ in their expression level of phosphorylated 
SFK (pSFK). In addition, the effects on hypoxia and proliferation, two important 
mechanisms involved in resistance to radiotherapy, were examined. 
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MatErial and MEthods
Xenograft tumor models and treatment
Tumor models SCCNij153 and SCCNij202 were derived from human larynx carcinomas. 
Viable 1 mm3 tumor pieces were implanted subcutaneously in 6- to 10-week-old athymic 
BALB/c nu/nu mice and passaged at a diameter of 1 cm. Tumors with a mean diameter 
of 4 to 5 mm transplanted at the hind leg were used in the experiments. 
Animals were treated with DSB (70 mg/kg per day, oral; LC Laboratories, Woburn, 
MA, USA) for 5 days, 10 Gy single-dose radiotherapy (320 KV, dose rate 3.8 Gy/min, 
X-RAD; RPS Services Limited, Surrey, UK) or a combination of DSB and 10 Gy (radio-
therapy given on day 4 of DSB treatment). 
For effects on tumor growth delay, tumor diameters were measured twice a week 
in three perpendicular directions and tumor volumes were determined by the formula: 
V= (a*b*c*π)/6. Endpoint was reached when the tumor volume tripled compared to 
the volume at start of treatment. Maximal follow-up was 60 days.   
For effects on protein expression, proliferation and hypoxia, tumors were har-
vested 1 day after 10 Gy radiotherapy and/or on day 5 of DSB treatment. One hour 
before euthanasia, animals were injected with 80 mg/kg of the hypoxia marker 
pimonidazole hydrochloride (1-[(2-hydroxy-3-piperidinyl) propyl]-2-nitroimidazole 
hydrochloride; Natural Pharmaceuticals International Inc., Research Triangle Park, 
NC, USA) and 15 minutes before euthanasia with 50 mg/kg of the proliferation marker 
bromodeoxyuridine (BrdUrd; Sigma, St Louis, MO, USA). After excision, tumors were 
snap frozen in liquid nitrogen. 
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines. All experiments were approved by the Animal Experiments Committee of 
the Radboud University Nijmegen Medical Centre.
Western blot analysis
Tumor sections were lysed in NP-40 lysis buffer and protein was quantitated using 
a standard Bradford absorbance assay. Proteins (35 μg per lane) were separated by 
SDS-PAGE and blotted onto PVDF membrane. Membranes were incubated with the 
appropriate primary antibodies followed by incubation with HRP-conjugated anti-
bodies and proteins were detected with an ECL chemiluminescence system. Antibodies 
against the following antigens were used: EGFR, AKT, and HRP-conjugated goat-anti-
mouse IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). DNA-
PK, pDNA-PK(S2056), SFK, pSFK(Y416), pAKT(S473), ERK1/2, pERK1/2(T202/Y204) and 
HRP-conjugated goat-anti-rabbit IgG were purchased from Cell Signaling Technology 
(Beverly, MA, USA) and α-tubulin was obtained from Calbiochem (San Diego, CA, USA).
Immunohistostochemical staining 
For quantification of hypoxia and proliferation, frozen tumor sections (5 μm) were 
stained for pimonidazole and BrdUrd, respectively, vessels and nuclei. For quantifica-
tion of DNA damage, tumor sections were stained for 53BP1 or Rad51, pimonidazole, 
vessels and nuclei. To evaluate colocalization of pSFK and hypoxia tumor sections 
were stained for pSFK(Y416), pimonidazole, and vessels. 
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The antibody against pimonidazole was a gift from J.A. Raleigh (University of North 
Carolina). Vessels were detected with 9F1, a rat monoclonal antibody against mouse 
endothelium (Department of Pathology, Radboud University Nijmegen Medical Centre). 
The antibody against BrdUrd was purchased from Genetex (Irvine, CA, USA), antibody 
against 53BP1 from Thermo Scientific (Waltham, MA, USA), and the antibody against 
Rad51 from Epitomics (Burlingame, CA, USA). 
Primary antibodies were detected by appropriate Cy3-conjugated (Jackson 
Immuno Research Laboratories Inc., West Grove, PA, USA), Alexa488-, Alexa647- or 
Alexa555-conjugated (Molecular Probes, Leiden, The Netherlands) secondary antibodies. 
All secondary antibodies were tested for specificity for the primary antibody by per-
forming the staining procedures without the primary antibody. Nuclei were stained 
with Hoechst 33342 (Sigma) or DAPI (Abcam, Cambridge, UK). 
Image acquisition and computerized analysis of DNA repair
Approximately 8 single fields were randomly chosen and recorded in tumor sections 
stained for 53BP1 or Rad51 using a fluorescence microscope (Zeiss, Göttingen, Germany). 
Each single field was acquired with different filters at 400x magnification to yield 
images of the different fluorescent signals. Single fields were acquired in both nor-
moxic and hypoxic tumor areas based on pimonidazole staining. Grey value images 
of 53BP1, Rad51 and nuclei were converted to binary images by setting thresholds for 
the fluorescence signals above the background using ImageJ software (NIH, Bethesda, 
MD, USA). Hypoxic tumor areas were delineated using the pimonidazole grey value 
images. The nuclear area positive for 53BP1 or Rad51 and the number of nuclei were 
quantified in hypoxic and normoxic regions separately. The average area positive for 
53BP1 or Rad51 per nucleus was calculated by dividing the total nuclear area of 53BP1 
or Rad51 by the total number of nuclei. At least 600 nuclei per tumor section were 
analyzed. 
Image acquisition and computerized analysis of hypoxia and proliferation
Stained tumor sections were scanned with a fluorescence microscope (Zeiss). Each 
section was sequentially scanned at 100x magnification to yield images of the different 
fluorescent signals. Thresholds for the fluorescence signals were interactively set 
above the background and the grey value images were converted to binary images. 
The hypoxic fraction (HF) was calculated by dividing the tumor area positive for 
pimonidazole by the total tumor area and the BrdUrd labeling index (LI) by dividing 
the nuclear area positive for BrdUrd by the total nuclear area of the tumor, as 
described before [20,21]. Necrotic areas and staining artifacts were excluded from 
analysis. 
Statistics
Tumor growth delay data were analyzed using Kaplan-Meier survival curves and Cox 
proportional-hazards regression. To determine whether DSB and radiotherapy had a 
synergistic effect on growth delay, the relative excess risk due to interaction (RERI) 
was calculated as described by Andersson et al. [22]. RERI values above 0 indicate 
biological interaction between treatments.
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Changes in hypoxia, proliferation and DNA damage after treatment were tested for 
significance using unpaired t tests. All tests were performed using Prism (GraphPad 
Software, Inc., LA Jolla, CA, USA) and p-values <0.05 were considered significant. 
rEsults
Combining DSB with radiotherapy induces significantly enhanced growth delay  
in HNSCC xenograft tumors
SCCNij153 and SCCNij202 tumors both expressed high levels of EGFR and pEGFR 
indicating active EGFR signaling in these tumor models (Figure 1A). SFKs and their 
activated form were also expressed in both tumor models, although the level of pSFK 
was markedly lower in SCCNij202 tumors (Figure 1A).
In both SCCNij153 and SCCNij202, the combination of DSB and radiotherapy 
significantly delayed tumor growth compared to untreated tumors (p<0.05), while 
DSB or radiotherapy alone did not induce a significant delay (Figure 1B). These results 
figure 1: Expression of EGFR and pSFK, and effects of DSB and/or radiotherapy on tumor growth 
delay. a) Expression of (p)EGFR and (p)SFK in untreated SCCNij153 and SCCNij202 tumors. two 
tumors per line were analyzed and both tumor lines were blotted on the same membrane. α-tubulin 
was used as loading control. b) Kaplan-Meier survival curves showing the effect of DSB and/or radio-
therapy on the tumor growth of SCCNij153 and SCCNij202. Events were scored when the tumor 
volume tripled compared to the start volume and % tumor response represents the percentage of 
tumors that did not reach the event. tumors were treated with DSB (five times 70 mg/kg), 10 Gy 
radiotherapy or combined DSB and radiotherapy. Number of animals per group: 6 to 8.
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indicate a synergistic effect of DSB and radiotherapy and RERI (relative excess risk 
due to interaction) values of 2.0 and 0.70 for SCCNij153 and SCCNij202, respectively, 
confirm this interaction. Although significant, the absolute delay in growth was 
small in SCCNij202 tumors, as is also reflected by the relative low RERI value of 0.70. 
DSB inhibits DNA-PK, but not AKT or ERK signaling 
Using Western blot analyses, clear inhibition of pSFK was observed in both tumor 
models when tumors were treated with DSB or the combination of DSB and radio-
therapy (Figure 2). DSB also decreased EGFR in SCCNij202 tumors, but not in SCCNij153 
tumors, while DSB slightly decreased pAKT in SCCNij153 tumors. However, no large 
effects on pAKT or pERK1/2 levels were observed in both tumor models after radio-
therapy, DSB or combined treatment. In contrast, DNA-PK levels were clearly decreased 
by DSB in both tumor models. Activated DNA-PK (pDNA-PK) was also inhibited by DSB 
in SCCNij202 tumors, although variation was present in tumors treated with combined 
DSB-radiotherapy treatment. In SCCNij153 tumors pDNA-PK levels were non-detectable 
and effects of treatment could not be assessed. 
figure 2: Effects of DSB and/or radiotherapy on EGFR signaling. Expression of EGFR, pSFK, (p)AKt, 
(p)ERK1/2, and (p)DNA-PK in SCCNij202 and SCCNij153 tumors. α-tubulin was used as loading con-
trol. tumors were treated with DSB (five times 70 mg/kg), 10 Gy radiotherapy or combined DSB and 
radiotherapy. tumors were harvested 24 hours after radiotherapy or after the fifth DSB treatment. 
three tumors per line were analyzed and tumor lines were blotted on separate membranes. 
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DSB increases residual DNA damage after radiotherapy, but only in the tumor  
compartment where pSFK is expressed
To determine whether decreased DNA-PK levels resulted in reduced repair of DNA 
double strand breaks, tumors were harvested 24 hours after radiotherapy with and 
without DSB and immunofluorescently stained for 53BP1. In SCCNij153 tumors, the 
area of 53BP1 per nucleus increased when DSB was combined with radiotherapy 
compared to radiotherapy alone in both hypoxic and normoxic tumor regions (p<0.01) 
(Figure 3A). This indicates increased residual DNA damage and thus a reduction of 
DNA repair due to DSB. In SCCNij202 tumors only hypoxic regions showed increased 
53BP1 staining after addition of DSB (p<0.01). 
Rad51 staining was also analyzed to determine the effects on DNA repair by 
homologous recombination (HR; Figure 3B). Again, the Rad51 area was increased in 
both hypoxic (n.s.) and normoxic (p<0.05) regions of SCCNij153 tumors treated with 
DSB and radiotherapy compared to radiotherapy alone, while in SCCNij202 this effect 
of DSB was only observed in hypoxic regions (p<0.01). 
figure 3: Effects of DSB and/or radiotherapy on residual DNA damage. Average area positive for 
53BP1 (a) or Rad51 (b) per nucleus in untreated tumors and tumors harvested 24 hours after treat-
ment with radiotherapy (10 Gy) or DSB (five times 70 mg/kg) and radiotherapy. Differences between 
10 Gy and DSB+10 Gy in hypoxic or normoxic areas were tested for significance using t tests, *: 
p<0.05, **: p<0.01. Error bars represent SEM. Number of animals per group: 3 to 4. 
a
b
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The hypoxia-specific effects of DSB in SCCNij202 tumors could be due to a higher 
expression of pSFK under influence of hypoxia in this tumor model. Therefore, 
untreated tumors of both SCCNij153 and SCCNij202 were immunofluorescently 
stained for pSFK and hypoxia (Figure 4). In SCCNij153 pSFK was widely expressed in 
both normoxic and hypoxic regions of the tumor, while pSFK expression in SCCNij202 
tumors was restricted to hypoxic regions of the tumor. This difference in pSFK expres-
sion pattern between SCCNij153 and SCCNij202 is also reflected in total pSFK levels 
of these tumors as observed with western blot (Figure 1A).
Hence, these data indicate that DSB reduces radiation-induced DNA repair and 
that this effect is restricted to regions of the tumor where pSFK is expressed.
No effect of DSB on hypoxia or proliferation
No consistent effects of DSB on hypoxia or proliferation were observed (Figure 5). 
Only the combination of DSB and radiotherapy reduced proliferation significantly in 
SCCNij202 (p<0.05), while DSB alone did not induce any reduction in proliferation. 
discussion
In the present study, we show that DSB enhances the effect of radiotherapy in two 
HNSCC xenograft models with EGFR expression. Moreover, we show that this inter-
action is likely due to inhibition of pSFK-mediated activation of DNA-PK by DSB, 
resulting in increased residual DNA damage after radiotherapy. However, the effects 
on tumor growth delay and DNA repair differed between tumor models, which has 
important implications for further research.
DSB has earlier been shown to induce degradation of EGFR and consequently 
inhibition of downstream pAKT and pERK1/2, resulting in induction of apoptosis in 
HNSCC in vitro [23]. In addition, Raju et al. reported that DSB only enhances radiation 
sensitivity in HNSCC cell lines in which DSB reduces pAKT levels [18]. Moreover, activa-
tion of AKT by radiation has been observed in various in vitro models, while Kim et al 
established that c-Src signaling is involved in this activation of AKT [24]. Although EGFR 
levels were slightly reduced after DSB treatment in SCCNij202, we neither observed 
activation of pAKT or pERK1/2 after radiation, nor inhibition of pAKT or pERK1/2 
after DSB treatment. This lack of change in pAKT and pERK1/2 levels could be due to 
activating factors present in our in vivo tumor models that are not present in the in 
vitro cell culture conditions applied by others [18,23,24]. In the study of Lin et al. cells 
can be rescued from DSB-induced apoptosis by increasing EGFR activation through 
ligand administration [23]. We did not measure EGFR ligand levels, but as both tumor 
models show high pEGFR levels it is likely that these ligands are indeed present in our 
tumor models. In addition, we have shown that in vivo expression of these kinases can 
be substantially affected by the tumor microenvironment [25]. The lack of inhibition 
of pERK1/2 and pAKT by DSB is also consistent with the observation that DSB alone 
did not have an effect on growth delay in either of our tumor models. 
 In contrast to pAKT and pERK1/2, we did observe significant inhibition of DNA-PK 
by DSB. In addition, pDNA-PK levels were decreased in SCCNij202 tumors treated with 
DSB. In SCCNij153 tumors pDNA-PK levels were below the detection limits and we 
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figure 5: Effects of DSB and/or radiotherapy on proliferation and hypoxia. Effects of DSB and/or 
radiotherapy on the BrdUrd labeling index (Li) (a) and hypoxic fraction (HF) (b). tumors were treated 
with DSB (five times 70 mg/kg), 10 Gy radiotherapy or combined DSB and radiotherapy. tumors were 
harvested 24 hours after radiotherapy or after the fifth DSB treatment. Differences between treat-
ment groups were tested for significance using t tests, *: p<0.05. Error bars represent SEM. Number 
of animals per group: 3 to 4.
a
b
figure 4: Expression of pSFK in relation to hypoxia in SCCNij153 and SCCNij202. Expression of pSFK 
in relation to hypoxia was visualized by immunofluorescence staining in untreated SCCNij153 and 
SCCNij202 tumors. pSFK: red, hypoxia: green, vessels: blue. Non-specific staining present in 
necrotic regions. Scale bars represent 500 µm. Magnification: 200x.
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could not confirm inhibition by DSB in this tumor model. Western blot analysis of 
whole tumor lysates also includes non-tumor tissue and this could decrease the 
expression levels of tumor proteins. This can make detection of proteins expressed at 
very low levels, like pDNA-PK, very difficult. EGFR signaling has been shown to affect 
DNA-PK activity by two ways, i.e., by indirect activation via the PI3K-AKT pathway 
(cytoplasmic pathway) or by direct interaction between EGFR and DNA-PK after trans-
location of EGFR to the nucleus (nuclear pathway) [26]. pSFK is involved in the nuclear 
translocation of EGFR and our observations that DNA-PK is inhibited by DSB inde-
pendent of pAKT levels suggests that DSB blocks only the nuclear signaling pathway 
of EGFR in our tumor models but not the cytoplasmic pathways. 
Importantly, we further observed that irradiated tumors that also received DSB showed 
an increase in residual DNA damage as detected by 53BP1 staining, which indicates 
that the inhibition of DNA-PK resulted in a functional reduction of DNA repair. Hence, 
our data indicate that DSB enhances radiosensitivity in vivo by inhibition of radiation-
induced DNA repair. DNA double strand breaks can be repaired through two main 
pathways: non-homologous end joining (NHEJ) and homologous recombination 
(HR) [27]. DNA-PK is a key protein of NHEJ, which acts throughout the cell cycle and 
repairs the majority of all DNA double strand breaks. However, we also observed an 
effect of DSB on radiation-reduced repair via homologous recombination (HR) as we 
detected increased levels of Rad51, a key protein in HR. Inhibition of EGFR-signaling 
has been shown to regulate HR, but this seems to be regulated via the cytoplasmic 
and not the nuclear pathway of EGFR [28].
HR acts only in S and G2 phase of the cell cycle. The observed effect of DSB on 
HR cannot, however, be explained by changes in cell cycle distribution. No effects on 
proliferation by DSB were observed in SCCNij153, and although combined DSB-radio-
therapy did decrease proliferation in SCCNij202 compared to untreated tumors, a 
decrease in proliferation should result in a decrease in Rad51 and not an increase as 
we observed. Several other mechanisms could explain the effect of DSB on HR. It has 
been shown that inhibition of DNA-PK activity increases the activity of HR suggesting 
that the observed increase in Rad51 is due to a compensatory increase of double 
strand breaks repaired via HR [29]. Lastly, DSB targets many kinases and the effect on 
HR could be independent of pSFK inhibition. Nonetheless, the observation that the 
effect of DSB on DNA repair was only present in the tissue compartment where pSFK 
is expressed does suggest that pSFK is involved in the effect on DNA repair. 
We observed striking differences in the expression pattern of pSFK between the two 
tumor models. pSFK was expressed diffusely throughout the tumors in SCCNij153 and 
only expressed in hypoxic regions in SCCNij202. This differential expression pattern 
probably explains the smaller effect of DSB on growth delay in SCCNij202 as only the 
hypoxic cells could be targeted by DSB in this tumor model. Both in vitro and in vivo 
studies have shown that pSFK is involved in the hypoxic response of tumor cells and 
is important for cell survival under hypoxic conditions [30,31]. The hypoxia-dependent 
expression of pSFK in SCCNij202 thus seems a more ‘physiological’ response, while 
the diffuse expression in SCCNij153 indicates constitutive activation of SFKs, which 
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can arise through multiple mechanisms [3]. Hence, the expression pattern of pSFK 
could be an important predictive biomarker for response to combined treatment with 
DSB and radiotherapy. 
Next to lower pSFK expression, the modest growth delay in SCCNij202 is also 
due to large variation in growth delay that was induced by DSB and radiotherapy in 
this tumor model; some tumors reached the endpoint at time points comparable to 
controls, while other tumors showed a clear growth delay. In addition, the variation in 
pDNA-PK levels between tumors treated with DSB and radiotherapy demonstrates the 
variation in response to treatment. This variation is probably also due to the hypoxia-
related expression pattern of pSFK in this tumor model. This expression pattern 
suggests that tumors with a higher hypoxic fraction will have a higher pSFK fraction. 
Although we treated all tumors at approximately the same volume, the extent of 
hypoxia varied between these tumors. Using immunofluorescence we did indeed 
observe that untreated tumors with a higher hypoxic fraction also had a higher pSFK 
fraction (data not shown), although the number of tumors is too low to draw firm 
conclusions. Together, these data suggest that tumors with a higher hypoxic fraction 
have a higher fraction of cells that can be targeted by DSB, resulting in a larger effect 
on tumor growth. Thus even tumors of the same tumor model can differ significantly 
in their response due to small differences in tumor microenvironmental parameters. 
DSB itself did not affect microenvironmental characteristics that are relevant for 
radiosensitivity, i.e., hypoxia and proliferation. The combination of DSB and radio-
therapy only reduced proliferation in SCCNij202 tumors. However, as we measured 
tumor cell proliferation only at 24 hours after radiotherapy, we possibly missed the 
effect of DSB and radiotherapy on proliferation in SCCNij153 tumors. At 24 hours 
after radiotherapy there can be BrdUrd labeling of cells that are doomed to die after 
one or two cell divisions and effects due to these doomed cells cannot be excluded. 
In conclusion, DSB has the potential to enhance the efficacy of radiotherapy in vivo 
by inhibition of radiation-induced DNA repair. DSB is thus a promising additive to 
radiotherapy to improve outcome in patients. However, the extent of effects differed 
between tumor models and further investigation is warranted to determine which 
tumor characteristics are predictive for response (e.g. EGFR and pSFK expression lev-
els, hypoxic fraction). Addition of another kinase inhibitor, like a pAKT inhibitor, 
which blocks cytoplasmic pathways important for radiation resistance could enhance 
outcome even further. This knowledge will be critical for optimal use of the combi-
nation of DSB and radiotherapy in the clinic. 
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The recently acquired increased insight in the molecular factors involved in tumor 
responses to radiotherapy has opened new possibilities to improve patient outcome 
after radiotherapy. Although successes have been achieved with the combination of 
agents targeting one of these molecular factors and radiotherapy, the impact on sur-
vival is relatively small due to intrinsic and acquired resistance. To be more successful 
in the clinic in the future, it will be critical to perform preclinical research in which 
not only effectiveness of a new treatment is investigated, but also predictive tumor 
characteristics are determined. These predictive markers will aid in selecting patients 
that are likely to respond to these new treatment strategies.
Value of preclinical cancer models 
The first essential factor for preclinical research to be reliable and predictive for a new 
treatment is the use of models that represent the human tumor. Primary tumor xeno-
grafts, established by implanting patient tumor material into immunocompromised 
mice, have been shown to resemble the original tumor histologically and molecularly 
and are, therefore, believed to be valuable models to validate newly developed thera-
pies [1-5]. However, many therapies that have been proven to be successful in xenograft 
models fail in clinical trials. This has given rise to the question to what extent these 
models represent the clinical reality and variability [6]. In this thesis the question was 
addressed to what extent head and neck xenograft tumors resemble patient tumors 
in their behavior in relation to hypoxia, metabolism and growth factor signaling 
(chapter 2). As also shown by others [3,5], good correlations were observed between 
the HNSCC primary tumor-xenograft pairs for some markers. Nevertheless, these 
correlations were never perfect and were also not observed for all markers. However, 
these mismatches between primary tumor and xenograft do not diminish the useful-
ness of xenografts as the variation observed in the primary tumors remained in the 
xenografted tumors. Hence, by choosing a representative panel of xenograft models 
that reflects the variation observed in patients, xenografts can be valuable tools to 
investigate the effects of new anti-cancer treatments. Nonetheless, results obtained 
with xenograft models will always have to be interpreted with caution as these models 
differ from the human situation in various aspects that are important for treatment 
response in the patient; e.g. the stromal component including the vasculature, which 
is not human but rodent, and the immune system of the host (the mice are immuno-
deficient). 
An important observation in chapter 2 was that the HIF-1α related proteins CAIX, 
MCT-4 and GLUT-1 were not always observed in hypoxic areas of the tumor, but were 
also expressed more diffusely in normoxic areas. This variation in expression pattern 
can have important consequences for the behavior of a tumor as it has been shown 
that tumors with perinecrotic expression of HIF-1α have a worse prognosis compared 
to tumors with a diffuse expression pattern [7,8]. Hence, not only the expression 
level, but also the expression pattern is an important tumor characteristic that can 
influence tumor response to treatment and consequently has to be taken in account 
when choosing a representative xenograft panel. 
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In chapter 3 the difference between standard cell culture (in vitro) and cells grown as 
xenograft tumors (in vivo) was investigated. In vitro cancer models are used widely as 
preclinical models for studying new anti-cancer treatments and resistance mecha-
nisms influencing the efficacy of these treatments [9-12]. These in vitro models have 
the advantage of being easy to modulate and a large quantity of data can be obtained 
quickly. However, these in vitro models lack the complexity of the tumor microenvi-
ronment, which can have a great impact on the behavior of tumor cells. Indeed, it 
was observed that the in vivo expression of activated kinases of important signaling 
pathways differed from the in vitro expression. Additionally, we found that in vivo pAKT 
expression was predominantly observed in hypoxic tumor regions, which indicated 
that hypoxia might activate AKT. However, hypoxic regions not only have low oxygen 
levels, but also low nutrient and pH levels that can activate signaling pathways as well 
[13]. By using the less complex in vitro models, it could be verified that hypoxia itself 
is one of the activating factors of AKT. Moreover, it was shown that pAKT inhibition 
decreased survival specifically in hypoxic cells and not in normoxic cells. Hypoxia is 
an inherent negative factor for treatment outcome in solid tumors, including outcome 
after radiotherapy [14-16]. Consequently, targeting hypoxic cells by pAKT inhibition 
could improve patient outcome after radiotherapy and further research is warranted 
to confirm this hypothesis. 
Although they lack the complexity of the tumor microenvironment, in vitro cancer 
models are useful and valuable models to get insight in mechanisms and targets of 
anti-cancer treatments. However, it will be essential to confirm these mechanisms in 
in vivo models that represent the variability observed in patients. 
Prediction of response to EGFR inhibition and radiotherapy in HNSCC 
Combining EGFR inhibition and radiotherapy has been shown to be effective in HNSCC 
in the clinic [17]. However, only a small proportion of patients benefit from the addition 
of EGFR inhibition and extensive research has been focused on identifying resistance 
mechanisms, mostly using various in vitro models [9-11,18-21]. Multiple mechanisms 
involved in resistance to EGFR inhibition have been proposed, including overexpres-
sion of other growth factor receptors, receptor-independent activation of down-
stream pathways and epithelial-mesenchymal transition (EMT) [22]. Unfortunately, 
few mechanisms have been confirmed in vivo and no selection criteria have been 
established in the clinic to select HNSCC patients for EGFR inhibition at this moment. 
In colorectal cancer K-RAS mutations have been shown to be a negative predictor for 
cetuximab sensitivity [23] and mutations in the kinase domain of EGFR have shown 
to be a positive predictor for EGFR tyrosine kinase inhibitor efficacy in lung cancer [24]. 
However, both these types of mutations are rare in HNSCC [25-27] and consequently 
do not play a major role in resistance to cetuximab in this tumor type. Hence, there is 
still a great need for biomarkers that can predict outcome after EGFR inhibition and 
radiotherapy in HNSCC. 
EGFR inhibition has shown to enhance radiosenstivity by affecting all three 
radiation resistance mechanism; intrinsic radiosensitivity, accelerated tumor cell 
proliferation and hypoxia [28]. The effects of cetuximab and radiotherapy on these 
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three radiation resistance mechanisms were correlated with response to treatment 
in a panel of 4 HNSCC xenograft models in this thesis (chapter 4-5). Although changes 
in hypoxia and DNA repair were observed after cetuximab and/or radiotherapy, 
changes in hypoxia and DNA repair were not predictive for response. Actually, repair 
of radiation-induced DNA damage was inhibited by cetuximab in the model that did 
not show any additional effect of cetuximab to radiotherapy in tumor growth delay 
assays. In contrast, changes in proliferation did correlate with treatment response, 
as proliferation was decreased after cetuximab treatment in cetuximab-sensitive 
SCCNij202 tumors and after combined cetuximab-radiotherapy in SCCNij185 tumors, 
which showed a synergistic effect when cetuximab was combined with radiotherapy. 
Moreover, the reduction of proliferation after combined treatment in SCCNij185 
suggests that cetuximab radiosensitizes these tumors by reducing their ability to 
repopulate after radiotherapy. Tumor cell repopulation in between fractions is an 
important cause of failure for radiotherapy and strategies that reduce this repopula-
tion can have large impact on patient outcome after radiotherapy [29]. 
Another interesting observation was the increase in apoptosis in time after 
combined cetuximab-radiotherapy in SCCNij185. Other studies have also linked the 
induction of apoptosis by cetuximab to its effect on cell radiosensitivity and tumor 
response after radiotherapy [30].
Although we did not identify predictive biomarkers that can be used before start 
of treatment, our results do point to the possibility to assess response at an early phase 
of treatment by assessing changes in proliferation or apoptosis. Imaging proliferation 
by 3’-deoxy-3’-18F-fluorothymidine (18F-FLT) has already been shown to detect prolifera-
tion changes after (chemo-)radiotherapy and EGFR inhibition [31-33] and also several 
PET tracers are under development to image apoptosis to assess treatment response 
[34-36]. By assessing response at an early phase of treatment it will be possible to 
customize treatment and only treat patients that will benefit from the addition of 
EGFR inhibition while adaptations can be made at an early stage for those who require 
alternative treatment strategies. 
Enhancing radiosensitivity via kinase inhibitors
Overexpression of other growth factor receptors is one of the proposed mechanisms 
involved in resistance to EGFR inhibition [20,37,38]. Radiation does not only activate 
EGFR, but also other tyrosine kinase receptors including other members of the ErbB 
receptor family [39] and the MET receptor [40]. These receptors activate similar down-
stream pathways and can thereby bypass the effect of EGFR inhibition. We also 
observed relative high levels of (p)HER3 and (p)MET in our HNSCC xenograft model 
that showed resistance to EGFR inhibition (chapter 4). In addition, downstream path-
ways can be constitutively activated via multiple mechanisms, including activating 
mutations in kinases or reduced activity of negative regulators [41]. Due to this con-
stitutive activation, inhibition of the receptor will not influence activation of the 
pathway and consequently will not improve outcome. This is demonstrated by the 
example that K-RAS mutated colorectal cancers are resistant to EGFR inhibition [23]. 
Hence, small molecule inhibitors of kinases that are important for tumor cell sur-
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vival after radiotherapy have the potential to overcome resistance to radiotherapy in 
a larger proportion of patients compared to receptor inhibitors. This approach has 
shown to increase radiosensitivity of tumor cells in in vivo models [42,43]. 
Findings presented in this thesis also demonstrate that kinase inhibitors can 
increase radiosensitivity both in vitro (chapter 6) and in vivo (chapter 7). However, the 
various kinase inhibitors were not effective in all HNSCC cell lines and intrinsic 
resistance is thus also a problem for these kind of targeted agents. Several potential 
resistance mechanisms could decrease the effectiveness of these kinase inhibitors. 
Firstly, numerous feedback systems are present between growth factor receptors and 
their downstream pathways, whereby inhibition of one kinase can lead to activation 
of receptors and consequently activation of other downstream pathways [44,45]. This 
compensatory activation can greatly diminish the effect of the kinase inhibitor on 
radiosensitivity. This can potentially be counteracted by either combining a receptor 
and a kinase inhibitor or by combining two or more kinase inhibitors against different 
pathways. However, combining multiple targeted therapies and radiotherapy will 
increase the chance of excessive toxicity and thereby diminish the applicability in the 
clinic. Another potential problem with the use of kinase inhibitors is the differential 
expression of kinases between tumors. Kinases can be constitutively activated by e.g. 
mutations, but can also be activated by factors in the tumor microenvironment like 
hypoxia. These differential expression patterns can have important consequences for 
the radiosensitizing effect of a kinase inhibitor as demonstrated in chapter 7 of this 
thesis. Conversely, the activation of kinases by microenvironmental factors also offers 
the opportunity to overcome resistance to kinase inhibitors by modulating the tumor 
microenvironment via other ways than targeted therapies. For example, hypoxia can 
be decreased via inhalation of hyperoxic gasses such as carbogen (98% oxygen + 2% 
carbon dioxide) and administration of nicotinamide [14,46] and in this way hypoxia-
induced activation of resistance pathways could be counteracted. The addition of 
carbogen and nicotinamide to accelerated radiotherapy (ARCON) has no significant 
impact on toxicity [47]. ARCON is, therefore, potentially a more feasible therapy to 
combine with a kinase inhibitor than the combination of multiple targeted therapies 
and radiotherapy. Also radiotherapy itself has important effects on the tumor micro-
environment (e.g. hypoxia) and can activate various signaling pathways [39,40,48]. 
Hence, it will be important to optimize the timing of the administration of the kinase 
inhibitor and the fractionation schedule of radiotherapy as this could significantly 
impact tumor cell kill and consequently patient outcome.
Overall, kinase inhibitors have the potential to increase radiosensitivity of 
tumors and thereby improve the outcome of patients. Nonetheless, kinase inhibitors 
also encounter various resistance mechanisms. Further research is warranted to 
increase insight in these resistance mechanisms and how they can be tackled to 
increase the efficacy of these kinase inhibitors. It will be essential to validate these 
mechanisms in vivo as the tumor microenvironment has large effects on pathway 
activation. 
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HNSCC as a model for overcoming radioresistance in solid tumors
The experiments described in this thesis were all performed in HNSCC models and 
patients. However, the results obtained are not exclusively applicable to HNSCC. The 
major radioresistance mechanisms investigated in this thesis are not only a cause of 
failure in HNSCC patients, but also present major obstacles in other solid tumor types. 
For example, hypoxia has also shown to affect radiotherapy response in other tumor 
types, including cervical cancer [49]. Furthermore, hypoxia is not only a negative 
predictor for radiotherapy response, but also an independent prognostic factor for 
poor outcome [50]. Hence, targeting the survival of hypoxic cells by pAKT inhibition 
has not only the potential to improve outcome in patients treated with radiotherapy, 
but also patients treated with surgery and/or chemotherapy. Our lab has shown that 
pAKT expression is present in hypoxic tumor areas of breast cancer patients and that 
pAKT expression is correlated with poor outcome in these patients [51]. These data 
indicate that inhibition of pAKT could also improve outcome in breast cancer.
Activation of growth factor receptor signaling pathways is not only a character-
istic of HNSCC, but occurs in a wide variety of solid tumors, including lung, breast and 
colorectal cancer [41]. EGFR overexpression is extensively observed in these tumor 
types and EGFR inhibitors have been used with varying success [22]. In addition to 
EGFR, overexpression of other growth factor receptors, including other members of the 
ErbB family and MET, or mutations of downstream kinases, like RAS, are a common 
feature of various solid tumors. Although the cause of growth factor receptor signaling 
activation differs between tumor types (i.e. HER2 overexpression in breast cancer vs. 
K-RAS mutations in colorectal cancer), the activated downstream pathways are mostly 
similar and induce the same oncogenic properties. Hence, especially results with 
inhibitors of kinases of these pathways can be translated from one tumor type to the 
other. The challenge for the future will be to determine which kinase pathway(s) are 
crucial for tumor cell survival in an individual patient. This characteristic is not spe-
cific for a tumor type, but specific for an individual tumor. It will be essential to 
determine this characteristic to personalize treatments and achieve the best possible 
outcome with the least toxicity for each individual patient. 
Concluding remarks and future directions
The development of targeted therapies against growth factor receptors and their 
downstream kinases has offered the opportunity to decrease radioresistance and 
thereby enhance radiotherapy outcome in the clinic. However, despite the opportu-
nities these inhibitors offer, a remaining challenge is to determine which cancer 
patient would benefit from which inhibitor. It will be critical to increase insight in 
the mechanisms involved in enhancing radiosensitivity via targeted therapies and 
the potential resistance mechanisms involved. Preclinical xenograft models offer the 
possibility to represent the variation in the clinic and are valuable models to increase 
knowledge and thereby increase the potential of a new anti-cancer treatment to be 
successful in the clinic. Nonetheless, even tumors from the same site and with the 
same histology vary widely in their genome, transcriptome, proteome and kinome, 
and as a result numerous resistance mechanisms can be present in one tumor type. 
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Consequently, it will be challenging to find a comprehensive set of biomarkers that 
has a high predictive value and is easy to incorporate in clinical practice. Therefore, 
effort has to be invested in developing methods that can reliably assess response in 
an early phase of treatment. These methods are more likely to predict treatment 
response in a larger proportion of patients, because different resistance mechanisms 
will result in the same negative response. 
Although challenging, combining inhibitors of growth factor receptor signaling 
with radiotherapy holds the promise to increase patient outcome without inducing 
excessive toxicity and, therefore, need to be an important topic of both preclinical 
and clinical research in the future.
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Radiotherapy is an integral part of the treatment of locoregionally advanced head 
and neck squamous cell carcinoma (HNSCC). Although optimization of radiotherapy 
fractionation schedules and addition of chemotherapy have improved outcome, cure 
rates are still relatively poor for HNSCC patients with advanced-stage disease. Hence, 
there is a great need for new therapeutic strategies that could further increase radio-
therapy effectiveness and consequently improve outcome in these patients. Increasing 
insight in the molecular basis of radioresistance has revealed that signaling via growth 
factor receptors, including the Epidermal Growth Factor Receptor (EGFR), is involved 
in the three major radioresistance mechanisms: intrinsic radiosensitivity (DNA repair), 
accelerated tumor cell proliferation, and hypoxia (low oxygen tension). Consequently, 
agents that target growth factor receptor signaling have the potential to increase radio-
sensitivity in HNSCC. The combination of EGFR inhibition (cetuximab) and radio-
therapy has indeed shown to improve outcome in HNSCC patients. However, this 
approach is not successful in all patients and to optimize treatment effectiveness 
predictive biomarkers for response to EGFR inhibition and radiotherapy have to be 
determined as this will make it possible to only treat patients that are likely to respond. 
Furthermore, it will be critical to develop new therapeutic strategies that are effective 
in a larger proportion of the patient population. Preclinical in vitro and in vivo models 
offer the opportunity to investigate both effectiveness and possible resistance mech-
anisms of new treatment combinations. However, to be able to reliably translate results 
from preclinical models to the patient it will be essential that preclinical models 
represent the variation in biological characteristics observed in patients.
In this thesis predictive markers for response to EGFR inhibition and radio-
therapy were investigated as well as new therapeutic approaches combining kinase 
inhibitors with radiotherapy. In addition, the value of preclinical HNSCC models for 
research into growth factor receptor signaling was studied to validate the use of 
these models.   
Value of preclinical models for studying growth factor receptor signaling in HNSCC
Primary tumor xenografts, established by implanting patient tumor material into 
immunocompromised mice, are important preclinical models in cancer research. 
However, it is often questioned to what extent these models represent the clinical 
reality and variability. Hypoxia, metabolism, and growth factor receptor signaling 
are important prognostic features in most solid tumors. In chapter 2, the expression 
levels of various proteins involved in these features were examined in xenografts 
and the primary tumors they were derived from. Significant correlations between 
primary tumors and xenografts were observed for the percentage of cells positive for 
expression and the hypoxia-related expression pattern of some molecular markers 
(CAIX, GLUT-1, MCT-1, and MCT-4). However, correlations were not observed for all 
markers and often mismatches were observed between xenografts and primary tumors. 
Nevertheless, the xenografts did represent the variability in expression levels and 
patterns observed in the primary tumors. Hence, our data demonstrate the signifi-
cance of selecting a representative panel of xenograft models to match the variation 
observed in patients. Although xenografts not always resemble the primary tumor 
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exactly, when used critically they are valuable tools to investigate the effects of new 
anti-cancer treatments.
In chapter 3, the correlation between in vitro and in vivo expression of (activated 
i.e. phosphorylated) proteins of the EGFR-signaling network was studied in a panel of 
HNSCC cell lines that were both cultured in standard 2D cell culture (in vitro) and 
grown subcutaneously as xenografts in nude mice (in vivo). Using this approach, we 
observed strong in vitro -in vivo correlations for receptors (p)EGFR and HER2, but not 
for downstream kinases pAKT, pERK1/2, or pSTAT3. Moreover, pAKT expression was 
observed in hypoxic cells of xenografts and the pAKT fraction was significantly cor-
related with the hypoxic fraction in these tumors. This hypoxia-induced expression 
of pAKT was confirmed in vitro. Furthermore, pAKT inhibition caused a significant 
decrease in survival of hypoxic cells, but not of normoxic cells. Hence, we showed 
that hypoxia induces activation of AKT both in vitro and in vivo, and that hypoxic cells 
can be specifically targeted by pAKT inhibition. Targeting pAKT is thus a potential 
way to overcome therapy resistance induced by hypoxia.  
Prediction of response to EGFR inhibition and radiotherapy in HNSCC 
In part II of this thesis, chapters 4 and 5, the effects of EGFR inhibition via cetuximab 
on the three major radioresistance mechanisms were investigated in a panel of 
HNSCC xenograft models and correlated with response to EGFR inhibition and radio-
therapy. In chapter 4, it was shown that effects on proliferation, but not on hypoxia, 
correlated with response to combined cetuximab-radiotherapy in a panel of four HNSCC 
xenografts. In addition, expression of other growth factor receptors, including HER3 
and MET, seemed to be correlated with resistance to cetuximab and are potential 
clinically relevant predictive biomarkers that could be used to select patients for 
treatment with cetuximab and radiotherapy. In chapter 5, the effects of cetuximab 
on repair of radiation-induced DNA damage were investigated in a HNSCC xenograft 
model that shows a synergistic effect of cetuximab and radiotherapy and in a HNSCC 
model that shows no additive effect of cetuximab to radiotherapy. In both xenograft 
models an increase in residual DNA damage was observed when cetuximab was added 
to radiotherapy compared to radiotherapy alone. The effects of cetuximab on apoptosis 
did differ between the HNSCC models. After combined cetuximab-radiotherapy, 
apoptosis only increased in the tumor model that showed a synergistic effect of 
cetuximab. Hence, cetuximab inhibited DNA repair in both HNSCC models, but this 
effect was not predictive for the radiosensitizing effect of cetuximab. This lack of 
correlation may be related to a decreased induction of apoptosis by cetuximab and 
radiotherapy in the resistant model.
Enhancing radiosensitivity via kinase inhibitors
Resistance to inhibitors of growth factor receptors can be due to activation of other 
receptors or due to constitutive activation of downstream kinases. Inhibitors of kinases 
could circumvent these resistance mechanisms and consequently have the potential 
to increase radiosensitivity in a larger proportion of the patients than growth factor 
receptor inhibitors. Therefore, the aim of part III, chapter 6 and 7, was to determine 
whether inhibitors of kinases could enhance radiosensitivity in HNSCC. In chapter 6, 
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antibody-based arrays were used to identify kinases that correlated with radiosensi-
tivity in a panel of HNSCC lines. Kinases of the AKT, MAPK, STAT, and SFK pathways 
correlated with radiosensitivity. Inhibitors of these kinases, particularly of MEK1/2, 
STAT5, and STAT6, were able to decrease tumor cell survival in combination with 
radiotherapy. However, as with inhibitors against growth factor receptors, tumor cell 
lines displayed differential sensitivity. Hence, inhibitors against these kinases have 
the potential to improve radiotherapy outcome in a subset of HNSCC patients.
Src family kinases (SFKs) have been implicated in resistance to both radiation 
and EGFR inhibition and can be inhibited by dasatinib. In chapter 7, the combina-
tion of dasatinib with radiotherapy was tested in two HNSCC xenograft models. 
Dasatinib combined with radiotherapy induced a significant growth delay in both 
HNSCC xenograft models. Dasatinib did not inhibit the AKT or ERK pathway, but did 
inhibit (p)DNA-PK. The inhibition of this important DNA repair protein correlated 
with the effect of dasatinib on DNA repair; dasatinib reduced repair of radiation-
induced DNA damage in both models. Moreover, this effect on DNA repair was only 
observed in the cell compartment where pSFK was expressed. In the tumor model 
with diffuse pSFK expression effects on DNA repair were observed in both normoxic 
and hypoxic areas, while effects on DNA repair were only observed in hypoxic areas of 
the tumor model that showed hypoxia-related pSFK expression. Dasatinib did not have 
consistent effects on the other radioresistance mechanisms hypoxia and proliferation. 
Hence, dasatinib enhances the effect of radiotherapy in vivo by inhibition of radiation-
induced DNA repair and combining dasatinib with radiotherapy is a promising way 
to improve outcome in HNSCC patients. 
Conclusions
In this thesis it was shown that HNSCC xenograft tumors are valuable tools to inves-
tigate new anti-cancer treatments as they represent the variability in expression levels 
and patterns observed in primary tumors. Xenograft tumor models provide an excellent 
tool to investigate efficacy of treatments for which microenvironmental factors, such 
as hypoxia, are of crucial influence. Furthermore, by investigating differences in expres-
sion between in vitro and in vivo models, it was observed that hypoxia induces activation 
of AKT and that this activation of AKT is important for cell survival under hypoxia. 
Hence, targeting pAKT is a potential way to overcome therapy resistance induced by 
hypoxia and consequently improve outcome in patients with hypoxic tumors.
In search for predictive biomarkers for combined treatment with EGFR inhibi-
tion and radiotherapy, it was found that effects on proliferation and basal expression 
of other growth factor receptors are potential clinically relevant predictive biomarkers. 
In contrast, effects on hypoxia and DNA repair were not correlated with treatment 
response.  
Finally, it was shown that inhibitors of kinases important for cell survival after 
radiotherapy can increase the radiosensitivity of HNSCC both in vitro and in vivo. Hence, 
treatments that combine these kinase inhibitors with radiotherapy are promising 
new strategies to improve radiotherapy outcome in patients.
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Radiotherapie staat centraal in de behandeling van lokaal uitgebreide hoofd-hals-
kanker. Optimalisatie van het toegepaste fractioneringsschema en toevoeging van 
chemotherapie hebben geleid tot een betere overleving van patiënten met vergevor-
derde hoofd-halskanker. Ondanks deze verbeteringen is de kans op genezing echter 
nog steeds laag voor deze patiënten. Het is daarom van essentieel belang om nieuwe 
behandelstrategieën te ontwikkelen die de effectiviteit van radiotherapie kunnen 
vergroten en daarmee de uitkomst in deze patiënten kunnen verbeteren. Door toe-
nemend inzicht in de moleculaire basis van stralingsresistentie is duidelijk geworden 
dat signalering via groeifactorreceptoren, zoals de Epidermal Growth Factor Receptor 
(EGFR), betrokken is bij de 3 belangrijkste mechanismen die stralingsresistentie ver-
oorzaken: intrinsieke stralingsgevoeligheid (herstel van DNA-schade), versnelde pro-
liferatie van tumorcellen nadat de bestraling is gestart, en hypoxie (lage zuurstof-
spanning). Dit betekent dat therapeutische middelen die deze groeifactorreceptor- 
signalering remmen mogelijk de stralingsgevoeligheid van hoofd-halskanker kunnen 
vergroten. Zo is al bewezen dat de combinatie van een EGFR-remmer (cetuximab) en 
radiotherapie de overleving van patiënten met hoofd-halskanker verbetert. Deze 
combinatiebehandeling is echter niet succesvol in alle patiënten. Om de efficiëntie 
van deze behandeling te vergroten is het noodzakelijk om vast te stellen welke bio-
logische kenmerken de gevoeligheid voor EGFR-remming en radiotherapie kunnen 
voorspellen, om zo alleen die patiënten te behandelen die de grootste kans maken te 
reageren. Daarnaast is het belangrijk om nieuwe behandelmethoden te ontwikkelen 
die effectief zijn in een groter deel van de patiëntenpopulatie. Preklinische in vitro en 
in vivo kankermodellen maken het mogelijk om zowel effectiviteit als mogelijke 
resistentiemechanismen van nieuwe behandelcombinaties te onderzoeken. Om de 
resultaten van deze preklinische modellen te vertalen naar de patiënt is  het essentieel 
dat deze modellen een vergelijkbare variatie in biologische eigenschappen laten zien 
die ook bij patiënten wordt gevonden. 
In dit proefschrift zijn kenmerken onderzocht die de gevoeligheid voor EGFR-
remming en radiotherapie kunnen voorspellen en zijn ook nieuwe behandelmethodes 
getest, waarbij kinase-remmers gecombineerd werden met radiotherapie. Daarnaast 
is de waarde van preklinische hoofd-halskanker modellen bestudeerd om het gebruik 
van deze modellen voor onderzoek naar groeifactorreceptor-signalering te valideren.
Waarde van preklinische modellen voor het bestuderen van groeifactorreceptor- 
signalering in hoofd-halskanker
Primaire tumor xenografts, gevormd door implantatie van tumormateriaal van de 
patiënt in muizen met een verzwakt immuunsysteem, zijn belangrijke preklinische 
modellen in het kankeronderzoek. Niettemin wordt er vaak getwijfeld in hoeverre 
deze modellen de klinische realiteit en variabiliteit vertegenwoordigen. Hypoxie, meta-
bolisme en groeifactorreceptor-signalering zijn belangrijke prognostische kenmerken 
in de meeste solide tumoren. In hoofdstuk 2 werden de expressieniveaus van verschil-
lende eiwitten betrokken bij deze kenmerken bestudeerd in xenografts en de primaire 
tumoren waaruit deze xenografts gevormd waren. Significante correlaties tussen 
primaire tumoren en xenografts werden waargenomen voor het percentage cellen 
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met expressie als het hypoxie-gerelateerde expressiepatroon voor sommige mole-
culaire markers (CAIX, GLUT-1, MCT-1 en MCT-4). Correlaties werden echter niet voor 
alle markers gevonden en er waren vaak mismatches tussen xenografts en primaire 
tumoren. Niettemin lieten de xenografts wel de variatie in expressieniveaus en 
-patronen zien, die ook in de patiënt tumoren werd waargenomen. Dus al lijken de 
xenografts niet altijd precies op de primaire tumor, door ze wijselijk te gebruiken 
kunnen ze toch waardevolle middelen zijn om de effecten van nieuwe anti-kanker-
behandelingen te onderzoeken. 
In hoofdstuk 3 werd de correlatie tussen de in vitro en in vivo expressie van 
(geactiveerde; p) eiwitten van het EGFR-signaleringsnetwerk bestudeerd in een panel 
van hoofd-halskanker cellijnen, die zowel gekweekt werden in standaard 2D celkweek 
(in vitro) als subcutaan gegroeid werden als xenografts in naakte muizen (in vivo). Met 
deze aanpak hebben we sterke in vitro-in vivo correlaties waargenomen voor de recep-
toren (p)EGFR en HER2, maar niet voor de geactiveerde intracellulaire signaalmole-
culen (kinases) pAKT, pERK1/2 en pSTAT3. Verder werd pAKT expressie waargenomen 
in hypoxische cellen van xenografts en was de pAKT-fractie significant gecorreleerd 
met de hypoxische fractie in deze tumoren. Deze hypoxie-geïnduceerde expressie 
van pAKT werd in vitro bevestigd. Bovendien leidde remming van pAKT tot een signi-
ficante daling in de overleving van hypoxische cellen, maar niet van normoxische 
cellen. We hebben dus laten zien dat hypoxie zowel in vitro als in vivo de activatie van 
AKT induceert en dat hypoxische cellen specifiek aangepakt kunnen worden met pAKT 
remming. Remming van pAKT vormt hiermee een potentiële manier om behandel-
resistentie veroorzaakt door hypoxie tegen te gaan.  
De gevoeligheid voor EGFR-remming en radiotherapie in hoofd-halskanker voorspellen 
In deel II van dit proefschrift, hoofdstuk 4 en 5, werden in een panel van hoofd-hals-
kankerxenograftmodellen de effecten van EGFR-remming via cetuximab op de drie 
belangrijkste stralingsresistentie-mechanismen onderzocht en gecorreleerd met de 
gevoeligheid voor EGFR-remming en radiotherapie. In hoofdstuk 4 lieten we zien dat 
de effecten op proliferatie, maar niet op hypoxie, gecorreleerd waren met de gevoelig-
heid voor gecombineerde cetuximab-radiotherapie behandeling in een panel van vier 
hoofd-halskankerxenografts. Daarnaast leek de expressie van andere groeifactor-
receptoren, inclusief HER3 en MET, gecorreleerd te zijn met resistentie tegen cetuxi-
mab en zijn het daarmee potentieel klinisch relevante biomarkers die gebruikt zouden 
kunnen worden om patiënten te selecteren voor behandeling met cetuximab en radio-
therapie. In hoofdstuk 5 werden de effecten van cetuximab op herstel van stralings-
geïnduceerde DNA-schade bestudeerd in een hoofd-halskankerxenograftmodel dat 
een synergistisch effect van cetuximab en radiotherapie laat zien en een hoofd-hals-
kankermodel dat geen additioneel effect van cetuximab laat zien in combinatie met 
radiotherapie. In beide xenograftmodellen werd een toename in residuele DNA-schade 
gezien wanneer cetuximab toegevoegd werd aan radiotherapie ten opzichte van 
radiotherapie alleen. De effecten van cetuximab op apoptose verschilden wel tussen 
de hoofd-halskankermodellen; apoptose nam na gecombineerde behandeling met 
cetuximab en radiotherapie alleen toe in het model dat een synergistisch effect van 
cetuximab laat zien. Cetuximab remde dus DNA-herstel in beide hoofd-halskanker-
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modellen, maar dit effect was niet voorspellend voor synergie tussen cetuximab en 
radiotherapie. Dit gebrek aan correlatie is mogelijk gerelateerd aan een verminderde 
inductie van apoptose door cetuximab en radiotherapie in het resistente model. 
Stralingsgevoeligheid vergroten door kinase-remmers
Resistentie tegen remmers van groeifactorreceptoren kan veroorzaakt worden door 
activatie van andere receptoren of door constante activatie van intracellulaire kinases. 
Kinase-remmers zouden mogelijk deze resistentiemechanismen kunnen omzeilen en 
hebben daardoor de mogelijkheid om de stralingsgevoeligheid bij een groter deel van 
de patiënten te vergroten dan groeifactorreceptor-remmers doen. Daarom was het doel 
van deel III, hoofdstuk 6 en 7, om te bepalen of kinase-remmers de stralingsgevoelig-
heid van hoofd-halskanker kunnen vergroten. In hoofdstuk 6 werden antilichaam-
gebaseerde arrays gebruikt om kinases te identificeren die correleerden met stralings-
gevoeligheid in een panel hoofd-halskankercellijnen. Kinases van de AKT, MAPK, 
STAT en SFK signaleringsroutes correleerden met stralingsgevoeligheid. Remmers van 
deze kinases, vooral van MEK1/2, STAT5 en STAT6, waren in staat om de celoverleving 
te verminderen in combinatie met radiotherapie. De tumorcellijnen lieten echter wel 
verschillende gevoeligheid voor de remmers zien, net zoals bij remmers van groei-
factorreceptoren. Remmers tegen deze kinases hebben dus de potentie om de uitkomst 
na radiotherapie te verbeteren in een deel van de patiënten met hoofd-halskanker.  
Onderzoek heeft laten zien dat Src family kinases (SFKs) betrokken zijn bij resis-
tentie tegen zowel bestraling als EGFR-remming. In hoofdstuk 7 werd de combinatie 
van dasatinib, een remmer van SFKs, en radiotherapie getest in twee hoofd-halskanker 
xenograft modellen. Dasatinib gecombineerd met radiotherapie veroorzaakte een 
significante groeivertraging in beide xenograft modellen. Dasatinib remde de AKT en 
ERK signaleringsroutes niet, maar remde wel (p)DNA-PK. De remming van dit belang-
rijke DNA-herstel-eiwit correleerde met het effect van dasatinib op DNA-herstel; 
dasatinib verminderde het herstel van stralings-geïnduceerde DNA-schade in beide 
modellen. Bovendien werd dit effect op DNA-herstel alleen waargenomen in het cel-
compartiment waar pSFK tot expressie kwam. In het tumormodel met diffuse pSFK 
expressie werd het effect op DNA-herstel in zowel normoxische als hypoxische gebie-
den gezien, terwijl in het model met hypoxie-gerelateerde pSFK expressie het effect 
op DNA-herstel alleen in hypoxische gebieden werd gezien. Dasatinib had geen con-
sistente effecten op de andere stralingsresistentie-mechanismen hypoxie en prolife-
ratie. Uit deze resultaten blijkt dat dasatinib het effect van radiotherapie in vivo ver-
groot door remming van stralings-geïnduceerd DNA-herstel en dat de combinatie van 
dasatinib en radiotherapie een veelbelovende manier is om de uitkomst van patiënten 
met hoofd-halskanker te verbeteren.
Conclusies
In dit proefschrift werd de waarde van hoofd-halskankerxenografttumoren onder-
zocht, waarbij werd gevonden dat deze modellen waardevolle middelen zijn om nieuwe 
anti-kankerbehandelingen te testen aangezien ze de variabiliteit in expressieniveaus 
en -patronen vertonen die ook gezien wordt in primaire patiënt tumoren. Xenograft-
modellen zijn uitstekende middelen om de effectiviteit van behandelingen te onder-
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zoeken waarop factoren van het micromilieu, zoals hypoxie, een cruciale invloed heb-
ben. Daarnaast hebben we, door het onderzoeken van verschillen in expressie tussen 
in vitro en in vivo modellen, gevonden dat hypoxie de activatie van AKT induceert en 
dat deze activatie van AKT belangrijk is voor celoverleving onder hypoxische omstan-
digheden. Remming van pAKT is dus een potentiële manier om therapieresistentie 
veroorzaakt door hypoxie tegen te gaan en daarmee de uitkomst te verbeteren van 
patiënten met hypoxische tumoren. 
Tijdens de zoektocht naar biomarkers die de gevoeligheid voor gecombineerde 
behandeling met EGFR-remming en radiotherapie voorspellen, werd er gevonden dat 
effecten op proliferatie en de basale expressie van andere groeifactor receptoren 
mogelijk klinisch relevante voorspellende biomarkers zijn. Daarentegen waren effec-
ten op hypoxie en DNA-herstel niet gecorreleerd met gevoeligheid voor behandeling 
met EGFR-remming en radiotherapie.
Ten slotte werd er aangetoond dat remmers van kinases, die belangrijk zijn 
voor celoverleving na radiotherapie, de stralingsgevoeligheid van hoofd-halskanker 
zowel in vitro als in vivo kunnen vergroten. Hiermee zijn dit veelbelovende nieuwe 
strategieën om de overleving van patiënten na radiotherapie te verbeteren.  
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op mijn project heb je je altijd volledig ingezet voor dit onderzoek en begon je altijd 
weer met goede moed aan een nieuw experiment, al was het alweer de zoveelste 
herhaling van het experiment. Wat zou onderzoek toch makkelijk zijn als alles in 1 
keer lukte... Beste Wenny, Jasper en Hans, ook jullie kon ik moeiteloos vinden als ik 
hulp nodig had bij kleuringen en analyses; zelfs als ik thuis zat met weer een 
gescheurde band of in het buitenland zat gaf ik jullie geen rust. 
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Heel erg bedankt voor al jullie inzet en voor het aanleveren van de vele data! Naast 
deze praktische hulp, wil ik jullie natuurlijk ook bedanken voor alle gezelligheid die 
een hele dag pipeteren of ‘ondergedoken’ zitten in de microscoopkamer een stuk 
aangenamer maken!
Beste Paul, begonnen als kamergenoten hebben we elkaar zowel als collega en als 
persoon goed leren kennen. Het was en is altijd een plezier om met je samen te werken 
en daarnaast ben je natuurlijk ook essentieel voor het onderzoek op onze afdeling 
als onze ‘beeld-analyse-man’. Bedankt voor alle oplossingen die jij aandroeg als wij 
onderzoekers weer iets bedacht hadden om te willen meten!
Beste mede-promovendi en kamergenoten, beste Marloes, Monique, Anika, Tineke, 
Laura en onze laatste toevoeging Sven, wat is het fijn om alle positieve kanten, maar 
ook vooral alle negatieve kanten (misschien toch nog maar een keer die boksbal 
kopen?!) van het promoveren te kunnen delen met mensen die in hetzelfde schuitje 
zitten. We hebben heel wat uren over onze onderzoeken gediscussieerd en dat moest 
natuurlijk ook (ruim) gecompenseerd worden met discussies over onderwerpen die 
‘iets minder’ met ons onderzoek te maken hadden... Bedankt voor alle steun, hulp en 
gezelligheid! 
Ook wil ik hierbij natuurlijk Esther, Ilse, Saskia en Bianca, de dames van de 
‘bovenverdieping’, niet vergeten; ook dank voor jullie input in mijn onderzoek en de 
fijne samenwerking!
Dit proefschrift beschrijft vele dierexperimenten en zonder de hulp van vele mede-
werkers van het centraal dierenlab hadden deze experimenten niet kunnen plaats 
vinden. Dank aan allen en met name aan de biotechnici, Geert, Jeroen, Debby, Henk, 
Janneke, Bianca, Iris en Kitty, voor de goede zorgen, inzet, en flexibiliteit die ervoor 
gezorgd hebben dat deze dierexperimenten succesvol zijn uitgevoerd. 
A part of my project has been performed in collaboration with the group of Deric 
Wheeler at the University of Wisconsin. This collaboration gave me the unique 
opportunity to work and live in a whole different environment. Dear Deric, thank 
you for giving me the possibility to work in your lab. Your new view on my project 
has improved my project and led to new interesting paths to pursue. Thank you very 
much for all your input! 
Dear Mari, Toni and Chunrong, you made me feel welcome from the start! Thank 
you for all your help with my experiments. You made performing experiments in 
your lab a lot more fun and you also learned me a little bit about your life and the 
Madison life (I still miss the home-made sushi and the pizza at Madison Memorial 
Union Terrace). I will never forget this amazing experience thanks to you!
Tijdens mijn project heb ik meerdere stagiaires mogen begeleiden, wat niet alleen 
voor hun, maar ook voor mij persoonlijk een zeer leerzame ervaring is geweest. In 
het bijzonder wil ik Simone en Stijn bedanken die als coauteurs van mijn artikelen 
een belangrijke bijdrage hebben geleverd aan dit project. 
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Ook wil ik hierbij nog kort de vele andere collega’s van de afdeling radiotherapie 
bedanken voor al hun praktische hulp bij de muizenbestraling, en ook voor alle 
gezelligheid bij de koffieautomaat, tijdens het skiën, of de ‘maandelijkse’ borrel!
Om succesvol je promotie af te ronden is het ook erg belangrijk dat je goed in je vel 
zit en vele mensen buiten mijn werk hebben hierbij geholpen. 
Lieve Linda en Marye, ik ken jullie al zolang ik me kan herinneren en dat is onder-
hand toch al heel wat jaar... Het is erg fijn om vriendinnen te hebben die je zo goed 
kennen en zoveel gezamenlijke herinneringen met je delen, waar we ook nog vaak 
om kunnen lachen (bijvoorbeeld het verhaal van de rode auto bij Flophouse en ver-
geet ook vooral het handdoekenrekje niet...). Ook delen we ons fanatisme en plezier 
in het spelen van spelletjes en we hebben hier al vele uren mee doorgebracht. 
Bedankt voor al jullie steun, ook in de mindere tijden, en alle gezelligheid! Op naar 
een toekomst om nog veel meer leuke herinneringen erbij te maken!
Lieve BMW-meiden, lieve Annet, Saskia, Inge, Anne en Ilse, niet te geloven dat het 
alweer 10 jaar geleden is dat we elkaar tegen kwamen in onze eerste werkgroep! 
Vanaf het begin hebben we altijd al veel lol met elkaar gehad en elke keer als we 
elkaar nu zien (altijd minder vaak dan we zouden willen) is het weer als vanouds. 
Onze gezamenlijke basis heeft ervoor gezorgd dat ik altijd goed met jullie over mijn 
promotie project kon praten, alhoewel het erg leuk is om te zien dat we onderhand 
allemaal erg verschillende wegen bewandelen. Bedankt voor jullie vriendschap, jullie 
steun in moeilijkere tijden, en onze leuke gezamenlijke feesten tijdens de mooie 
tijden! 
Lieve Peter en Anita, al lukt het maar niet om heel vaak af te spreken, is het 
altijd weer erg gezellig om elkaar weer te zien en om zowel over promoveren als 
allerlei andere dingen te praten. Jullie zijn nu ook bijna klaar met jullie promotie, 
succes met de laatste loodjes!
Lieve volleybal teamgenoten, we hebben natuurlijk samen genoten van volleybal, 
maar ook veel samen gedeeld rondom onze trainingen en wedstrijden. Volleybal was 
en is voor mij een manier om even alles achter je te laten; niets is zo lekker om na 
een frustrerende werkdag er alles uit te slaan tijdens een potje volleybal. Hierbij wil 
ik ook specifiek mijn teamgenoot Nicolet bedanken voor de prachtige lay-out van dit 
boekje! En last but not least, natuurlijk ook een special thanks to Fred, Ed & The 
Seabanquets! Op naar nog vele festivals, gezellige etentjes en dat we nog maar vele 
biertjes (en 1 witte zoete wijn) samen mogen drinken!
Lieve paranimfen, het is fantastisch dat jullie me willen steunen tijdens deze bijzon-
dere dag! 
Lieve Lisa, wat hebben we al veel meegemaakt met elkaar sinds dat we begon-
nen in de mini’s bij Side Out. We hebben al heel wat afgelachen, allerlei plekken 
bezocht en leuke avonturen meegemaakt, maar ook de minder mooie kanten van 
het leven samen gedeeld en dat maakt dat jouw vriendschap me heel dierbaar is. Jij 
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bent voor mij het voorbeeld dat je alles in het leven kan bereiken door positief te zijn 
en er hard voor te werken! Ik ben heel blij dat je, zoals beloofd, naast me zal staan 
op 5 december! 
Lieve Anne, samen zijn we aan het grote promotie avontuur begonnen en, zoals 
helaas gebruikelijk is, is dit niet altijd soepel verlopen. Het is erg fijn geweest om al 
onze promotie perikelen met elkaar te bespreken en elkaar daarbij te steunen. Ook 
ben je altijd een grote steun voor me voor alle dingen buiten werk. Maar vooral wil ik 
je toch bedanken voor alle gezelligheid tijdens onze vele lunches, café- en bioscoop-
bezoekjes (en bijbehorende biertjes), die ervoor zorgden dat ik even alles kon verge-
ten en heerlijk kon ontspannen. Jij bent zelf nu ook bijna klaar en al duurt het altijd 
weer langer dan je hoopt weet ik zeker dat dankzij jouw doorzettingsvermogen je ook 
binnenkort in die Aula zal staan! 
Dames, we gaan er 5 december een mooie dag en vooral een mooi feestje van 
maken, zoals we altijd doen! 
Naast mijn vele lieve vrienden, wil ik als laatste graag mijn lieve familie bedanken, 
die er altijd voor me zijn.
Lieve Jeroen en Ronald, zoals grote broers horen te doen hebben jullie altijd goed 
je best gedaan om je kleine zusje uit te dagen en te plagen. Ondanks dat, weet ik dat 
ik op jullie onvoorwaardelijke steun kan rekenen bij wat ik ook doe en hebben jullie 
altijd veel interesse getoond in mij en ook in mijn onderzoek. Ik ben heel erg blij dat 
jullie mijn broers zijn en hopelijk zal de ‘Donald Duck’ versie van mijn onderzoek op 
5 december jullie meer leren over wat ik nu de afgelopen jaren uitgespookt heb!
Lieve paps en mams, jullie hebben me altijd de vrijheid gegeven om te doen wat 
ik wilde en me daarin ook altijd gesteund. Ook hebben jullie me geleerd dat het goed 
is om niet altijd voor de makkelijke weg te kiezen en mede hierdoor ligt dit mooie 
proefschrift hier nu. Heel erg bedankt voor alle liefde en steun die jullie mij hebben 
gegeven, jullie zijn mijn thuis waar ik altijd bij aan kan kloppen!  
     
        
Hanneke Stegeman
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Hanneke Stegeman werd op 20 september 1985 geboren te Warnsveld. In 2003 behaalde 
zij haar VWO-diploma aan het Baudartius College te Zutphen, en begon ze aan de 
studie Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen. Zij kwam 
voor het eerst in contact met het radiobiologisch onderzoek tijdens haar bachelor-
stage bij de afdeling Radiotherapie van het UMC St Radboud te Nijmegen onder bege-
leiding van prof. dr. Bert van der Kogel. Na het cum laude behalen van haar bachelor-
diploma, vervolgde ze in 2006 haar masterstudie met de hoofdvakken Pathobiologie 
en Toxicologie. Hiervoor liep ze stages bij de afdeling Antropogenetica van het UMC 
St Radboud, onder begeleiding van prof. dr. Barbara Franke, en bij de afdeling Toxico-
logie van TNO Quality of Life te Zeist, onder begeleiding van dr. Didima De Groot. In 
2008 verkreeg ze cum laude de Master of Science titel en keerde ze in september weer 
terug bij het radiobiologisch onderzoek en bij de afdeling Radiotherapie van het UMC 
St Radboud om daar haar promotieonderzoek te starten. Onder begeleiding van dr. Jan 
Bussink, dr. Paul Span, prof. dr. Hans Kaanders en prof. dr. Bert van der Kogel voerde 
ze het onderzoek uit wat geresulteerd heeft in dit proefschrift. Dit onderzoek is ook 
uitgevoerd in samenwerking met de afdeling Human Oncology van de University of 
Wisconsin in Madison, WI, Verenigde Staten, waar Hanneke 3,5 maand heeft gewerkt 
in het lab van dr. Deric Wheeler. Tijdens haar promotieonderzoek heeft zij op haar 
beurt verschillende bachelor- en masterstudenten begeleid. Daarnaast heeft ze haar 
onderzoek op meerdere internationale congressen gepresenteerd en heeft ze ook 
meerdere reisbeurzen gewonnen met het hier beschreven onderzoek.
Op dit moment vervolgt Hanneke als postdoc haar onderzoek waarmee ze 
gestart is tijdens haar promotie en wat gericht is op het vergroten van het effect van 
radiotherapie via remmers van groeifactorreceptor signalering.  
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